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ABSTRACT 
 
 
Background and objectives 
 
Apoptosis is a process in which a cell programmes its own death. It is a highly organized 
physiological mechanism in which injured or damaged cells are destroyed. Apart from 
physiological stimuli however, exogenous factors can induce apoptosis. Many anti-cancer 
drugs work by activating apoptosis in cancer cells. Natural substances have been found to 
have the ability to induce apoptosis in various tumour cells and these substances have 
been used as templates for the construction of novel lead compounds in anticancer 
treatment. On the other hand, alkylating agents such as cisplatin, cis- [PtCl2 (NH3) 2] 
have been widely used as antineoplastic agents for a wide variety of cancers including 
testicular, ovarian, neck and head cancers, amongst others. However, the use of cisplatin 
as an anticancer agent is limited due to toxicity and resistance problems.  
 
The aim of this present study was to screen the leaves of Rhus laevigata, a South African 
indigenous plant, for the presence of pro-apoptotic and anti-proliferative natural 
compounds and also to screen newly synthesised palladium based complexes (15 and 57) 
and a platinum based complex (58) for their antineoplastic activities tested against a panel 
of cell lines. 
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Results. 
 
The results showed that crude methanol extracts from Rhus laevigata as well as the newly 
synthesised palladium based complexes (15 and 57) and a platinum based complex (58) 
induced apoptosis in the cell lines tested, as demonstrated by the 
externalization of phosphatidylserine, mitochondrial membrane permeabilization, 
caspase-3 activation, and DNA fragmentation. Caski (cervical cancer) and H157 (non 
small cell lung carcinoma) cell lines treated with the methanol extract from Rhus 
laevigata however, were more resistant to apoptosis induction. Among the metallo-
complexes, complexes 15 and 57, palladium based complexes, were the most active.  
 
Conclusion 
 
The methanol extract from the leaves of Rhus laevigata contain pro-apoptotic and anti-
proliferative natural compound(s), which need to be characterised and elucidated as they 
could provide the much-needed lead compounds in the fight against cancer. On the other 
hand the newly synthesized palladium complexes also need further evaluation to see if 
they can be used as anticancer agents that can overcome the problems associated with 
cisplatin. 
  
Key words: Rhus laevigata; cisplatin; palladium; antineoplastic; apoptosis; natural 
products; alkylating agents; novel lead compound; screen; cytotoxicity; resistance. 
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CHAPTER 1: LITERATURE REVIEW 
             Natural Products 
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  Cancer and the cell cycle 
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  Metallo-compounds in anticancer drug discovery 
  Aims of this project 
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           1.1 NATURAL PRODUCT 
            1.1.1 Definition 
 
Natural products have been defined by Singh (2004), and Cannell (1998), as biological 
molecules, which are not necessarily essential or are not directly implicated in the normal 
growth, reproduction or survival of an organism. They are said to be secondary 
metabolites which have a molecular weight of less than 1500 atomic mass unit (amu) 
approximately and are often species dependent with restricted occurrence in nature. 
Verpoorte (2000), also said that natural products play a role in the interaction of the 
organism with its environment, so as to ensure the survival of the organism in its 
ecosystem.  
 
               1.1.2 Primary Metabolites 
 
 
On the other hand primary metabolites have been described by Buchanan et al., (2002), as 
being compounds which are essential for the growth and metabolism of the organism, and 
these include proteins, lipids, nucleic acids, phytosterols, polysaccharides, and organic 
acids. These compounds are mostly ubiquitous. 
 
            1.1.3 The boundary between Primary and Secondary Metabolism 
  
Buchanan et al., (2000), further said that there is no clear cut distinction between primary 
and secondary metabolites on the basis of precursor molecules, chemical structures, or 
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biosynthetic origins as both, primary and secondary metabolites are found among the 
diterpenes (C20) and triterpenes (C30). Buchanan et al., (2000) , gave the example of the 
diterpene series, in which both kaurenoic and abietic acids are formed by a very 
comparable sequence of related enzymatic reactions. They reported that kaurenoic acid is 
an essential intermediate in the production of gibberellins, which are growth hormones 
found in all plants. On the other hand, abietic acid is a resin constituent which is largely 
restricted to members of the Fabaceae and Pinaceae.  On the other hand, the essential 
amino acid proline is said to be a primary metabolite, whereas the C6 analog pipecolic acid 
is regarded as an alkaloid and therefore a natural product. The basic structural polymer in 
wood is lignin and is second only to cellulose as the most plentiful organic substance in 
plants. Lignin however, is considered a natural product rather than a primary metabolite. 
Based on either structure or biochemistry between primary and secondary products there 
is no clear distinction. For this reason Buchanan et al., (2000) have therefore described 
primary products as products participating in nutrition and secondary metabolic processes 
inside the plant. Secondary products have been described as those products that influence 
ecological interactions between the plant and its environment. 
 
           1.1.4 Roles of Secondary Metabolites (SMs) to the organism 
 
             
Koskinen (1995), stated that the real role of secondary metabolites (SMs) is chiefly 
unclear. Nevertheless, the function or importance of these SMs to the organism is usually 
of ecological nature (Verpoorte, 2000), since they are used as defense against predators 
(herbivores, pathogens etc), or for territorial defense by producing antibiotics agents and 
 
 
 
 
  4 
mycotoxins, which prevent insect predation. Secondary metabolites are also used as 
allelopathic agents, antifeedants (chemicals that inhibit feeding), attractants for pollinators 
and seed-dispersing animals, sex hormones as sex attractants and enhancers of the 
reproductive processes (Koskinen, 1995; Croteau et al., 2000; Cotton, 2002; Singh, 2004). 
Even though plants are better known as a source of secondary metabolites, however, 
bacteria, fungi and many marine organisms (sponges, tunicates, corals, and snails) have 
also been reported to be sources of secondary metabolites (Cannell, 1998; Wink, 1999).  
 
           1.1.5 Uses of Secondary Metabolites to man 
 
 
Man has used secondary metabolites for thousands of years. Some uses of secondary 
metabolites to man include the following: dyes (e.g. shikonin, and indigo), flavors (e.g. 
vanillin, mustard oils, and capsin), fragrances (e.g. rose and, 
lavender oils), stimulants  (e.g. nicotine, ephedrine and caffeine), polymers, waxes, hallucin
ogens  (e.g. morphine, and cocaine), waxes, fibers, glues, insecticides (e.g. coniine, 
strychnine, and aconitine), and as therapeutic agents (e.g. atropine, quinine, carenolides, 
codeine, etc), (Cannell, 1998; Wink, 1999; Buchanan et al., 2000). 
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           Figure 1.1: Schematic diagram on the utilization of secondary metabolites in biotechnology 
           (From Wink, 1999). 
 
            1.1.6. Metabolism of secondary metabolites.  
 
Carbohydrates are primary metabolites, which are produced by the action of photosynthesis 
in plants and these carbohydrates provide the carbon skeleton for the secondary 
metabolites. Dennis and Turpin (1995) and Wink (1999), estimated that higher plants 
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produce more than 100,000 secondary metabolites out of which 15,000 have reportedly 
been characterized as drugs. Such secondary metabolites may include: alkaloids, phenolics, 
steroids, tannins, terpenoids, iridoids, saponins, and polyketides. The recognition of the 
biological properties of many natural products has encouraged the search for new drugs, 
antibiotics, insecticides, and herbicides. With regards to their biosynthetic origins of natural 
products, Dennis and Turpin, (1995); Buchanan et al., (2002), divided the plant natural 
products into three major groups and these were: tepenoids, alkaloids and 
phenylpropanoids. 
 
            1.1.7 The Shikimic acid pathway 
 
The shikimic acid pathway was named after one of the key intermediates, shikimic acid. 
The shikimic acid pathway has been described by Mann et al., (1994); and Dewick, (2003), 
as a universal process whereby aromatic metabolites are produced, but in particular the 
three amino acids, phenylalanine, tyrosine, and tryptophan. Herrmann and Weaver, (1999), 
showed that this pathway changes simple carbohydrate precursors developed from 
glycolysis and the pentose phosphate pathway to the aromatic amino acids. In a sequence 
of seven metabolic steps, phosphoenolpyruvate and erythrose 4-phosphate are converted to 
chorismate, the precursor of the aromatic amino acids (figure 1.2) and many aromatic 
secondary metabolites (Herrmann, 1999; Dewick, 2003). All pathway intermediates are 
also considered branch point compounds that may serve as substrates for other metabolic 
pathways. One of the pathway intermediates is shikimic acid, which has given its name to 
this whole series of reactions. The shikimic acid pathway occurs in plants and 
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microorganisms but not in animals. Herrmann, (1999) and Dewick, (2003), have further 
stated that animals have no way of producing the three aromatic amino acids, 
phenylalanine, tyrosine, and tryptophan, which are essential nutrients in animal diets and 
they have said that the pathway provides important targets for herbicides, antibiotics, and 
vaccines. They said that the chemical compound(s) that obstruct with any enzyme activity 
in this pathway are regarded as “safe” for humans when handled within reasonable 
concentrations and therefore the shikimate pathway is important in the biosynthesis of 
many compounds of commercial interest. 
                             Phosphoenolpyruvate + Ethyrose-4-phosphate 
                                                                       
                                                           Shikimate                                                                             
                                                                                        
                                                           Chorismate           
                                                                          
          ALKALOIDS             Anthranilate           Arogenat 
 
 
                                                                                                    
 
 
              ALKALOIDS                     PHENOLICS                   ALKALOIDS 
                                                             
Figure 1. 2: Schematic representation of the Shikimic acid pathway. The condensation of 
phosphoenolpyruvate (PEP) from glycolysis and ethyrose-4-phosphate from the pentose phosphate 
pathway is catalysed by 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthase. Through 
a series of reactions shikimic acid is produced, which is converted to chorismate, the final precursor 
for the synthesis of phenylalanine, tyrosine and tryptophan. Phenylalanine, tyrosine and tryptophan 
are the precursors for alkaloids (From Edwards and Gatehouse, 1999). 
Phenylalanine & Tyrosine Tryptophan 
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1.1.8 The four major classes of secondary metabolites briefly explained 
          1.1.8.1 Alkaloids 
 
The term alkaloid is reported to have been coined in 1819 in Halle, Germany, by Carl 
Meissner (Buchanan et al., 2000). It is derived from alkali. The word alkali is derived 
from the Arabic al qalay, the plant from which soda was first obtained (Kutchan, 1995), 
and it means to roast (Koskinen, 1995).  All alkaloids are basic compounds containing 
nitrogen in a heterocyclic ring and they are common to about 15 to 20% of all vascular 
plants but are found to a lesser extent in microorganisms and animals (Aniszewski, 2007). 
The degree of their basicity however, varies depending on the structure of the alkaloid 
molecule, and the presence and location of other functional groups. Some alkaloids are 
essentially neutral (Dewick, 2003). In plants, both true and protoalkaloids are precursors 
and alkaloids are synthesized mainly from aromatic amino acids, phenylalanine, tyrosine, 
and tryptophan. Pseudoalkaloids however, are synthesized from other compounds, e.g. 
acetate and non-protein amino acids for instance ornithine.  A variety of classes of 
alkaloids are distinguished, depending on the ring system or skeleton that is present 
(Aniszewski, 2007).  Most alkaloids are reported to be toxic and are said to have a wide 
range of different pharmacological effects. Alkaloids are mostly used as drugs, medicines 
and poisons (Kutchan, 1995; Koskinen, 1995; Cotton, 2002). 
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Figure 1.3: The three main types of alkaloids (Aniszewski, 2007). 
 
 
 
 
 
 
 
 
 
 
True Alkaloids Proto Alkaloids Pseudo Alkaloids 
Have heterocyclic ring with 
nitrogen 
Do not have 
heterocyclic ring with 
nitrogen 
Have heterocyclic ring 
With nitrogen 
Not derived from 
amino acids 
Derived from amino acids 
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Table 1.1: Skeleton structures of alkaloids 
 
  SKELETON STRUCTURE DESCRIPTION  
ALKALOID 
TYPE 
 
Nitrogen is part of the 
heterocyclic ring system 
True alkaloids 
 
Nitrogen atom is outside 
the ring system 
Protoalkaloids 
 
Purine ring is pieced 
together with small 
components from primary 
metabolites 
Pseudoalkaloids 
 
1.1.8.2 Flavonoids 
 
Flavonoids are compounds composed of a three-ring structure with various substitutions. 
These compounds are phenolic and are generally found as water-soluble pigments in 
plants. This basic structure is shared by tocopherols (vitamin E). Flavonoids can be 
subdivided according to the presence of an oxy group at position 4, a double bond between 
carbon atom 2 and 3, or a hydroxyl group in position 3 of the C (middle) ring (Middleton et 
al., 2000). Different types of flavonoids are distinguished, such as flavones, flavonols, 
isoflavone, flavanones, chalcones and anthocyanidins (van Wyk et al., 2000). 
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Figure 1.4a: Basic structure of a flavonoid (Crozier, et al., 2000; Beecher, 2003; Taylor and Grotewold,  
2005). General structure and numbering pattern for common food flavonoids. For most food flavonoids, 
R4=H, R5=OH, and R6=H. Exceptions include, biochanin A, R4=CH3; formononetin, R4=CH3, R5=R6=H; 
glycitein, R5=H, R6=OH; and hesperitin, R4=CH3. Aditional individual flavonoids within each subclass are 
characterized by unique functional groups at. R3, R3', and R. 
 
                         Figure 1.4b: Structures of the six main classes of flavonoids 
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 1.1.8.2.1 Functions of flavonoids 
 
There are many functions of flavonoids. One major function of flavonoids is that they act 
as signaling compounds, in the attraction of pollinating and seed-dispersing animals. These 
compounds have shown that they have anti-inflammatory, anti-oxidant, anti-allergic, 
antibacterial and antiviral effects, (Wink, 1999; Casctaldo and Capasso, 2002).  It is also 
reported that they contribute to plant colors (Shirley, 2002).   Even though various 
flavonoids have been reported to slow down the development of chemically induced 
cancers in animal models such as lung, oral, esophageal, stomach, colon, skin, prostate, and 
mammary cancers, epidemiological studies do not however, give convincing evidence that 
high intakes of dietary flavonoids are connected with significant reductions in human 
cancer risk (Benbrook, 2005). 
        1.1.8.3 Terpenoids 
 
The name “terpene” is derived from “turpentine” (Buchanan et al., 2000). Terpenes are 
derived from isoprene C5H8 units and have the basic formula of multiples of it, i.e., (C5H8) 
n. This is called the isoprene rule. The isoprene units may be arranged in a linear or 
forming rings. When terpenes are further altered, for example by addition of  hydroxyl 
groups or removal of a methyl group, the resulting compounds are called terpenoids, e.g. 
menthol and thujone (Dubey et al.,2003). Moss et al., (1995), said that some authors also 
call these compounds terpenes.  
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Terpenoids, are also called isoprenoids, and are produced by the head-to-tail joining of C5 
isoprene units. Isoprenoids are classified according to the number of C5 units, (table 1.2) 
for example hemiterpenes (C5), monoterpenes (C10 and 2 isoprene units, like limonene, 
carvone or carveol), sesquiterpenes (C15 and 3 isoprene units), diterpenes (C20 and 4 
isoprene units and these may include the retinoids), sesterterpenes (C25), triterpenes (C30 
and 6 isoprene units), tetraterpenes (C40 and 8 isoprene units and these include all 
different carotenoids like !-and "-carotene, lutein, lycopene, zeaxanthine and 
cryptoxanthine). Polyterpenes have a large number of isoprene units e.g. rubber (Wagner 
and Elmadfa, 2003; Dubey et al., 2003). Triterpenoids and steroids are usually present in 
plants in the form of saponins. It means therefore that they have more than one or more 
sugar groups attached to them and this makes them water-soluble.  
 
Terpenoids play diverse roles in plants such as hormones, photosynthetic pigments, 
electron carriers, mediators of polysaccharides assembly, structural components of 
membranes as well as communication and defense. They provide a range of commercially 
useful natural products for instance, the anticancer drug taxol, fragrances, insecticidal 
pyrethrins, carotenoids and antioxidants. (McGarvey and Croteau, 1995). For this reason, 
Dewick, (2003), stated that probably terpenoids are the most promising class of natural 
products, with the potential of discovering of a wide variety of compounds that are of 
economic importance.  
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           Table 1.2: Classification of terpenes based on number of isoprene units 
Tepernoid structure Composition Molecular 
Formula 
Example 
 
 
Hemiterpene 
Single 
isoprene unit 
C5H8 Isoprene 
 
Monoterpenes 
Two isoprene 
units 
C10H18O Geraniol 
 
Sesquiterpenes 
Three isoprene 
units 
C15H26O Farnestol 
 
Diterpenes 
Four isoprene 
units 
C20H32 Cambrene 
 
Triterpenes 
Six isoprene 
units 
C30H50 Squalene 
 
Tetraterpenes 
Eight isoprene 
units 
C40H56 Lycopene 
                                     
Polyterpenes 
Many isoprene 
units 
(C5)n* Rubber 
(Gutta-
percha) 
 
• Where “n” may be 9-30,000 
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             1.1.8.4 Phenylpropanoids 
 
Phenylpropanoids are compounds that are produced through the shikimic acid pathway. 
This group includes phenylalanine-derived chemicals that have a diverse group of 
secondary metabolites (Noel et al., 2005), and this includes flavonoids, lignin, coumarins 
and phenolic molecules, that have a variety of functions such as structural support, 
pigmentation, defense and signaling (Douglas, 1996; G#mez et al., 2004). The structural 
variety of phenylpropanoids is due to the action of enzymes and enzyme complexes, 
which bring about regio-specific condensation, aromatization, acylation, hydroxylation, 
glycosylation, cyclization prenylation, sulfation, and methylation reactions (Noel et al., 
2005).  These compounds are distinguished by the presence of a phenol group 
(hydroxylated aromatic ring). 
 
Figure 1.5: Biosynthesis of phenylpropanoids  (from Douglas, 1996). Environmental stress e.g. wounding, 
pathogen infection, and/or UV irradiation in specific tissues and cell types can activate the production of 
phenylpropanoid compounds in plants. Phenylpropanoids are obtained from cinnamic acid by the action of 
the enzyme phenylalanine ammonia-lyase (PAL) which catalyzes the gateway metabolic step from primary 
metabolism into phenylpropanoid metabolism. The de-amination of phenylalanine then produces cinnamic 
acid. Cinnamic acid is further modified by the actions of hydroxylases and O-methyltransferases, and most 
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phenylpropanoid compounds are derived from such hydroxycinnamic acids. (Hahlbrock and Scheel, 1989; 
Dixon et al., 2002; Achnine et al., 2004; Noel et al., 2005;). 
1.2 OVERVIEW OF TRADITIONAL MEDICINE: DEFINITIONS   
AND TERMINOLOGY  
  
             1.2.1 Traditional medicine 
           Definition:  
The term “Traditional Medicine” has been described by Sofowora (1982), as being the 
total combination of knowledge and practices of indigenous people which they may either 
understand or not. The knowledge and practices are used to diagnose, prevent or eliminate 
a physical, mental or a social disease and this may rely entirely on the past knowledge and 
careful observation as handed down from generation to generation either verbally or in 
writing.  
 
               1.2.2 Herbal medicine 
             Definitions: 
The term “Herbal medicine” has been described by Kayne, (2002) as being unrefined or 
refined and labelled products from plants that contain effective ingredients for the remedy 
of illness. These ingredients could come from the aerial or underground parts of plants, or 
other plant material, or could just be a combination of different parts of the plant. The 
herbal preparation could also be combined with other ingredients such as juices, gums, 
fatty oils, essential oils and any other substances of this kind. Sofowora (1982), has 
described herbal medicine as the use of any plant either in whole or in part or the use of 
more of its parts, that contain substances that can be used for healing purposes or can be 
 
 
 
 
  17 
used in combination with other ingredients with the aim of making useful drugs for 
healing purposes.  
 
               1.2.3 Brief history of traditional medicine 
 
Kayne, (2002), indicated that the exact origins of traditional medicine are not known.  He 
said that there is a possibility that several different primitive people discovered that some 
herbs were good to eat, and yet others had healing powers. Newman et al., (2000) further 
stated that opium poppy, Papaver somniferum, was perhaps the earliest medicinal plant, 
because it was well known in ancient Greece. In addition, Kayne, (2002) pointed out that 
Hippocrates mentioned the use of poppy juice as cantharic, hypnotic, narcotic and styptic. 
Sofowora, (1982), also reported that seeds of the opium poppy and castor oil (Ricinus 
communis) were unearthed from some ancient Egyptian tombs an indication that those 
seeds were used in that area most likely as far back as 1500BC. One obvious thing is that 
nature has provided humans with basic needs such as food-stuffs, protection, clothing, 
fertilizers, flavors and of course, medicines for thousands of years (Gurib-Fakim, 2006). 
The knowledge of herbal treatment by indigenous people was probably developed through 
trial and error over several thousand years. This knowledge was passed on verbally from 
one generation to the next generation  
           
    1.2.3.1 Isolation of  pure active compounds from medicinal plants. 
 
Table 1.3 shows some of the pure active compounds that have been isolated from 
medicinal plants through bioassay-guided isolation (Gurib-Fakim, 2006). Numerous other 
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methods have been utilized to acquire compounds for drug discovery including synthetic 
chemistry, combinatorial chemistry, and molecular modeling (Lombardino and Lowe, 
2004). It was indicated by Newman et al., (2000; 2003), that in spite of the fact that in 
recent times there has been a lot of interest in molecular modeling, combinatorial 
chemistry, and other synthetic chemistry techniques by pharmaceutical companies and 
organizations which provide financial support to research institutions, natural products, 
and particularly medicinal plants, remain an important source of new drugs, new drug 
leads, and new chemical entities (NCEs). It has been shown that known compounds 
isolated from medicinal plants act on newly confirmed molecular targets, e.g. 
kamebakaurin, which has been shown to inhibit NF-$B (Balunas and Kinghorn, 2005) and 
"-lapachone, which is reported to selectively kill cancer cells over normal cells because it 
targets an enzyme elevated in various tumors (Reinicke et al., 2005).  
Pieters and Vlietinck (2005) and Kim, (2005), have reported that most of the world’s 
developing countries still depend on traditional medicine for their primary health care 
needs. They said this is because most developing countries cannot afford to import 
western medicine, therefore developing countries are encouraging the use of traditional 
medicines as an essential component in their public health care programs. Additionally, 
Pieters and Vlietinck (2005), have said that traditional are locally available and the local 
population eagerly accepts them. However, there is the danger that some of the traditional 
drugs are not safe for human consumption and that sustainability might not be possible 
due to over exploitation of plant population in the wild.  
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Table 1.3: Botanical drugs used in traditional medicine which have given useful modern drugs (adapted 
from Gurib-Fakim, 2006).A summary of some of the traditional medicines, which have given useful modern 
drugs. It can be seen that plants used for medicinal purposes by indigenous peoples has provided novel 
compounds or lead compounds that are in use in this modern society. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      1.3 METHODOLOGY IN PLANT DRUG DISCOVERY 
The process in plant drug discovery involves a multidisciplinary approach and is a complex
 one.  Pieters and Vlietinck,  (2005), reported that the   process can begin with a botanist, 
ethno botanist, ethno pharmacologist, or plant ecologist who collects and identifies the 
plant(s) of interest. Plant species, which are known to treat specific ailments but their active 
compound(s) have not yet been isolated may be collected, or the plants maybe randomly 
collected for a large screening program. After the plants are collected, a phytochemist 
Botanical names 
English 
names 
Indigenous use Origin 
Uses in 
biomedicine 
Biologically active 
compounds 
Adhatoda vasica – 
Antispasmodic, 
antiseptic, 
insecticide, fish 
poison 
India, Sri 
Lanka 
Antispasmodic, 
oxytocic, cough 
suppressant 
Vasicin (lead molecule 
for Bromhexin and 
Ambroxol) 
Catharanthus roseus Periwinkle Diabetes, fever Madagascar 
Cancer 
chemotherapy 
Vincristine, Vinblastine 
Condrodendron 
tomentosum 
– Arrow poison Brazil, Peru 
Muscular 
relaxation 
 
d-Tubocurarine 
Gingko biloba Gingko 
Asthma, 
anthelmintic 
(fruit) 
Eastern 
China 
Dementia, 
cerebral 
deficiencies 
Ginkgolides 
Harpagophytum 
procumbens 
Devil’s 
claw 
Fever, 
inflammatory 
conditions 
Southern 
Africa 
Pain, rheumatism 
Harpagoside, Caffeic 
acid 
Piper methysticum Kava 
Ritual stimulant, 
tonic 
Polynesia 
Anxiolytic,mild 
stimulant 
Kava pyrones 
Podophyllum peltatum May apple 
Laxative, skin 
infections 
North 
America 
Cancer 
chemotherapy, 
warts 
Podophyllotoxin and 
lignans 
Prunus africana 
African 
plum 
Laxative, ‘Old 
man’s disease’ 
Tropical 
Africa 
Prostate 
hyperplasia 
Sitosterol 
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(natural product chemist) prepares extracts from the plant materials and subjects the 
extracts to biological screening in pharmacologically relevant assays.  If a plant extract 
shows that it contains active compound(s) the process of isolating and characterizing the 
active compound(s) through bioassay-guided fractionation commences. As these plants 
may be collected from different countries, Baker et al., (1995), have said that it is 
important to protect the intellectual property rights of those given countries from where the 
plants were collected.    
 
 
  Figure 1.6: The study of plants as used in traditional medicine (adapted from Pieters and Vlietinck, 2005). 
The flow chart shows that in a “standard” drug discovery procedure active compounds are obtained by a 
bioassay-guided isolation. Crude extracts of medicinal plants, are subjected to structure–activity relationship 
studies (SAR). Toxicity and safety studies as well as clinical tests are later carried out. Active compounds are 
then prepared on an industrial scale, where appropriate pharmaceutical formulations are developed before the 
compound(s) are approved as a drug(s). Careful quality control procedures are done at every step. In the 
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“traditional” medicinal system, however, pharmacological evaluation of extracts may only lead to the 
establishment of standardized extracts. Toxicity and safety studies can be carried out on the standardized 
extracts and thereafter, industrial production of these standardized extracts can start. If clinical tests are good, 
formulation of the standardized extracts may lead to approval as drugs. 
 
 1.3.1 Medicinal plants in anticancer drug discovery  
                 
As reported by Butler, (2004), drug discovery from medicinal plants has played an 
important role in the treatment of cancer.  Newman et al., (2003) reported that between 
1940 and 2002, 40% of cancer drugs were natural products as such, or were natural 
product-derived, with about 8% considered to mimic natural products. Presently 
anticancer agents from medicinal plants which are in clinical use have been categorized 
into four main classes of compounds and these are: vinca (or Catharanthus) alkaloids, 
epipodophyllotoxins, taxanes, and camptothecins. Ngan et al., (2001); Okouneva et al., 
(2003), have reported that vinca alkaloids and their semi-synthetic derivatives block 
mitosis with metaphase arrest by binding specifically to tubulin resulting in its 
depolymerization. The epipodophyllotoxins are reported to bind tubulin, causing DNA 
strand breaks during the G2 phase of the cell cycle by permanently inhibiting DNA 
topoisomerase II (Gordaliza et al., 2004; Cragg and Newman, 2004, 2005; Balunas and 
Kinghorn, 2005;). The taxanes, as well as paclitaxel and their derivatives, are reported to 
act by binding tubulin and once this is done, depolymerization of the microtubule does not 
take place. Camptothecin acts by inhibiting topoisomerase I, which is involved in the 
removal of supercoils of DNA during replication (Cragg and Newman, 2004, 2005).  
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Table 1.4: Summary of mode of action of some of the commonly used natural product anticancer 
drugs. 
Drug Class  Mechanism of Action 
Anthracyclines Topoisomerase II inhibitors 
Camptothecin Topoisomerase I inhibitors 
Epipodophyllotoxins Topoisomerase II inhibitors 
Taxanes Tubulin- binding agents 
Vinca alkaloids Tubulin- binding agents 
 
 
 1.3.2 Plant drug discovery for cancer chemoprevention  
 
Khan and Partin, (2003); De Flora and Ferguson, (2005), have defined cancer 
chemoprevention as the administration of agents, which prevent the induction, restrain, or 
delay the progression of cancer. Greenwald et al., (2002), mentioned that for a normal cell 
to be transformed into a cancerous cell it goes through several stages. Firstly is the 
initiation stage, which is normally caused by DNA damaging agents. Secondly is the 
promotion stage, in this stage the cell increasingly proliferates. Thirdly the cell is 
genetically altered and it still proliferates. Chemoprevention therefore targets each of these 
steps including anti-initiation strategies for example, DNA repair, removal of toxic 
substances, removal of free radicals, metabolism of cancer causing agents and also 
involvement of  anti-promotion/anti-progression  strategies,  example inflammation 
reduction, increase in apoptosis, altered gene expression, and decrease in angiogenesis. It 
has been suggested by Liberman et al., 2001; Khan and Partin, 2003; Kinghorn et al., 
2004), that herbal medicines, dietary supplements, edible plants, fruits and vegetables are 
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important in cancer chemoprevention because they contain compounds, which can prevent 
the onset of cancer and some chemopreventive agents are in clinical trials. Some of such 
potential cancer chemopreventive agents include: curcumin which is in Phase I, for colon 
cancer, genistein in Phase I, for breast and endometrial cancers, soy isoflavones in Phase II, 
for prostate cancer, indole-3-carbinol in Phase I, for breast recurrence cancer, perillyl 
alcohol in Phase I, for breast cancer and green tea/epigallocatechin gallate in Phase II, for 
breast cancer. These chemopreventive agents are said to work by targeting initiation, 
promotion, and progression stages of carcinogenesis.  Dorai and Aggarwal, (2004), have 
also reported that some chemopreventive agents have been found to reverse 
chemoresistance and radioresistance in patients that are undergoing cancer treatment. 
 
 1.3.3 Problems and challenges in drug discovery from medicinal plants 
 
Although plants have provided useful drugs, there are however, many problems that go 
with drug discovery from medicinal plants. Reichert, (2003), stated that the first major 
problem is that the process is lengthy and he estimated that it takes an average of 10 years 
from the time of collecting the plants to the time the drug is ready for use. The second 
problem is the cost involved. The general cost for all drug discovery research for an 
average of one new “blockbuster” drug to mature has been estimated to be more than US$ 
800 million pre-tax in 2000 dollars (Dickson and Gagnon, 2004; Verkman, 2004). A recent 
survey by DiMasi et al., (2003), showed that 68 randomly selected new drugs from 
medicinal plants, totalled 802 million US dollars for research and development costs which 
also included unsuccessful projects. The survey showed that the cost was exorbitantly high 
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because much time was spent on numerous leads that were disposed of during the drug 
discovery process.  The survey further showed that out of 5000 lead compounds probably 
only one successfully advanced through clinical trials stage and approved as a drug with 
New Chemical Entity (NCE). Balunas and Kinghorn (2005), have also pointed out other 
problems faced with drug discovery from medicinal plants. Some of such problems 
included: dereplication of the active compound, purification of the new compound by 
chromatographic methods, structure determination methods, and scale-up of the 
production. In spite of the many problems that face plant drug discovery, Pieters and 
Vlietinck, (2005), and Balunas and Kinghorn, (2005), have however, pointed out that 
plants could still be envisaged to have a major role in the search for new medicines.     
 1.4 APOPTOSIS 
 Definition: 
The term “apoptosis” has been defined by Kroemer et al., (1998) and Tsujimoto and 
Shimizu, (2000), as a cell process whereby the cell programs its own death. This process 
involves activation of catabolic processes and enzymes, which occurs before the cell dies. 
The process is an important physiological mechanism that selectively removes unwanted 
cells. It plays a very vital part in a variety of biological events, which include 
morphogenesis and elimination of harmful cells. 
  
 1.4.1 History of the Name “apoptosis” 
 
The term apoptosis was introduced into modern scientific writing by Kerr, Willey and 
Currie (1972), in which they described it as a cell death (programmed cell death/cell 
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suicide) different from necrosis. The term was chosen for its meaning for it represented 
the falling of leaves as used in ancient Greek (Kerr et al., 1972; Cruchten, 2002).  Since 
then this term has been in accepted use in biomedical sciences. It is a process whereby 
unwanted cells in a multicellular organism deliberately give up life i.e. deliberately die. 
The term was also used in philosophical writings of the orthodox world, mainly in 
political and social contexts in which it was used to mean “failure, ruin, refuse, decay or 
dissolve” (Hetts, 1998; Maysinger, 2006).  
 
  1.4.2 Cell membrane and mechanisms of apoptosis 
 
The mammalian cell membrane was described by Singer and Nicolson, (1972), as a semi-
fluid mosaic structure made of phospholipids, proteins and some cholesterol.  
Phospholipids are the major components of the membrane and are arranged in a form of a 
'bi-layer' each arranged in an amphipathic structure (Singer and Nicolson, 1972; Fadeel, 
2004). The outer leaflet of the lipid membrane is mostly made of the choline-containing 
phospholipids, (phosphatidylcholine and sphingomyelin). This layer makes contact with 
the out side matrix, (in vivo), or with cell culture medium, (in vitro). The inner membrane 
is mostly made of phosphatidylethanolamine and phosphatidylserine molecules and is in 
contact with the  cytoplasm. Phospholipids contain non-polar, hydrophobic fatty acid tails, 
which in both leaflets make up the interior volume of the membrane, giving the 
characteristic bi-layer structure. It is this bi-layer structure composition and its essential 
phospholipids that maintain a 'viable' cell. The membrane, and its component parts, 
provide a semi-permeable barrier and generates a concentration gradient between the 
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inside of the cytoplasm and the extracellular environment (Avers, 1982). The major 
feature associated with apoptosis is the loss of the phospholipid asymmetry and exposure 
of the negatively charged phosphatidylserine from the inner to the outer surface of the cell 
membrane. This change is necessary for recognition and engulfment of the apoptotic cell 
by macrophages (Fadok et al., 2001). The plasma membrane asymmetry in viable cells is 
said to be maintained by the activity of an aminophospholipid translocase, which is 
believed to be a 120-kDa Mg2+-dependent adenosine triphosphatase (ATPase) (Fadok et 
al., 2001). This adenosine triphosphatase (ATPase) transfers any phosphatidylserine (and, 
to a lesser extent, phosphatidylethanolamine) that may have reached the outer leaflet back 
to the inner leaflet of the plasma membrane. However, the rapid appearance of 
phosphatidylserine on the cell surface during cellular activation and during apoptosis is 
mainly due to the activation of a lipid-nonspecific membrane phospholipid scrambling 
activity, which moves phospholipids bidirectionally across the plasma membrane, in so 
doing increasing the surface expression of phosphatidylserine (Fadok et al., 2001). 
Therefore phosphatidylserine is commonly used as a marker for apoptosis (Barrett et al., 
2001). 
The enzymatic scramblase activity depends on calcium concentration present inside the cell 
(Wyllie et al., 1984). Under normal condition the calcium concentration inside the cell is 
very low. An increase in calcium concentration however, triggers the phospholipid 
transportation mechanism, which results in a symmetric distribution of negatively charged 
phospholipids between both leaflets of the plasma membrane. Since transportation of 
scramblase does not require energy, therefore ATP is not involved. Fadeel, (2004), said 
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that in healthy cells scramblase activity is inactive and activation only occurs under 
stressful conditions.  
 
Figure 1.7: The regulation and physiology of membrane phospholipid asymmetry (from Zwaal and Schroit, 
1997). 
Membrane lipid asymmetry is regulated by the cooperative activities of three transporters. The adenosine 
triphosphate (ATP)-dependent aminophospholipid-specific translocase, which rapidly transports 
phosphatidylserine (PS) and phosphatidylethanolamine (PE) from the cell outer-to-inner leaflet; the ATP-
dependent nonspecific lipid floppase, which slowly transports lipids from the cell's inner-to-outer leaflet; 
and the Ca2+-dependent nonspecific lipid scramblase, which allows lipids to move randomly between both 
leaflets. 
 
 
 
 
 
 
 
 
  28 
   1.4.3 Characteristics of apoptosis and necrosis 
An apoptotic cell has characteristic sequence of biochemical and physical changes. These 
changes affect the cytoplasm, nucleus and plasma membrane. Frédérich et al., (2003), said 
that during apoptosis the cell shrinks and loses contact with neighboring cells. In the 
cytoplasm, the endoplasmic reticulum dilates and the cisternae swell to form vesicles and 
vacuoles. In the nucleus, the chromatin condenses and activation of an endonuclease 
cleaves genomic DNA into nucleosomal DNA which collects into multiples of 
internucleosomal 180-bp fragments which upon agarose gel electrophoresis give rise to 
characteristic DNA ladder. The nucleus becomes convoluted and buds off into several 
fragments, which encapsulate within the apoptotic bodies. In the plasma membrane, cell 
junctions disintegrate, whereby the plasma membrane becomes convoluted and eventually 
blebs.  Finally, the cell itself fragments with all its cellular contents inside thereby forming 
apoptotic bodies of various sizes (Lawen, 2003). The apoptotic cell/bodies are then easily 
engulfed by macrophages (Duke and Ojcius, 1996: Hetts, 1998). Since the apoptotic 
bodies are surrounded by an intact plasma membrane, apoptosis usually occurs without 
leakage of cell contents and usually without inflammation. On the other hand, in cell 
oncosis the cell swells and disintegrates in an unordered manner, eventually leading to the 
destruction of the cellular organelles and finally rupture of the plasma membrane and 
leakage of the cell contents  (Frohlich and Madeo 2000; Skulachev, 2002; LaCasse et al, 
2005). 
  
It was stated by Zamzani and Kroemer, (1999), that when normal cells are induced with 
death-inducing stimuli (figure 1.8) they react by initiating several other molecular 
 
 
 
 
  29 
pathways, which lead to cell death. If cells fail to die, embryogenesis and organ 
dysfunction results and this contributes to the onset of cancer. Apoptosis pathways lead to 
cell death by activating initiator caspases, which in turn activate effector caspases to 
cleave cellular substrates. Zamzani and Kroemer, (1999), further said that apoptotic cells 
show cytoplasmic and nuclear condensation, the DNA is damaged, the cells form 
apoptotic bodies, and they have intact plasma membranes. These cells also expose surface 
molecules which phygocytic cells target for phagocytosis. In addition to that Otsuki et al., 
(2003), said that in the absence of phagocytosis, apoptotic bodies may proceed to lysis and 
may result in secondary or apoptotic necrosis. 
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Figure 1.8: Pathways leading to cell death (from Fink and Cookson 2005). 
Lysosomes may initiate cells to digest their own contents in autophagic vacuoles. Morphologically 
autophagic cells are vacuolated, cytoplasmic contents are degraded and the chromatin is slightly condensed. 
Autophagic cells can also be taken up by phagocytes. Oncosis is the prelethal pathway leading to cell death 
accompanied by cellular and organelle swelling and membrane breakdown, with the eventual release of 
inflammatory cellular contents. Pyroptosis is described as the cell death pathway caused by the activation of 
caspase-1, a protease that also activates the inflammatory cytokines, IL-1ß, and IL-18. This pathway is 
therefore naturally proinflammatory. Pyroptosis also involves cell lysis and also the release of inflammatory 
cellular contents. There is a possibility that other pathways exist but have not yet been described.  
 
 
 
 
 
  31 
 1.4.4 Apoptosis detection methods 
 
When the term “apoptosis” was introduced by Kerr et al., (1972), its study mainly 
focused on cell morphology by the use of transmission electron microscopy (TEM). In 
recent times however, there has been noticeable progress in the study of apoptosis. 
Sciences such as biochemistry, molecular cell biology and genetics have provided more 
information on apoptosis and this has equipped researchers with a range of apoptosis 
detection methods. Most of these detection methods have mainly focused on apoptotic 
cell signaling (Schultz and Harrington, 2003; Jayaraman, 2005). The table 1.5 shows 
some of the features measured in apoptosis cell research and some of the detection 
methods used to measure those features.  One feature associated with apoptosis is DNA 
fragmentation. Not all cells that die by apoptosis however show DNA fragmentation, 
which can be visualized by DNA laddering. This feature has been proven in cells which 
are deficient of Caspase-3 activation (Yuste et al., 2001), and in cells lacking cell nuclei 
e.g. red blood cells and lens fiber cells (Nagata, 1997, 2005). 
 
 
 
 
  32 
Table 1.5: Some features measured in apoptosis studies and some of their   detection 
methods. 
Feature measured Detection method 
Morphological evaluation 
Light microscopy/TEM/Phase contrast microscopy 
Fluorescence microscopy 
Phosphatidylserine exposure Annexin V/ APOPercentage™ Apoptosis assay 
Caspase activity/cleavage Flow cytometric/colorimetric/western blot 
DNA fragmentation Gel electrophoresis/TUNEL 
PARP-1 cleavage Western blot/Flow cytometric 
Mitochondrial depolarization TMRE/JC-1/DiOC6
 /Mito Flow 
Bad/Bax/Bak Western blot (anti-Bad/ -Bax/-Bak antibodies) 
p53 Western blot (anti-p53 antibodies) 
DNA perturbations  Propidium Iodide/Acridine orange (Cell cycle analysis) 
IC50 Neutral Red/Annexin V /MTT assay 
Bcl-2 Western blot (anti-Bcl-2 antibodies) 
Bcl-xL Western Blot (anti-Bcl-XL antibodies) 
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 1.4.5 Diseases associated with apoptosis 
 
Several pathways are involved in order for apoptosis to be achieved. First when stimulated 
to undergo apoptosis, initiator caspases are activated and secondly the initiator caspases 
activate effector caspases to cleave cellular substrates. If there are any defects in the 
apoptotic pathways however, this may result in complications and diseases. Reed, (2002), 
reported that many diseases are due to too much cell death or too little cell death. Some of 
the diseases which he said are due to defective apoptosis regulation are: (i) cancer, 
restenosis, autoimmune diseases and persistent infections (these are due to insufficient 
apoptosis) (ii) ischaemia, heart failure (due to loss of myocytes), neurodegenerative 
diseases such as (Alzheimer’s, Parkinson’s, Huntington’s and myotrophic lateral 
sclerosis), osteoarthritis involving chondriocyte depletion, Human immunodeficiency 
virus which depletes T lymphocytes (Badley and Dockrell, 1997), and Type 1 diabetes 
which involves destruction of immune-mediated islets of Langerhans, (these diseases are 
due to excessive apoptosis).  
 
 1.4.6 Pathways of apoptosis 
 
Apoptosis is induced through two main pathways involving either the mitochondria (the 
intrinsic pathway) or the activation of death receptors (the extrinsic pathway). Both 
pathways converge to induce the activation of caspases, which are the final executioners of 
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cell death. It should be well known however, that caspase-independent forms of apoptosis 
have been reported (Leist and Jaattela, 2001; Yuste et al., 2001; Reed, 2002). 
 
 1.4.6.1 The extrinsic pathway 
 
According to Farrow (2000), all cells of a multicellular organism interact with and become 
accustomed to the environment they are in. He said that this responsiveness comes about 
largely through the expression of a range of specific receptors at the cell surface. The 
receptors transmit extracellular signals across the plasma membrane to the inside of the 
cell through intracellular signaling pathways (Reed and Pellecchia, 2005). Once the signal 
is received, the suitable functional response is carried out. The signals could be soluble 
factors, which are produced locally by the cell or the signal could be produced distantly 
for example hormones and growth factors. In order to achieve this, cells have a range of 
receptors on their surfaces which respond specifically to each stimulus. These receptors 
are divided into families, according to the way in which they generate the intracellular 
signals that give rise to the particular functional response. Some cell surface receptors are 
needed to transmit apoptotic signals initiated by ligands (for example, specific antibodies) 
or by natural ligands called death receptors (DRs) (table 1.6). These death receptors play a 
central role in instructive apoptosis (Schultz, and Harrington, 2003). Apoptotic cell death 
happens by the coordinated action of many different proteins.  
 
It is said that cells maintain asymmetry of the inner and outer leaflets of the plasma 
membrane by continuously translocating phosphatidylserine (PS) to the inner leaflet 
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(Zwaal and Schroit, 1997; Vermes et al., 1995). But if the cell translocates 
phosphatidylserine (PS) on the outer leaflet of the plasma membrane, then it is a signal for 
removal of the cells (Schlegel and Williamson, 2001). Death receptors are part of the 
tumor necrosis factor (TNF) gene super-family and these supply a speedy and efficient 
route to apoptosis (Ekert and Vaux, 1997; Kumar et al., 2005). These receptors can 
activate caspases within seconds of ligand binding, causing an apoptotic destruction of the 
cell within hours (Ekert and Vaux, 1997; Walczak et al., 1997). The death receptors best 
described to date are listed in Table 1.3 together with their various similar names (Ekert 
and Vaux, 1997; Walczak et al., 1997; Ashkenazi and Dixit, 1998; Kumar et al., 2005). 
 
In addition to death receptors, the TNF super family contains decoy receptors (DcR), 
which restrain death signaling through the sequestration of the ligand. Decoy receptors 
include DcR1, DcR2 and osteoprotegerin (OPG), which bind to TRAIL and DcR3 
particularly binds to Fas ligand and inhibits FasL activity (Ashkenazi and Dixit, 1999; 
Müllauer et al., 2001). Signalling by death receptor is also controlled by cellular FLICE-
like inhibitory protein (c-FLIP) an endogenous inhibitor that interacts with (Fas associated 
death domain) FADD so as to prevent apoptosis from taking place  (Irmler et al., 1997). 
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Table 1.6: Summary of the best-characterized death receptors and their related ligands 
(Kumar et al., 2005). 
 
ACTIVATING LIGAND DEATH RECEPTOR 
TNF and Lymphotoxin alpha TNFR1/DR1/CD120a/p55 
FasL/CD95Land DAXX Fas/CD95/Apo1/DR2 
Apo3L/TWEAK DR3/Apo3/WSL-1/TRAMP/LARD 
TRAIL/Apo2L TRAIL-R1/DR4 
 TRAIL-R2/DR5 (Trail-R2, TRAIL-
R2/Apo-2/TRAILCK2/KILLER 
TRADD DR6 
 
  1.4.6.2 The intrinsic pathway (Mitochondrial mediated apoptosis) 
 
The intrinsic pathway is activated by mitochondrial disruption following cytochrome c 
release (Reed and Pellecchia, 2005). This pathway is initiated by growth factor 
withdrawal, UV irradiation, ischaemia, oxidative stress and cytotoxic drugs (Gupta, 2002; 
Ashe and Berry, 2003;). An ‘apoptosome’ is an approximately 1MDa oligomeric 
structure, which is formed by the interaction of cytochrome c, Apaf-1, d-ATP/ATP and 
procaspase-9 with the consequence of initiating a caspase cascade (Lawen, 2003). 
Members of the Bcl-2 family control this pathway (Budihardjo et al., 1999; Gupta, 2002; 
Schultz and Harrington, 2003; Lawen, 2003). Mitochondria contain a voltage-dependent 
anion channel (VDAC) through which molecules of ! 1.5 kD pass (Green and Reed, 
1998) and their intermembrane space also contain several molecules such as cytochrome 
c, certain pro-caspases, adenylate kinase 2, Endo G, Diablo/Smac (Second Mitochondria-
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Derived Activator of Caspases/direct IAP-Associated binding protein with low pI) and 
apoptosis-inducing factor (AIF) (Zamzami et al, 1996; Srinivasula et al., 2001). When the 
outer membrane (OM) is permeabilized, these molecules get released into the cytoplasm 
and inner membrane (IM) permeabilization leads to changes in mitochondrial membrane 
potentials ("#m). The release of cytochrome c is one of the major steps in the 
mitochondrial apoptosis pathway that is associated with permeabilization of mitochondrial 
outer membrane. As mentioned earlier, the release of cytochrome c results in the 
formation of the apoptosome, which in turn activates executioner caspases to induce 
apoptosis (Green and Reed, 1998; Regular et al., 2003). 
 
A third major pathway of apoptosis induction that does not primarily involve DRs or 
mitochondria is the p53 pathway. According to Mak and Yeh, (2002), the p53 is activated 
in response to DNA damage. Mak and Yeh, (2002); Ashe and Berry, (2003), have said the 
pathway blocks cells with damaged DNA in the G1 and G2 phases of the cell cycle. They 
further said that if the DNA damage is severe, and depending on cell type and oncogene 
composition of the cell, p53 initiates apoptosis by mechanisms that to some extent depend 
on the transcription of apoptosis executionary genes like Bax and genes whose products 
produce reactive oxygen species. 
 
Müllauer et al., (2001) and Budd, (2003), have pointed out that some human diseases are 
due to mutations in genes that are associated with cell surface receptors. Different genes 
are involved at different levels in the apoptosis pathway and if these genes are mutated, 
they may be the causative or contributing factors for some of the human diseases.  
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Figure 1.9: Diagrammatic representation of intrinsic and extrinsic pathways of 
apoptosis (from Mak and Yeh, 2002). 
The extrinsic pathway is triggered by death receptor stimulation, which starts a signaling 
cascade. This cascade results in caspase-8 activation. The activation of caspase-8 leads to 
the activation of caspase-3 and also stimulates the release of cytochrome c by the 
mitochondria. The activation of caspase-3 leads to the degradation of cellular proteins, 
which are necessary for the maintenance of the cell survival and integrity. On the other 
hand, the intrinsic pathway arises when various apoptotic stimuli trigger the release of 
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cytochrome c from the mitochondria. Cytochrome c interacts with Apaf-1 and caspase-9 
to promote the activation of caspase-3, which leads to the degradation of cellular proteins. 
 
 
 Death signals               Stress, UV and chemotherapy            Death Receptor 
Ligands 
 
Signal sensor                        Mitochondria                                     Death Receptors 
 
Adaptors                                 Apaf-1                                             Multiple (FADD) 
 
Initiator Caspases                  Caspase-9                                        Caspase-8, 10 
 
Effector Caspases                 Caspase-3, 6, 7                                  Caspase-3, 6, 7 
                       
APOPTOSIS                        APOPTOSIS                                     APOPTOSIS 
 
Figure 1.10: Diagrammatic summary of steps in signaling pathways of apoptosis (Gupta, 2002). 
 
The death receptor pathway involves the interaction of its ligand with adaptor proteins 
(the most common is FADD, Fas-associated death domain) and initiator caspases 
(caspase-8 and -10). In the mitochondrial pathway, death signals directly trigger 
mitochondria resulting in the release of cytochrome c that binds to an adaptor protein 
Apaf-1 and then recruits the initiator casapse-9. Active caspase-9 triggers effector 
caspases to induce apoptosis. It can be seen that although there are two distinct initiator 
caspase pathways; however, both pathways have common effector caspases pathways.  
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 1.4.7 Caspases (Cysteine Aspartate Specific ProteASEs) 
 
The term “Caspases” stands for (cysteine aspartate-specific proteases) (Yuan and Horvitz, 
1990; Alnemri, 1996). It is a highly conserved family of enzymes found inside the cell and 
these enzymes initiate execution of apoptosis and inflammation. All caspases exist within 
the cell as inactive zymogens. Once the caspases are activated, they signal a cascade of 
events, which eventually cause the cell to commit its own suicide. Riedl and Shi (2004), 
further reported that in humans and mice, there are about 14 caspases that have been 
recognized and these can be sub-grouped depending on how similar their amino acid 
sequences are or how specific their proteases are.  
 
1.4.7.1 Types of caspases 
 
Functionally, the caspases can be viewed in two ways and these are the upstream (or the 
initiator) caspases or the downstream (or the effector caspases). According to Kilicc, 
(2002); Stennicke and Salvesen, (1998), the caspases have been classified as initiator 
caspases which are categorized by their long prodomains (i.e. having >90 amino acids) 
and they contain either death effector domain (DED) (for instance caspase-2, -8, -9 a -10 
and-12) in mammals or Dronc and Dredd in fruit flies. The executioner or effector 
caspases contain short prodomains (such as caspase-3, caspase-6 and caspase-7) in 
mammals and Drice, Decoy, Damm, Dcp1 and Strica in fruit flies. The cell-death 
abnormality-3 (CED-3) is the only apoptotic caspase which is found in the nematode 
worm Caenorhabditis elegans and works as both initiator and effector caspase and the 
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remaining caspases-1, -4, and -5 are mainly involved in cytokine maturation but are not 
necessarily involved in apoptosis.   
 
1.4.7.2 Functioning of caspases 
 
The caspases work in such away that once they have been activated, the prodomains cleave 
and the large and small subunits separate. The active caspases then form heterotetramers 
(Lawen, 2003). Initiator caspases cleave and trigger effector caspases. It is these effector 
caspases that cleave cellular substrates and eventually the cell dies (Liston et al, 2003). 
Effector caspase-3, when activated is able to cleave many important cellular substrates, 
such as inhibitor of caspase-activated DNase (ICAD), Rho-associated coiled-coil forming 
kinase (ROCKI), poly (ADP-ribose) polymerase, (PARP) a DNA repair enzyme, actin, 
fodrin and lamin (Sabraham and Shaham, 2004). 
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             Figure 1.11:  Caspase structure (adapted from Lavrik et al., 2005). 
The caspase family. Three major groups of caspases are shown. Group I: inflammatory caspases; 
group II: apoptosis initiator caspases; group III: apoptosis effector caspases.  
 
 1.4.8 The Bcl-2 family 
 
The Bcl-2 family members have been described by Hu et al., (2003), as the major 
controllers of the apoptotic process, while caspases carry out the execution process. 
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According to Hu et al., (2003), the mechanism through which the Bcl-2 family members 
regulate apoptosis is due to their ability to change the mitochondrial function. The 
members of this family are divided into pro-and anti-apoptotic molecules and there are 
more than 20 members of this family, which have been identified in humans and this 
includes proteins that suppress apoptosis for example, Bcl2, Bclxl, Mc1, A1, Bclw and 
Bclg and proteins that promote apoptosis such as Bax, Bak, Bok, Bad, Bid, Bik, and 
Bim1. Hu et al., (2003), further reported that the release of cytochrome c from the 
mitochondria acts as a switch as it is central in turning apoptosis on or off and is 
controlled by the pro-apoptotic proteins and the anti-apoptotic proteins of the Bcl2 family.  
 
The Bcl-2 proto-oncogene was discovered at the chromosomal breakpoint of t (14; 18) 
bearing human B-cell lymphomas (Friend et al., 1986; Vaux et al., 1988). The gain of 
chromosome 18q and translocation t(14;18) are commonly found in B-cell non-Hodgkin's 
lymphomas (B-NHL). Increased transcription and expression of BCL2 have been 
implicated to be the result of the gain of chromosome 18. (Galteland et al., 2005). The 
study by Vaux et al., (1988), showed that when B cells were transfected with Bcl-2 they 
showed resistance towards apoptosis, which was normally induced in B cells by 
interleukin-3 (IL-3) withdrawal. It was shown for the first time that the development of 
tumours depended not only on the capability of the cells to escape growth control but also 
depended on the capability of the cells to prevent apoptosis. The study found that when 
there was an excess of pro-apoptotic proteins the cells were more prone to apoptosis, but 
when there was an excess of anti-apoptotic proteins the cells tended to be more resistant to 
apoptosis (Vaux et al., 1988).  
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The pro-apoptotic proteins of the Bcl-2 family are often found in the cytosol where they 
act as detectors of cellular damage or stress. Once the cell(s) have cellular stress these 
proteins relocate to the surface of the mitochondria where the anti-apoptotic proteins are 
located. The interaction between pro- and anti-apoptotic proteins disrupts the normal 
function of the anti-apoptotic Bcl-2 proteins and this leads to the formation of pores in the 
mitochondria and this causes the release of cytochrome c and also the release of pro-
apoptotic molecules from the intermembrane space. Following this activation, the 
apoptosome is formed, which leads to the activation of the caspase cascade (Gross et al., 
1999).  
           1.4.8.1. The members of the Bcl-2 family 
 
 
The Bcl-2 family proteins have been subdivided into three classes (Gross et al., 1999; 
Breckenridge and Xue, 2004).  This subdivision is determined by the functions of the 
proteins and also the number of Bcl-2 homology (BH) domains that are present: for 
instance the first subdivision comprises the anti-apoptotic members such as Bcl-2 and Bcl-
xL which have four BH domains (BH1 to BH4), the second subdivision comprises of the 
pro-apoptotic members such as Bax and Bak which have three BH domains (BH1 to BH3), 
and the third subdivision is the ‘BH3-only’ pro-apoptotic members such as Bim and Bid 
which share the homology only within the BH3 domain (Regula et al., 2003). All the 
proteins in these three classes are able to form either homo-oligomer or hetero-dimer with 
one another and seem to have well-defined functions in the regulation of mitochondrial 
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membrane permeabilization (MMP). Gross et al., (1999), said that most of the anti-
apoptotic members show sequences which are maintained in all the four domains and that 
the pro-apoptotic molecules mostly display less sequence conservation of the first !-helical 
segment, BH4. Accordingly, studies using deletion and mutagenesis show that the 
amphipathic !-helical BH3 domain serves as a significant death domain in the pro-
apoptotic members. Gross et al., (1999) and Borner, (2003), have further indicated that 
studies involving separation of "BH3-domain-only" members have shown sequence 
homology only within the BH3 domain and that to date these are all pro-apoptotic. In 
addition Korsmeyer, (1999); Igaki et al., (2000), said members of the Bcl-2 family have 
been implicated in a number of cancers, such as melanoma, breast, and lung cancer and  
said that the members of the Bcl-2 family are involved in resistance to cancer treatment. 
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Figure 1.12: Schematic classification of some members of the Bcl-2 protein family (from Kuwana 
and Newmeyer, 2003). 
‘TM’ refers to a hydrophobic region in the carboxyl terminus of several of these proteins that was 
originally assumed to be a transmembrane domain. The pro-apoptotic multidomain (BH1–3) 
proteins might contain a weak BH4 homology (not shown).  
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1.5 CANCER AND THE CELL CYCLE 
Cancer is a disease which results when control of the cell cycle goes wrong and normal 
cell growth and behavior are completely lost. Generally, cancer can be said to be a 
compilation of diseases or disorders whereby abnormal cells spread within the body or 
tissue. The cell division of these abnormal cells is uncontrolled and the cells may have the 
capacity to invade other cells or tissues (metastasize). The uncontrolled and mostly fast 
growing cells may cause growths in those tissues in which they are proliferating, which 
might either form benign or malignant tumors (Rang and Dale, 1991; Lowe et al., 2000). 
Under normal circumstances, cells grow and divide in an orderly manner, following the 
regulation of the cell cycle. The cell cycle is therefore a significant controller of cell 
proliferation and growth, as well as cell division following DNA damage (Shah and 
Schwartz, 2001). Several proteins are involved in the normal function of proliferative 
pathway and these proteins may function to sensitize the cells to apoptosis so as to keep a 
balance between proliferating cells and dying cells. However, several disorders such as 
cancer, viral infections, autoimmune diseases, neurodegenerative disorders, stroke, anemia 
and AIDS occur due to improper regulation of the cell cycle (Pucci et al 2000). In the case 
of cancer, many factors are involved. Some of such factors may be that cells avoid the 
apoptotic program through both down-regulation of apoptotic inducers e.g. p53 (Bennett, 
1999), inappropriate or excessive induction of survival signals e.g. P13K (Dong et al., 
1999) or because proto-oncogenes or tumour suppressor genes are mutated thereby 
allowing a cancerous cell to grow and divide (Dong et al., 1999). Since improper 
regulation of the cell cycle may lead to diseases such as cancer, it is therefore important to 
have a basic understanding of the stages of the cell cycle so that novel therapies may 
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target those genes which are involved in circumventing apoptosis or inhibiting the proper 
function of the cell cycle for example the cyclin dependent kinase inhibitors (CDKIs) 
(Pucci et al., 2000; Bertino et al., 2003). 
 
The regulation of the cell cycle is a very complicated process because it involves a large 
selection of factors, in particular the cyclins and cyclin-dependent kinases. Bertino et al., 
(2003), said that there are two general ways by which genes control the cell cycle 
regulation. Some genes control the production of proteins whose functions are required for 
the cell cycle to take place, and there are genes that control the initiation of each phase of 
the cell cycle. Other genes however, serve as negative regulators of the cell cycle and they 
stop the cell from proceeding to the next step/phase of the cycle. 
 
1.5.1 Cyclin-dependent kinase (Cdks) and cell cycle regulation. 
 
 Cyclin-dependent kinase (Cdks), are proteins, which belong to a well-conserved family of 
serine/threonine protein kinases and they act as control switches in the regulation of the 
cell as it goes through several stages of the cell cycle  (Pucci et al., 2000). Their kinase 
activity relies on the presence of activating subunits known as cyclins. Specific cyclins are 
in abundance during the phase of the cell cycle in which they are required and they 
decrease during phases in which they are not needed (Shah and Schwartz, 2001). They are 
in fact key to the progression of the cell through the cell cycle.  As the cell progresses 
through the cell cycle it is helped by a number of Cdks, which, when bound to specific 
regulatory proteins called cyclins, move the cell forward through the cell cycle. 
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Correspondingly there are cell cycle-inhibitory proteins called cyclin dependent kinase 
inhibitors (CDKIs), which hinder the cell from moving to the next phase of the cell cycle 
(Golsteyn, 2005). So far there are at least 9 structurally related CDKs (CDK 1-9), which 
have been identified, even though the role of some of them in the cell cycle regulation is 
not clear. A considerable number of cyclins have also been identified to date (cyclins A-
T). It is clear however, that as the cells express cyclins D, A, E, and B1, they can 
subdivide the cell cycle into different clear stages of the cell cycle, (Golsteyn, 2005). For 
instance, the expression of cyclin D1 can be detected in early G1 of the cell cycle, while 
the expression of cyclin E can be detected in G1/S peak. Expressions of cyclin A can be 
detected during G2/M phases and that of B1 can be detected in late G2/M phase 
(Golsteyn, 2005; Nakayama and Nakayama, 2005). 
 
1.5.2 p53 and cell cycle regulation 
 
 One other important protein in the cell cycle regulation is p53, a transcription factor 
located on human chromosome 17p13 and consists of 393 amino acids that bind to DNA, 
activating transcription of a protein called p21 
Waf1/Cip1 which blocks the activity of a 
cyclin-dependent kinase required for progression of the cell through G1 (Minnella et al., 
2002; Lozano and Zambetti, 2005). This block allows time for the cell to repair the DNA 
if damaged before it is replicated. If the DNA damage is so extensive that it cannot be 
repaired, p53 triggers the cell to commit suicide through the activation of transcription 
factors. The most common mutation leading to cancer is in the gene that encodes p53. For 
example, Li-Fraumeni syndrome, an inherited condition whereby a person is susceptible 
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to multiple cancers, results from a germ line mutation in p53 (Senzer et al., 2006). Other 
proteins that stop the cell cycle by inhibiting cyclin dependent kinases are p16 and p27. It 
has been shown that a single amino acid substitution can lead to a loss of function of the 
p53 protein (Hupp et al., 1994). Defective p53 can allow abnormal cells to grow, resulting 
in cancer and it is widely accepted that p53 is the most commonly mutated tumor-
suppressor gene linked with human cancers (Vousden, 2000). 
 
Other functions of p53 include the ability to relocalise death receptors like Fas from the 
golgi to the cell surface (el-Deiry et al., 1992; Bennett et al., 1998) and the direct 
involvement of p53 in the mitochondria (Marchenko et al., 2000). Despite the fact that p53 
protein is a transcription factor, el-Deiry et al., (1992) said under normal conditions, it is 
extremely unstable; therefore it usually does not build up to high enough levels to bind to 
p53-control elements to initiate transcription. el-Deiry et al., (1992), further said that 
damaged DNA in some way stabilizes p53, leading to an increase in its concentration and 
that cells with mutations in both p53 alleles do not exhibit delayed entry into the S phase 
following low levels of DNA damage and do not undergo apoptosis following more 
extensive DNA damage. If the DNA of such cells is damaged, the damaged DNA can 
replicate, thereby producing additional mutations that add to the development of an 
extremely transformed, metastatic cell.  
 
There are three independent pathways that take part in activating p53 network. One 
pathway is triggered by DNA damage, e.g. ionizing radiation. This pathway depends on 
two protein kinases: ATM (ataxia telangiectasia mutated) and ChK2 (checkpoint kinase 2) 
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(Carr, 2000). ATM is activated by double stranded breaks in DNA, and in turn stimulates 
Chk2. 
 
The second pathway is stimulated by aberrant growth signals, resulting from the 
expression of the oncogenes Ras and Myc. In humans, the activation of p53 network 
depends on p14
ARF  tumor suppressor protein (Lowe and Lin, 2000). 
 
The third pathway is triggered by a wide range of chemotherapeutic drugs, UV light and 
protein kinase inhibitors. It involves kinases called ataxia telangiectasia related (ATR) and 
casein kinase $$ (Meek, 1999). 
 
1.5.3 PARP-1 and DNA repair 
 
Poly(ADP-ribose) polymerase (PARP-1) is an  abundant nuclear enzyme that helps in the 
repair of single-stranded DNA strand breaks through the activation of DNA repair 
enzymes and check point controls. It is a DNA strand break-sensing molecule, which is 
involved in response to DNA damage and the safeguarding of genomic stability (Tong et 
al., 2001; Süsse et al., 2004). The enzyme typically binds to only one strand of a broken 
DNA and then recruits XRCC1, DNA ligase III%, DNA polymerase & and polynucleotide 
kinase to the broken end (Caldecott et al., 1996). This complex then repairs the broken 
part. It has been suggested that there is an interaction between PARP and p53. Malanga et 
al (1998) and Tong et al., (2001), suggested that PARP can bind to specific domains of 
the p53 protein and can modify the activity of p53 by poly ADP-ribosylation.  
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1.5.4 The Retinoblastoma (Rb) gene  
 
 The human retinoblastoma (Rb) gene is a nuclear protein that is implicated as a tumour 
suppressor and regulator of the cell cycle control check point specifically at the G1 phase 
of the cell cycle (Feakins et al., 2003; Mancini et al., 1994).  The gene contains 928 amino 
acids and was the first tumor suppressor gene to be identified and was isolated from 
retinoblastoma tumors (Lee et al., 1987).  
 
1.5.4.1 The role of Retinoblastoma (Rb) gene 
 
It can be stated that the major two functions of Rb are the inhibition of cell proliferation 
and stimulation of cell differentiation (Zhu, 2005). Rb studies have identified two Rb 
related proteins p107 and p130, which are more closely related to each other than either 
one of them to Rb. These three proteins (Rb, p107 and p130) have been reported by Zhu, 
(2005), to be targets for viral onco-proteins that share onco-protein binding sequences and 
are known as “pocket” domains therefore the three proteins are usually called “pocket 
proteins”.  The three pocket domains A,B and C are situated at residues 379-928.  
According to Wiman, (1993), some studies involving the deletion of both Rb alleles have 
shown to play a rate-limiting role in retinoblastoma and also in the sarcomas that mainly 
arise in families that carry the mutated Rb gene. Such sarcomas include; small cell 
carcinoma of the lung, carcinoma of the breast, bladder, and prostate. 
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 The Rb gene product (Wiman, 1993), binds a number of cellular proteins and one of them 
is the transcription factor E2F. The transcription factor E2F is needed for the transcription 
of cellular genes, which take part in growth and DNA synthesis of the cell. There are 
several genes that contain E2F binding sites and some of such genes are c-myc, cdc2 and 
Rb. In cells, which are resting, the Rb proteins are present in their least phosphorylated 
form and Rb interacts with E2F, while in rapidly growing cells, the Rb proteins are greatly 
phosphorylated. Maximum phosphorylation of Rb proteins is related with S phase of the 
cell cycle (Mancini 1994; Zhu 2005). The active hypophosphorylated form of the 
retinoblastoma protein (pRb) binds and blocks the action of the transcription factor E2F, 
inhibiting transition from the G1 phase to the S phase of the cell cycle (Hanahan and 
Weinberg, 2000). The increased concentration of Rb protein at promoter site coupled with 
E2F, binds adjacent transcription factors, preventing their contact with the basal 
transcription complex, in so doing blocking transcription (Wiman, 2005; Day et al., 1997). 
 Also cyclin D1 stimulates phosphorylation of Rb by associating with cyclin-dependent 
kinases (CDKs) and p16 binds to CDKs 4 and 6, blocking their association with D-type 
cyclins. Therefore, preventing the phosphorylation of Rb blocking the activity of E2F 
(Bertino et al., 2003; Feakins et al., 2003). Mutations of Rb in retinoblastoma have 
therefore been implicated in disturbing the ability of Rb to interact and repress E2F, and 
this therefore suggests that repression of E2F is crucial to Rb tumour suppression activity 
(Hanahan and Weinberg, 2000; Zhu, 2005).   
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Figure 1.13: Model of Rb in the regulation of cell differentiation (adapted from Wiman, 2005). 
Phosphorylation of Rb allows progression of the cell through G1 and continuation of a self-
maintenance pathway. Un-or hypophosphorylated Rb blocks cell cycle progression in the G1 phase 
(adapted from Wiman, 2005).  
                 
1.5.5. Stages of the cell cycle 
 
The cell cycle has been described by Bertino et al., (2003), as a significant controller for 
cell proliferation, growth and cell division following DNA damage. It is a well-organized 
series of events, which results in the production of two genetically identical daughter cells. 
Before the cell divides its genetic material, it goes through several stages.  From 
quiescence (G0) phase, to cell proliferation and as it goes through the stages, there are 
check points which ensure that all the genetic material are kept intact, not damaged or 
incomplete or miscopied.  Otherwise the checkpoints stop the cell from proceeding to the 
next stage of the cell cycle until there is a repair to the damage. If the damage cannot be 
repaired, the cell is eliminated through apoptosis (Pucci et al., 2000).  According to 
Schwartz and Rotter (1998), there are four key checkpoints in the cell cycle. At the end of 
the G1 phase, G2 phase and after DNA has been replicated in the S phase it checks for 
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damages. Again at the end of the M phase a checkpoint is available, which stops 
cytokinesis in case the chromosomes are not properly aligned on the mitotic spindle. 
Bertino et al., (2003) and Schwartz and Rotter, (1998), have further indicated that these 
check points allow proliferation to occur in the presence of stimulatory signals for 
instance growth factors and are also activated by DNA damage as well as mis-aligned 
chromosomes at the mitotic spindle. Accordingly cells that are not in the process of 
dividing are normally found in the G0 stage, and this includes most of the adult cells. In 
addition, Pucci et al., (2000), said  most cells remain in interphase, i.e. the period between 
cell divisions (comprising G1, S and G2 phases), for at least ninety percent of the cell 
cycle and that DNA repair genes are active throughout the cell cycle, particularly during 
G2 after DNA replication and before the chromosomes prepare for mitosis.  
 
Most anticancer drugs are designed to target different stages of the cell cycle so that the 
cell should not proceed through to the next stage. Some anticancer agents for instance, 
work in such away that they bind to DNA in the S phase of the cell cycle in order to stop 
DNA synthesis. Such agents include alkylating, anti-tumor antibiotics, platinum 
compounds and other miscellaneous agents (Gonzalez et al., 2001; Pasettoa et al., 2006). 
Since cells in G2 synthesize their components for cell division, other plant-derived 
anticancer agents in clinical use such as vinca alkaloids (vinblastine, vincristine, 
vinorelbine), docetaxol and paclitaxel target the microtubules to stop the cells from 
making spindles needed for mitosis (Jordan and Wilson, 2004). In particular, paclitaxel 
mainly interferes with the mitotic spindle assembly, which results in the failure of 
chromosomes to separate (Shah and Schwartz, 2006). For mitosis to take place, the cyclin 
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B1-CDK 1 complex (which is also called cyclin B1-cdc2 kinase), has to be initiated and 
once mitosis proceeds however, cyclin B is destroyed by ubiquitin-mediated-proteolysis. 
Shah and Schwartz, (2001) and (2006), have further reported that cyclin B and Cdc2 
kinase activity are directly related to paclitaxel function. Expression of cyclin B and the 
activation of CDK 1 occur with paclitaxel-induced apoptosis and destruction of cyclin B1 
can be inhibited by paclitaxel. On the other hand, the taxanes are known to stabilize the 
microtubules, and this causes a G2/M arrest, followed by apoptosis  (Cragg and Newman, 
2004, 2005 and Darwiche et al., 2007). Yet other anti-metabolites used as anticancer 
agents such as 6- mercaptopurine (6-MP), methotrexate, azathioprine, 6-thioguanine (TG) 
and 5-fluorouracil (5-FU) have been shown to target cells in the G1 phase in order to stop 
them from synthesizing nucleotides for DNA (Bertino et al., 2003). Another drug 
methotrexate (MTX), which is normally used in mixture with 5-fluorouracil and 
cyclophosphamide in the adjuvant treatment of breast cancer, works by interfering with 
the metabolic processes that are involved in the continued existence and reproduction of 
the cell. Methotrexate mainly targets cells that are rapidly growing and reproducing  (Bast 
et al., 2000; Su and Ciftci, 2002), and specifically, the drug binds to and deactivates 
dihydrofolate reductase (DHFR), a key enzyme necessary for DNA synthesis.  
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Figure1.14: Stages of the cell cycle (Adapted from Garber, 2001). 
 
 
             1.6 RHUS SPECIES. 
 
Rhus is a genus of woody shrubs and trees, which has spirally and pinnately arranged 
compound leaves, although some species have three leaflets. The flowers are in thick 
cluster or spikes 5-30 cm long, and each flower is very small, could be creamy white, 
greenish or red, with five petals. The fruit form thick clusters of reddish drupes, which are 
commonly called “sumac” (van Wyk et al., 2000). There are said to be roughly 250 
species of Rhus, which have been placed in the family Anacardiaceae. The name comes 
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from the Greek name for sumac, rhous, which means red, and this is probably because 
some species turn red in autumn. According to Moffett, (1993), some species of this genus 
such as poison ivy, poison oak and poison sumac have been placed in the genus 
Toxicodendron and have grayish-white fruit.  
 
          1.6.1.  Rhus laevigata. 
 
Rhus laevigata is a plant mostly found in subtropical and warm temperate regions of the 
world and is very common in South Africa especially in Western Cape (Watt, 1962).  The 
common names for Rhus laevigata are Rankataaibos, Duinetaaibos, Dune taaibos, in 
Afrikaans, Inhluti and Isihlakoti in Zulu (Low and Scott, 1983; Hutchings et al., 1996). 
This plant is a shrub of about 2 m and produces many branches and is mostly deciduous. 
Its leaves may either be hairy or smooth and are also divided into three leaflets, the middle 
one being large (about 40 x 25 mm). The veins of this plant are translucent when held up 
to the light and its flowers are unisexual, found on separate branches. The plant produces 
little fruits which are edible and a tasty juice can be made from them (Watt, 1962). 
 
1.6.2. Medicinal usage of Rhus laevigata 
 
Traditionally Rhus laevigata is used as a medicinal plant. As a medicinal plant, the leaves, 
bark and roots are used and some of the traditional uses include chewing of its leaves for 
chest colds and preparation of leaf decoctions for post partem problems (van Wyk et al., 
2000). Also milk infusions of leaves are administered as enemas for abdominal upsets in 
children (Hutchings et al., 1996). Again, the roots are claimed to be of therapeutic value in 
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infective disorders of the gastro-intestinal tract and also used as an anti-inflammatory 
medicine (van Wyk et al., 2000).  
 
Presently there is no data that indicates that extracts from Rhus laeivigata induce 
apoptosis in cancer cell lines. There is no data either to show that active compounds from 
Rhus laevigata have ever been isolated and identified. Traditionally reports only indicate 
that the plant is used for medicinal purposes such as colds, post partem problems and anti-
inflammatory medicines but there are no scientific reports, which prove these claims. 
Other studies have however, shown that extracts from Rhus verniciflua have inhibiting 
activities on human cancer cell lines (Lee et al., 2002, 2004; Lim. et al., 2003; Ko et al., 
2004; Son et al., 2005).   
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1.7  METALLO-COMPOUNDS IN CANCER TREATMENT. 
 
“Cytotoxic drugs" are drugs that can damage or kill cells specifically by inhibiting cell 
division and for this reason they are used as antineoplastic agents (Zhang, 2002 Sato et al., 
2005). The major cytotoxic drugs have been grouped into four general groups, namely, 
alkylating agents; antimetabolites; natural products and miscellaneous agents. Platinum 
compounds fit in the group of miscellaneous agents. However, platinum compounds can 
also be classified as alkylating agents because they act in a similar fashion as alkylating 
agents. Of the platinum agents currently available today, cisplatin cis-
diamminedichloroplatinum (II) is the most effective and extensively used anticancer 
chemotherapeutic drug (Trzaska, 2005). At the centre of this drug is an atom of the metal 
platinum.  It is these atoms that poison the cancer cells, by forming DNA adducts which 
are thought to be the primary cause of cisplatin cytotoxicity (Elwell et al., 2006). 
 
1.7.1 Platinum (II) Complexes and Cisplatin 
 
The development of metal-containing anticancer drugs started with cis-[PtCl2(NH3)2] 
which is often referred to as cisplatin. In spite of the fact that the compound was initially 
described in 1845, its anti-tumor activities were however, not discovered until 1964 
(Rosenberg et al., 1969). It is known to be particularly effective against solid tumors such 
as testicular, ovarian, head, neck and against small-cell lung cancer with a cure rate as 
high as 90% (Reedijk, 2003).  It has been found that cisplatin exhibits anti-tumor activity 
while its trans isomer does not show any activity (Reedijk and Lohman, 1985). 
Interestingly, minor variations in the structure of these ligands have shown to have 
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powerful effect on the anti-tumour activity and toxicities. Many studies with cisplatin 
trans-compounds have shown to be ineffective against solid tumors, while the cis-
counterparts have shown completely opposite results (Ciccarrelli et al., 1985; Brabec, et 
al, 2003).    
 
 
  Figure 1.16: Isomeric forms of diamminedichloroplatinum. 
 
           1.7.2. Cisplatin’s proposed mode of action 
Although cisplatin, cis-diamminedichloroplatinum (II), has been successfully used in 
chemotherapy treatment for more than 25 years, its biochemical mechanism of action is 
still unclear (Elwell et al., 2006), however, the drug is thought to induce cytotoxicity 
through binding to nuclear DNA forming cisplatin–DNA adducts (Jamieson and Lappard, 
1999), which activate multiple signalling pathways including those involving p53, Bcl-2 
family, 
caspases, cyclins, cyclin dependent kinases  (CDKs), protein kinase c  (PKC),  retinoblast
oma protein (pRb) mitogen activated  protein  kinase (MAPK)  phosphatidylinositol  3 kin
ase/protein kinase B  (PI3K/Akt)   and subsequent interference with normal transcription, 
and/or DNA replication mechanisms (Demarcq et al., 1994; Pasetto et al; 2006). If the cell 
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fails to process the cisplatin–DNA adduct, then cytotoxic processes eventually end up in 
the death of the cell (Areberg, 1999; Gonzalez et al., 2001). It is proposed that chlorine 
undergoes slow displacement with water molecules forming a positively charged 
molecule, which then cross links the DNA. Thus the drug needs to be administered in 
saline solution, to prevent inactivation (Alderdena et al., 2006). While the trans isomer 
does not have an anticancer effect, it is however, toxic and Alderdena et al., (2006), said 
that it is important to test every batch of cisplatin by HPLC to test for the absence of the 
trans isomer. 
 
Cancers treated with cisplatin however frequently develop resistance to cisplatin and 
many others show lack of sensitivity (Gonzalez et al., 2001). According to Gonzalez et al., 
(2001) and Alderdena et al., (2006), the limited effectiveness of cisplatin is due to many 
factors including: (a) a poor pharmacokinetic profile, (b) low accumulation in cells, (c) 
increased production of intracellular thiols (e.g. glutathione and metallothionein) (d) 
increased DNA repair capacity and (e) as cisplatin is administered intravenously due to its 
limited solubility in water accumulation of metal ions in the body can lead to harmful side 
effects including nausea, emetogenesis, hair loss, neurotoxicity (nerve damage), 
ototoxicity (hearing loss), nephrotoxicity (kidney damage), platelet reduction, 
myelosuppression, (the reduction of bone marrow function), angioedema, 
granulocytopenia, erythema, exfoliative dermatitis, facial edema, flushing, hyperhidrosis, 
rash, alopecia, hypomelanosis, anaphylaxis, gingival discolouration, injection-site 
cellulites, oral mucosal lesions, diarrhoea, anorexia and loss of appetite and taste which 
results in a patient finding it difficult to eat, among others (Kumar and Clark, 1990; Zhang 
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and Lippard, 2003; Brabec and Kasparkova, 2005; Elwell, 2006). These limitations have 
prompted a search for more effective and less toxic metal-based anti-tumor agents (Brabec 
and Kasparkova, 2005; Elwell, 2006). 
 
Fig. 1.17: Main adducts formed in the interaction of cisplatin with DNA (adapted from Gonzalez et 
al, 2001).(a), interstrand cross-link, (b), 1,2-intrastrand cross-link, (c), 1,3-intrastrand cross-link, (d), 
protein-DNA cross-link.  
     1.8 THE GOALS OF THIS PROJECT 
 
  The goals of this project are: 
1. As a herbal medicine Rhus laevigata is used as an anti-inflammatory. Basing 
on this claim there is no scientific evidence to show that the plant contains 
compound (s) which can induce apoptosis. The goal of this project is 
therefore aimed at carrying out biological assays on the crude extracts of 
Rhus laevigata and test the extracts for compound(s) that can induce 
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apoptosis in selected human, mouse as well as Chinese Hamster Ovary cell 
line.  
2.  Although cisplatin is the most effective agent against most solid tumors, 
however most cancers develop resistance to cisplatin and many are not 
sensitive at all to cisplatin treatment. The goal of this project is aimed at 
synthesizing new platinum and palladium complexes and biologically test 
them for their antineoplatic activities against a panel of cell lines.   
 To this end specific objectives will be:  
1. To screen the leaves of Rhus laeivigata for the presence of pro-apoptotic and 
anti-proliferative compound(s) (Natural products), with the potential of isolating 
and characterizing novel lead compound(s) which can be used in anticancer 
drugs discovery. 
2. To screen the newly synthesized platinum and  palladium  based complexes  for 
their antineoplastic activities against cancer cell lines and test the mechanisms 
underlying their apoptotic/biological activities with the potential of finding 
anticancer agents that can overcome the problems associated with cisplatin. 
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    CHAPTER 2: MATERIALS AND METHODS 
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2. 1 REAGENTS 
Chemical                                                               Supplier 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Burdick and Jackson 
Burdick and Jackson 
Sigma 
Merck 
Burdick and Jackson 
Roche 
Invitrogen 
Burdick and Jackson 
Sigma 
Burdick and Jackson 
Sigma 
Invitrogen 
Invitrogen 
Sigma 
Roche 
Roche 
Invitrogen 
Roche 
 
Sigma 
 
Invitrogen 
Chloroform 
Dichloromethane 
DMSO(dimethyl sulphoxide) 
Ethanol 
Ethyl acetate 
Foetal Calf Serum  
Ham’s F12  
Hexane  
L-glutamine 
Methanol  
Neutral red                                                                   
PBS without Ca2+/Mg2+ 
Penicillin-Streptomycin     
Propidium Iodide  
Proteinase K 
RNase 
RPMI medium 
Staurosporine 
Trypan blue 
Trypsin  
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2.1.1.  General solutions and Biochemical Assay kits 
 
Active caspase-3-FITC assay kit------------------------------------------ BD Biosciences 
Annexin V assay kit--------------------------------------------------------- BD Bioscience  
APO-Direct™ (TUNEL) assay kit. --------------------------------------- BD Bioscience  
APOPercentage ™ apoptosis assay kit------------------------------------ Biocolor Ltd 
PARP FITC Kit-------------------------------------------------------------- BD Bioscience 
Penicillin streptomycin 1%g/ml in culture media 
TMRE (Tetramethyl Rhodamine) kit------------------------------------- Invitrogen 
Trypan Blue Solution 0.4% in sterile ddH20 
Elution solution (50% EtOH/1% acetic acid) 
Neutral red dye 100%g/ml in serum free media pH 6.35 
PI (1mg/ml) in 3.8mM sodium citrate pH 7.0 
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2.2.  METHODS 
2.2.1. Tissue culture  
A vial of frozen cultured cells indicated in table 2.1 was taken from the -150oC freezer. 
The cells were quickly thawed in a water bath set at 37o C by submerging the lower half of 
the vial in the water to thaw only until a small amount of ice remained in the vial. The vial 
was then taken to the class II safety cabinet. Using a tissue paper moistened with 70% 
alcohol, the outside of the vial was wiped and the lid was loosened. The cells were then 
tipped into tissue culture flasks containing pre-warmed appropriate culture medium 
(Absher, 1973) per indicated in table 2.1. The culture media was supplemented with 10% 
FCS and streptomycin and penicillin was added at a concentration of 1%g/ml of culture 
media as indicated in general stock solution section. The flasks were properly labelled 
with the name of cell line and date of culture and incubated at 37o C, 5% CO2 humidified 
incubator over night. The following day the cells were inspected under inverted 
microscope to check for any signs of bacterial or fungal contamination and also to see 
how confluent the cells were. When the cells were not contaminated and not confluent 
enough, media was changed and cells were incubated for a further 12 hrs. When the cells 
were confluent, they were washed 1x with PBS without Ca2+/Mg2+ and trypsinized with 
0.125% trypsin. Upon addition of trypsin, the cells were incubated for 5 to 10 minutes. To 
see if the cells were detached and floating, the cells were examined under inverted 
microscope. If they were not detached, the flask was gently tapped on the side until the 
cells were completely detached and floating. Action of trypsinization was stopped by 
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addition of media containing FCS. The cells were then spun down and resuspended in 
trypsin free media.  
 
Apart from supplementing the media with 10% FCS and 1µg/ml penicillin and 
streptomycin, RPMI media used for culturing Jurkat cells was also supplemented with 
2mM L-glutamine and the rest of the procedure for growing cells from frozen culture as 
described above was followed.  
2.2.2.  Cell count  
 
Under sterile conditions, 100-200%l of the cell suspension was removed and mixed with 
an equal volume of Trypan Blue (dilution factor =2) and mixed by gentle pipetting. A 
haemocytometer counting chamber cover slip was moistened with water then slid over the 
chamber back and forth using slight pressure until Newton’s refraction rings appeared. 
Newton’s refraction rings are seen as rainbow like rings under the cover slip. Both sides of 
the chamber were properly filled with 10µl of the sample without overfilling or under 
filling. The cells were then viewed under a light microscope using the 10X ocular (and a 
10X objective) magnification. Cells were counted in each of the 10 squares (1 mm2 each).  
If over 10% of the cells were clumped, the entire sequence was repeated.  If fewer than 
200 or more than 500 cells were present in the 10 squares, a repeat with a more suitable 
dilution factor was done. Cells that touched the middle lines (of the triple lines) to the left 
and top of the square were counted, but those which were similarly located to the right and 
bottom were not counted.  
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2.2.3.  To calculate number of cells 
 
The hemacytometer consists of two chambers, each of which is divided into nine 1.0mm 
squares. A cover glass is supported 0.1 mm over these squares so that the total volume 
over each square is 1.0 mm x 0.1 mm or 0.1 mm3, or 10-4 cm3.  Since 1 cm3 is 
approximately equivalent to 1 ml, the cell concentration per ml will be the average count 
 per square x 104. To calculate the number of cells per ml, and the total number of cells in 
the original culture:  Therefore cells/ml = average count per square x 104 
Total cells = cells per ml (from above) x any dilution factor x total volume of cell 
preparation from which the sample was taken. 
NOTE: The correction factor of 104 converts 0.1mm3 to 1ml (0.1mm3 = 1mm2 x 0.1mm).  
To calculate the required number of cells per required volume. 
 
The required number of cells was multiplied by the required volume and then divided by 
the original concentration of the sample. Note that this formula works better if the 
concentration of the original sample is higher than the required concentration. 
E.g. if 10mls of cell culture was required and 2.5x104 cells per ml were required but the 
original sample contained 2.8x106 cells per ml:  
Required volume=10mls 
Required concentration=2.5x104 cells per ml 
Original concentration=2.8x106 
Therefore:     2.5x104 x 10mls       =8.9mls 
                      2.8x106    
 
Which means 8.9mls from the original 2.8x106 cells/ml will be withdrawn and made up to 
10mls with media to have a concentration of 2.5x104cells /ml. 
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2.2.4.  Cryo-preservation of cell lines. 
  
 
Freezing of cells was carried out as follows: Cells were viewed using an inverted 
microscope to assess the degree of cell density and confirm the absence of bacterial and 
fungal contaminants. Once the cells approached the required confluency and that they were 
free from bacterial or fungal contamination, they were washed with PBS and then 
incubated for 5-10 minutes with 5ml of 0.125% trypsin if cells were grown in 25 cm2 flask 
or 10mls if 75cm2 flask was used. Trypsinization was stopped by the addition of 1ml 
culture medium. Cells were recovered by aspiration and transferred into a centrifuge tube. 
The tube was centrifuged for 2 minutes at 200xg in a bench top centrifuge. The supernatant 
was discarded and cell pellet was re-suspended in a solution of 90% FCS and 10% DMSO. 
A small aliquot of cells (100-200µl) was removed and a cell viability count performed. If 
the cell viability was in excess of 90% the cells were frozen, if not the cells were discarded 
and a new culture was grown. This was done so as to achieve a good recovery after 
freezing. Cryo-vials were labelled with date of freezing, name of cell line, media in which 
the cell line was grown and the name of the person freezing the cells.  The cells were then 
dispensed into 1ml aliquots in the labeled cryo-vials at a concentration of 2.4x106 cells per 
ml and were frozen at –1500 C. Before freezing, another aliquot of 50-100 µl was removed 
from the tube and cultured as a quality control to assess if the vials being frozen were free 
from contamination. The cells for quality control were grown for 24-48hrs. If the cells were 
found to be contaminated, the vials were withdrawn from the freezer and discarded. 
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                 Table 2.1: Cell lines used, media and supplements used in this study. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CELL LINE SPECIES 
MEDIA SUPPLEMENTS 
Hek 293T  
(Renal epithelial) 
Human DMEM 
Foetal Calf serum,   
Penicillin/Streptomycin 
MG-63 
(Osteogenic Sarcoma) 
Human DMEM 
Foetal Calf serum,   
Penicillin/Streptomycin 
CaSki  
(Cervical Cancer) 
Human DMEM 
Foetal Calf serum,  
Penicillin/Streptomycin 
CHO 
(Chinese Hamster 
Ovary) 
Chinese 
Hamster 
F-12Ham Foetal calf serum, 
Penicillin/Streptomycin 
HeLa (Cervical 
Adenocarcinoma) 
Human DMEM Foetal calf serum, 
Penicillin/Streptomycin 
H157 (Non small cell 
Lung carcinoma) 
Human RPMI Foetal Calf serum,   
Penicillin/Streptomycin 
MCF-7  
(Breast 
adenocarcinoma) 
Human DMEM Foetal Calf serum,  
Penicillin/Streptomycin 
Jurkat 
(Leukemia, cells) 
Human RPMI Foetal calf serum, Penicillin, 
Streptomycin, 2mM L-
glutamine 
3T3 (Embryonic 
Fibroblast) 
Mouse DMEM Foetal Calf serum,  
Penicillin/Streptomycin 
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2.3.  STUDY METHODOLOGY  
 
2.3.1. Preparation of plant material and crude extracts 
 
The study methodology on the natural products was done as outlined in figure 2.1  
2.3.1.1. Aqueous/Polar Extraction 
Plants were collected from the nature reserve of the University of the Western Cape with 
the help of a botanist who helped to identify and name the plants. The plants were taken to 
the laboratory where the leaves of the plants were washed properly using distilled water 
and were divided into two parts (figure 2.2). One part was left to dry while the other part 
was immediately grounded to powder. To maximize extraction, the ground material was 
soaked in water for 24 hrs while stirring. After 24 hrs of soaking and stirring the 
plant/water mixture was filtered and the plant material was discarded. The water extracts 
were poured in 50ml tubes and then frozen over night at -80 °C or were frozen using liquid 
nitrogen. After freezing, the plant extracts were further dehydrated with the freeze dryer. 
A dry powder was obtained, and weighed. The same procedure was carried out on the 
dried plant material and the powder obtained from the dried and fresh plant materials were 
mixed. To avoid the samples from absorbing moisture, the samples were kept in glass-
covered bottles with desiccators. Standard concentrations were made from the powder 
dissolved in appropriate solvent. 
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Collection and identification of plants                                               
 
Preparation of aqueous extracts from the leaves of the plants     Assay for 
apoptosis 
                                                    
Organic solvent extraction from the leaves of the plants        Assay for apoptosis 
 
HPLC fractionations               Assay for apoptosis 
 
               Characterization of active  compound 
 
 
         Figure 2.1: Flow chart of the methodology used in the bioassay-guided fractionation. 
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Figure 2.2: Schematic overview of the preparation of aqueous extracts from the leaves of 
the plants. 
 
             2.3.1.2. Organic/Non polar extraction 
Organic extraction was performed as shown in figure 2.3 below. 
Preparation of Material 
1. Wash plant material with distilled water 
2. Dry one part 
3. Grind/blend both fresh and dried plant material 
Extraction 
        4. Soak plant material while stirring overnight using a stir bar. 
Filtration 
5. Filter through Buchner funnel with filter paper 
under vacuum pressure and discard unextracted 
material. 
Concentration of Extract 
6. Dry the filtrate using freeze dryer. 
7. Weigh obtained powder and dissolve to appropriate 
concentration in water. 
Bioassays  
8. Induce cells with various concentrations of the crude  
aqueous extracts prepared from standard concentration. 
           9.   Carry out bioassays. 
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Figure. 2.3: Organic/non polar extraction protocol overview.  The ground plant material was first 
soaked in hexane, which is used to remove non-polar high molecular weight substances/compounds 
Preparation of Material 
1. Wash plant material with distilled water 
2. Dry one part 
3. Grind/blend both fresh & dry to powder 
Non-polar Extraction 
4. Soak plant material in hexane and stir  
overnight with magnetic stir bar 
Filtration 
5. Filter through Buchner funnel with filter 
paper under vacuum pressure and DO NOT 
discard un extracted plant Material. 
 
     Further Extraction 
8.Soaked plant material in organic solvents of increasing polarity to the un 
extracted plant material and proceeded with the same procedure as above. 
(Chloroform, dichloromethane (DCM), ethyl acetate, ethanol, methanol) and 
lastly water.  Stirred overnight with magnetic stir bar. Organic filtrates were 
dried in rotary evaporators and water filtrate in freeze dryer. Carried out 
bioassays using standard concentrations from obtained powder. 
 
Concentration of Extract 
6. Dry the filtrate using vacuum (rotary evaporator) 
7. Weigh obtained powder and redissolve to 
appropriate concentration in organic solvent 
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such as oils, chlorophyll etc. The mixture was stirred overnight. Following soaking, the mixture was 
then filtered. The procedure was repeated three times and the filtrates obtained were combined. 
Following the same procedure, chloroform, ethyl acetate, dichloromethane, methanol and lastly 
water were added in sequence to the plant material and filtered. All filtrates obtained using organic 
solvents were dried by vacuum dryer while the water filtrates were dried using the freeze dryer 
(Lyntagaye, 2005).  
 
2.4. METALLO-COMPOUNDS (ALKYLATING AGENTS). 
 
The palladium and platinum complexes used in this study were synthesized by F. Keter 
University of Johannesburg, Department of Chemistry who prepared the complexes 
following the procedures described by Darkwa et al., (2002) with minor changes. All 
commercial chemicals and other reagents, other than those described by Darkwa et al., 
(2002), were used as received and manipulations of air and/or moisture sensitive 
compounds were performed under dry, deoxygenated nitrogen atmosphere, using Schlenk 
techniques. 
The following complexes (figures 2.4, 2.5, 2.6) were synthesized and were assigned 
numbers 15 (a palladium based complex), 57 (a palladium based complex) and 58 (a 
platinum based complex). 
 
2.4.1. Dissolving metallo-compounds 
The metallo compounds did dot dissolve in water but were soluble in dimethyl sulfoxide 
(DMSO). Stock solutions were prepared in DMSO and working concentrations were 
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diluted in culture media at less than 0.1% DMSO final concentration  (Lippard; 1987; 
Souktani et al., 2000; Ansar and Ansari, 2006). 
 
 
N NH
NHN
Pd
Cl
Cl
15  
 Figure 2.4: Synthesized complexes: Dichloro-bis (3,5-di-tert-butyl-1H-pyrazole) 
palladium (II), a palladium complex assigned complex 15.   
N N
OH
NN
OH
Pd
Cl
Cl
57  
 
Figure 2.5:  Dichloro-bis(3,5-di-methyl-hydroxymethyl-pyrazole)palladium(II) 
assigned complex 57. 
 
 
 
 
 
  80 
N N
OH
NN
OH
Pt
Cl
Cl
58
 
 
 
 
Figure 2.6:  Dichloro-bis(3,5-dimethyl-1-hydroxymethyl-pyrazole)platinum(II) 
assigned complex 58. 
 
 
2.5.  BIOASSAYS 
2.5.1.  Morphological evaluation  
 
Different cell lines shown in table 2.1 were cultured in 6 well culture plates to 90 % 
confluency. The cells were induced to undergo apoptosis with 0.5mg/ml and 0.25mg/ml of 
the crude plant methanol extract. As for the metallo-compounds 0.5mM of the metallo-
compounds were used to induce the cells to undergo apoptosis while negative control cells 
were left without inducement. The cells were incubated for 24 hrs at 37°C in 5% 
humidified incubator. Following incubation, the cells were inspected under an inverted 
(Nikon) light microscope using 20X objective and pictures were taken using a Leica EC3 
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digital camera. The morphology of the cells was evaluated and recorded as per 
recommendations by Fink and Cookson, (2005), Kroemer et al., (2005; 2007).  
 
2.5.2. Measurement of cell surface modifications (externalization of PS) using 
APOPercentage
™ 
apoptosis assay measured by colorimeter. 
 
Cells at a density of 2.5x104 cells per ml were prepared and 100µl was added in 
triplicate wells of 96 well culture plates and were let to grow to 90% confluence. 
When the cells reached the required confluency, the culture media was removed 
and replaced with media containing various concentrations of crude plant extracts, 
which ranged from 0.5mg/ml to 0.063mg/ml. The cells were incubated for 24 hrs at 
37oC in a humidified CO2 incubator. Thereafter, the cells were gently washed off 
twice with 200µl of PBS and immediately replaced with APOPercentage™ dye in 
complete culture media diluted 1:20. The cells were further incubated for 1hr at 
37oC in a humidified CO2 incubator as per manufacture’s manual. After a one-hour 
incubation period, the cells were washed twice with 200µl of PBS then inspected 
under an inverted Nikon microscope. The dye trapped inside the cells was released 
by addition of 100µl of dye release reagent as described in APOPercentage™ 
manual and Johnson et al., (2003). The plates were further incubated for ten 
minutes at room temperature. The bound dye recovered into solution was 
quantified by reading the plates with a plate reader at 560nm wavelength. The 
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results were plotted on linear graphs with absorbance on Y-axis and concentrations 
on X-axis. 
 
2.5.3. Measurement of cell surface modifications (externalization of PS) using 
APOPercentage'apoptosis assay measured by Flow cytometer. 
 
After cells were grown to 90% confluence in 6 well culture plates, they were treated with 
various concentrations of the plant crude extracts and metallo-compounds for 24 hrs.  
Staurosporine was used as a positive control for cells induced with the plant crude 
extracts. Positive control cells were treated with 1.0µM staurosporine for 3 hrs. The 
positive control cells were induced with staurosporine 3 hrs before the end of the 24 hrs of 
inducing the cells with the plant extracts. This was so because staurosporine induced cells 
were apoptotic within three hrs of induction. This was consistent with other studies 
(Belmokhtar et al., 2001 Zhang et al., 2004). It was within this 3 hrs time period that the 
flip-flop mechanism of PS occurred (Bratton et al., 1997) and APOPercentage' was 
positive. Inducing the cells with staurosporine for more than 6 hrs however, did not give 
good positive results. This was probably because translocation of the PS had already 
occurred and therefore the results appeared negative for APOPercentage'. On the other 
hand cisplatin was used as a positive control for the metallo-compound treated cells. The 
cells were induced for 24 hrs with 0.5mM cisplatin. The cells were induced for 24 hrs 
because APOPercentage' showed good positive results at 24 hrs of induction. Hence it 
was used as optimal time for inducing the cells with cisplatin. This was also consistent 
with other studies (Choi et al., 2001; Jirsova et al., 2006;). Negative control cells were 
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however, left untreated for 24 hrs so that they could be used to properly distinguish 
normal cells from apoptotic cells. Following incubation, floating (apoptotic) cells were 
transferred to 15ml centrifuge tube and the adherent cells were trypsinized and mixed with 
the tube containing the floating cells. The cells were washed two times with PBS, and 
resuspended in the residual PBS. APOPercentage' dye in complete culture media diluted 
1:160 was prepared. 250µl of the dye was added to the tube and the cells were incubated 
for 30 minutes at 37oC in a humidified CO2 incubator. After the incubation period, 500µl 
of PBS was added to the tube and spun down for 5 minutes at 300xg. The pellet was 
washed one more time with PBS. After which the pellet was resuspended in 400µl of PBS 
and the cells were acquired and analyzed on a FASCanTM (Becton Dickson) instrument 
equipped with a 488 nm Argon Laser as a light source within one hour.  Acquisition was 
done by setting forward scatter (FSC) and side scatter (SSC) on a log scale dot plot to 
differentiate population of cells and cellular debris. On a linear histogram dot plot, 
APOPercentage' (FL-3 channel) was measured against relative cell numbers. Negative 
control cells were used to set the cells in the negative quadrant before all samples were 
acquired.  A minimum of 10,000 cells per sample was acquired and analyzed using 
CELLQUEST Pro software by setting the non stained (untreated) cell population in the 
first quadrant (101) of the forward side scatter histogram dot plot and cells which appeared 
in the second (102) or third quadrant were regarded APOPercentage TM 
positive (apoptotic/necrotic).  
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2.5.4. Measurement of cell surface modifications (externalization of PS) 
confirmed by Annexin V-PE labeling measured by FACS. 
 
Cells were cultured at a concentration of 2.5x104 cells per ml in 24 well tissue culture 
plates at 37oC in a humidified CO2 incubator for 24 hrs. The cells were then induced to 
undergo apoptosis with various concentrations of the crude plant extract and the metallo-
compounds for 24 hrs. Positive control cells for the crude plant extracts were induced to 
undergo apoptosis with 1.0µM staurosporine for 3 hrs while the positive control cells for 
the metallo-compounds were induced to undergo apoptosis with 0.5mM cisplatin for 24 
hrs as previously indicated. Negative control cells were left untreated for 24 hrs. 
Following treatment, the culture supernatant containing apoptotic floating cells was 
transferred into a 15 ml tube. The adherent cells were gently washed once with 1000µl 
PBS trypsinized with 500µl of 0.125% trypsin and incubated for 5-10 minutes at 37oC in a 
humidified CO2 incubator. When the cells were detached, 500µl of complete culture 
media was added to the cells to stop the action of trypsinization, and then the cells were 
transferred into 15ml tube containing the floating apoptotic cells and the tube was 
subjected to centrifugation. The pellet was washed twice with 1ml cold PBS and 
resuspended in 1x binding buffer at a concentration of ~1.0x106 cells per ml.  After 
mixing the cells properly 100µl (~1.0x105 cells) was transferred into a 5ml FACS tube 
then 5µl of Annexin V-PE was added to the tube and gently vortexed.  The tube was 
incubated for 15 minutes in the dark at RT.  Five minutes before the completion of the 
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incubation, 5µl of 7-amino-actinomycin D (7-AAD) was added to the tube and also gently 
vortexed. To the mixture 400µl of 1x Annexin V binding buffer was added and the cells 
were acquired and analyzed on a FASCan' (Becton Dickson) instrument equipped with a 
488 nm Argon Laser as a light source within one hour as per manufacture’s directions and 
Vermes, (1995). Acquisition was done by setting Forward scatter (FSC) and side scatter 
(SSC) on a log scale dot plot to differentiate normal, early apoptotic, late apoptotic cells 
from cellular debris. Cell fluorescence was measured by using both the FL1 channel (7-
ADD) and FL2 channels (Annexin-V-PE).  On a histogram dot plot, Annexin-V–PE (FL-
2) was measured against relative cell numbers on a linear scale. Negative control cells 
were used to set the cells in the negative quadrant before all samples were acquired. A 
minimum of 10,000 cells per sample was acquired and analyzed using CELLQUEST Pro 
software. 
 
2.5.5. Measurement of Mitochondria membrane potential (!#) using TMRE.  
 
Cells were seeded at a density of 2.5x104 cells per ml in 24 well culture plates and were 
incubated at 37oC in a humidified CO2 incubator for 24 hrs. The culture media was then 
removed and replaced with media containing various concentrations of methanol extract 
of the plant or the metallo-compounds. The cells were incubated for various time points, 
in a humidified CO2 incubator. Thereafter, the cells were gently washed once with 1000µl 
PBS. The cells were then trypsinized with 500µl of 0.125% trypsin, and incubated for 5-
10 minutes at 37oC in a humidified CO2 incubator. When the cells were detached, 500µl of 
complete culture media was added to the cells to stop the action of trypsinization, and then 
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the cells were transferred into 15ml tubes and centrifuged for 5 minutes at 300xg. The 
pellet was washed twice with 1ml cold PBS and resuspended in 1x binding buffer at a 
concentration of ~1.0x106 cells per ml.  After mixing the cells 100µl (~1.0x105 cells) of 
cell suspension was transferred into a 5ml FACS tube and stained with 1ml of TMRE and 
incubated for 30 minutes at room temperature in the dark. TMRE was reconstituted in 
DMSO at a stock concentration of 50mM (Jayaraman, 2005). From the stock 1.3µl was 
withdrawn and added to 13mls complete culture media. (1:10,000). After incubation, the 
cells were acquired and analyzed on a FASCan™ (Becton Dickson) instrument equipped 
with a 488 nm Argon Laser as a light source. Acquisition was done by setting the Forward 
scatter (FSC) and side scatter (SSC) on log dot plot to differentiate population of cells and 
cellular debris. On a linear histogram dot plot, TMRE (FL-1 channel) was measured 
against relative cell numbers. Negative control cells were used to set the cells in the 
negative quadrant before all samples were acquired. A minimum of 10,000 cells per 
sample was acquired and analyzed using CELLQUEST Pro software. 
 
2.5.6. Measurement of caspase-3 activity.  
 
In this assay, cells were seeded at a density of 2.5x104 cells per ml in 24 well culture plate 
and were incubated at 37oC in a humidified CO2 incubator for 24 hrs. The culture media 
was then removed and replaced with media containing 0.5mg/ml of crude methanol extract 
of the plant and 0.5mM of the metallo-compounds. The cells were incubated for 24 hrs at 
37oC in a humidified CO2 incubator.  Positive control cells for the plant extract were 
induced with 1.0µM staurosporine for 3 hrs only since staurosporine induced the cells to 
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apoptosis within a short time while cisplatin induced positive control cells for the metallo-
compounds were induced with 0.5mM cisplatin for 24 hrs. Negative control cells received 
no treatment. Thereafter, the culture supernatant containing apoptotic-floating cells was 
transferred into a 15 ml tube. The adherent cells were gently washed once with 1000µl PBS 
trypsinized with 500µl of 0.125% trypsin and incubated for 5-10 minutes at 37oC in a 
humidified CO2 incubator. When the cells were detached, 500µl of complete culture media 
was added to the cells to stop the action of trypsin, and then the cells were transferred into 
the 15ml tube containing apoptotic cells and centrifuged to a pellet at 300xg for 5 minutes. 
The pellet was washed twice with 1ml cold PBS and resuspended in 0.5ml 
Cytofix/Cytoperm' at a concentration of ~1.0x106 cells/ml then incubated on ice for 20 
minutes.  After incubation on ice, the cells were spun down in a bench top centrifuge for 
two minutes at 2000xg. The Cytofix/Cytoperm' was aspirated and discarded and pellet 
washed twice with 0.5ml Perm/Wash' buffer at room temperature. Total number of 
samples was determined and the amount of Perm/Wash buffer and antibody calculated so 
that each sample received 100µl Perm/Wash' buffer and 20µl Antibody. The cells were 
incubated for 30 minutes at room temperature in the dark. At the end of the incubation 
period, the cells were washed twice in 1.0ml of Perm/Wash' buffer. The supernatant was 
discarded and the pellet resuspended in 0.5ml Perm/Wash' buffer by flicking the tube 
(Fujita and Tsuruo, 1998). The cells were acquired and analyzed on a FASCan' (Becton 
Dickson) instrument equipped with a 488 nm Argon Laser as a light source.  Using dot plot 
cell fluorescence was measured by setting the Forward (FSC) and Side Scatter (SSC) to 
differentiate cell populations and cell debris. On a log histogram dot plot, FL1 channel 
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(Active Caspase-3 FITC) was measured against relative cell numbers. Negative control 
cells were used to set the cells in the negative quadrant before all samples were acquired. A 
minimum of 10,000 cells per sample was acquired and analyzed using CELLQUEST PRO 
Software (BD Biosciences). 
 
2.5.7.  DNA Fragmentation detected by APO-DIRECT'
  
 
Cells were seeded at a density of 2.0x106 cells per ml in 6 well culture plates and were let 
to grow to 80% confluence incubated at 37oC in a humidified CO2 incubator. When the 
cells had reached the required confluency, the culture media was removed and replaced 
with media containing 0.5mg/ml of crude methanol extracts of the plant. The cells were 
induced with the crude extracts for 36 hrs at 37oC in a humidified CO2 incubator. The 36 
hrs time was chosen because DNA fragmentation is a late event and usually occurs at later 
time points occurring mostly after loss of cell viability (Collins et al., 1997; Pang and 
Geddes, 1997). Therefore it was necessary to check DNA fragmentation at a later time 
point and see if apoptosis occurred because at lower time points little or no DNA 
fragmentation occurred. Again necrosis cell death is usually an early event and can also 
result in DNA strand breaks. However, morphological evaluations coupled with DNA 
fragmentation results were necessary in aiding to know whether this was apoptosis or 
necrosis cell death. Positive control cells for the plant extract were induced with 1.0µM 
staurosporine for 6 hrs incubated at 37oC in a humidified CO2 incubator. Positive control 
cells for the metallo-compounds were induced with 0.5mM cisplatin for 24 hrs 37oC and 
were also incubated in humidified CO2 incubator. Negative control cells received no 
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treatment. Thereafter, the culture supernatant containing apoptotic-floating cells was 
transferred into a 15 ml tube. The adherent cells were gently washed once with 1000µl 
PBS, trypsinized with 2000µl of 0.125% trypsin, and incubated for 5-10 minutes at 37oC 
in a5 % humidified CO2 incubator. When the cells were detached, 500µl of complete 
culture media was added to the cells to stop the action of trypsinization, and then the cells 
were transferred into the 15ml tube containing the apoptotic floating cells and the tube 
was subjected to centrifugation for 5 minutes at 300xg. The pellet was washed twice with 
1ml cold PBS and resuspended in residual PBS. To fix the cells, the cell suspension was 
resuspended in 5mls of 1% (W/V) paraformaldehyde in PBS and placed on ice for 15 
minutes. Following the fifteen minutes incubation on ice, the cells were centrifuged for 5 
minutes at 300xg and the supernatant discarded. The pellet was washed twice with PBS 
and resuspended in 0.5ml PBS. After which the cell suspension was added to 5mls of ice-
cold 70% (v/v) ethanol in order to permeabilize the cells.  For proper permeabilization, the 
cells were stored at –200C for 48 hrs prior to staining. After permeabilization, the cells 
were pelleted by centrifuging the tube for 15 minutes at 300xg and the alcohol was 
removed by aspirating being careful not to disturb the cell pellet. The pellet was washed 
twice with wash buffer as provided for in the kit. Thereafter 50µl of staining solution also 
provided in the kit was added to the tube and incubated at 37oC for 4 hrs. At the end of the 
incubation time, 1.0 ml of rinse buffer was added to each tube and centrifuged for 300xg 
for five minutes. Supernatant was removed and discarded. This procedure was repeated 
then 1.0ml of PI/Rnase A (which was provided in kit) solution was added to the cell pellet 
and incubated for 30 minutes at room temperature. The cells were acquired and analyzed 
in PI/Rnase A solution on a FASCan' (Becton Dickson) instrument equipped with a 488 
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nm Argon Laser as a light source.  Using dot plot cell fluorescence was measured by 
setting the Forward (FSC) and Side Scatter (SSC) to differentiate cell populations and cell 
debris. Two dual parameter and two single parameter displays were created.  A gated 
standard dual parameter display was done by displaying DNA area signal on the Y-axis 
and the DNA width display on X-axis. Also DNA (Linear Red Fluorescence) was 
displayed on the X-axis and the FITC-dUTP (Log Green Fluorescence) on the Y-axis. 
Two single parameter–gated histograms, DNA and FITC-dUTP were displayed.  Negative 
control cells were used to set the cells in the negative quadrant before all samples were 
acquired. A minimum of 10,000 cells per sample was acquired and analyzed using 
CELLQUEST PRO Software (BD Biosciences). 
 
2.5.8. Cellular viability using Neutral Red Uptake (NRU) assay: Non-Adherent 
Cells (NAC). 
 
Cells were seeded in 24 well culture plates at a concentration of 2.4(105 cells/ml and 
incubated overnight at 37oC in a humidified CO2 incubator. The cells were then treated 
with increasing concentrations of the samples for 24 hrs while negative control cells were 
left untreated also for 24 hrs following which the cells were microscopically assessed for 
morphological alterations. Since the cells were non adherent, they were transferred to 
15ml tubes and spun down at 300xg for 5minutes. Media containing the test compounds 
was aspirated and then cells washed twice with Phosphate Buffered Saline (PBS). Neutral 
red dye was prepared as described in section 2.1.1. Following dye preparation 1ml of the 
dye was added to each tube and cells were incubated for 2-3 hrs at 37°C in 5% humidified 
incubator. The cells were then washed twice with PBS and spun down to a pellet. The 
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supernatant was decanted completely. Then 350µl of elution solution prepared as 
indicated in section 2.1.1 was added to each tube. The tubes were shaken to solubilize the 
dye. 100µl from each tube was transferred into triplicate wells of a 96 well culture plate. 
Using a microplate reader, sample absorbance was read at 540nm. To exclude background 
reading, three wells were seeded with untreated cells which were not stained with the dye 
while three other wells were seeded with untreated cells but were later stained with the 
dye. Results were expressed as a percentage of the untreated controls. Each sample was 
tested three times. On a linear scale graph, percentage absorbance values of each sample 
were plotted on Y-axis against concentrations on the X-axis. IC50 of each sample was 
determined from the graphs and averages calculated. Standard error of the mean of the 
three independent experiments were further calculated  (Babich and Borenfreund, 1991; 
Rixe et al., 1996; Fotakis and Timbrell, 2005).  
 
2.5.9.  Cellular viability using Neutral Red Uptake (NRU) assay: Adherent 
cells. 
 
 
Cells were prepared at a concentration of 2.4x105 in a 50 ml centrifuge tube from which 
100µl was withdrawn and transferred into triplicate wells of 96-well plates. The cells were 
left to form a sub-confluent monolayer. As usual before commencement of the 
experiment, the cells were inspected under inverted microscope for confluency and any 
possible contaminations. Cells in triplicate  wells were then induced to undergo apoptosis 
with increasing concentrations of the test compounds and negative control were left 
untreated for 24 hrs at 37°C in 5% humidified incubator. Following incubation, all wells 
were washed twice with PBS to remove the test compounds. Then 100µl of Neutral Red 
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dye in serum free media as indicated in section 2.1.1 was added to each well and plates 
were incubated for 2-3 hrs at 37oC. Thereafter the cells were washed twice with PBS, and 
then evaluated microscopically for morphological alterations and dye uptake. PBS was 
then completely decanted from all the wells by gently blotting the plates over tissue paper 
then100µl of elution solution was added to each well. The plates were shaken on a shaker 
for 10 minutes to release the dye. The absorbance values were read at 540nm with a 
microplate reader. To exclude background reading, three wells were seeded with negative 
cell which were not stained with the dye while three other wells were seeded with 
negative cells which were stained with the dye. Results were expressed as a percentage of 
the untreated controls. Each sample was tested three times. On a linear scale graph 
percentage absorbance values of each sample were plotted on Y-axis against 
concentrations on the X-axis. IC50 of each sample was determined from the graphs and 
averages calculated. Standard error of the mean of the three independent experiments were 
further calculated  (Rixe et al., 1996; Fotakis and Timbrell, 2005).  
 
2.5.10.  Cell cycle analysis  
 
 
The ethanol-based fixation technique offers an excellent CV for DNA analysis. 
(Darzynkiewicz, 1990). It is one of the methods used to detect DNA fragmentation. Using 
cell cycle analysis HeLa cells were tested for DNA fragmentation. HeLa cells were seeded 
in 6 well plates at 2.0x104 cells per ml and were grown to 90% confluence. Upon 
inspection and observance that the cells were free from contamination and that they had 
reached the required confluency, they were treated with 0.5mM of complexes 15 
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(palladium based complex), and 58 (platinum based complex) and incubated for 3hrs, 
6hrs, 12hrs, 24hrs and 36hrs at 37°C in 5% humidified incubator.   At the end of each time 
point, apoptotic floating cells were transferred into a 15ml centrifuge tube and the 
adherent cells were trypsinized and transferred to the same tube containing floating 
apoptotic cells. The cells were washed twice with PBS and centrifuged to a pellet. 
Thereafter the pellet was resuspended in 200µl of PBS and then fixed by the addition of 
cold 70% ethanol drop wise to avoid cell aggregation. Then the samples were left at -200C 
for 48hrs. After that, the samples were centrifuge at 250xg for 10 min at 4oC and washed 
twice with cold PBS. 250 %l of 500 units/ml Rnase A in PBS with 1.12% sodium citrate 
was added to the cell pellet. Vortexed gently and incubated at 37oC for 30 minutes. 
Samples were then stained with 100 µg/mL PI solution. Final PI concentration in the test 
mixture was 50 µg/mL. The samples were incubated at room temperature in the dark for at 
least 30 minutes then acquired and analyzed on a Flow cytometer (Becton Dickson) 
instrument equipped with a 488 nm Argon Laser as a light source.  Using dot plot, cell 
fluorescence was measured by setting the Forward (FSC) and Side Scatter (SSC) to 
discriminate cell populations and cell debris. Two dual parameter and two single 
parameter displays were created.  A gated standard dual parameter display was done by 
displaying DNA peak signal on the Y-axis and the DNA width displayed on X-axis dot 
plot while DNA content was displayed on linear histogram dot plot. Negative control cells 
were used to set the cells in the negative quadrant before all samples were acquired. A 
minimum of 10,000 cells per sample was acquired and analyzed using CELLQUEST PRO 
Software (BD Biosciences). 
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2.5.11.  PARP-1 cleavage.  
 
 
Cells were cultured at a concentration of 2.5x104 cells per ml for 24 hrs in 6 well tissue 
culture plates at 37°C in 5% humidified incubator. The cells were then treated with the 
crude methanol plant extract while negative control cells were left untreated and cultured 
for 24 hrs at 37°C in 5% humidified incubator.  Positive control cells were treated with 
1.0µM staurosporine for 4 hrs. Caspases are one of the major initiators of the apoptosis 
pathway components followed by the cleavage of their substrates. As reviewed in section 
1.5.2, PARP-1, is mostly involved in DNA repair, stability and other cellular events, and is 
cleaved by members of the caspase family during early apoptosis. PARP being a DNA-
binding protein specifically distinguishes DNA strand breaks, which are produced by 
genotoxic agents. PARP-1 measurement can be said to be one of the hallmark of apoptosis 
as it indicates that caspases are activated. If PARP-1 signal can be sustained, it can be 
measured even in late stages of apoptosis (Tong et al., 2001; Süsse et al., 2004; Riedl and 
Shi, 2004).  The 4 hrs time period for inducing the positive control cells was chosen as an 
optimal time to see if members of the caspase family activated PARP-1 early in the 
apoptosis pathway (an early marker of apoptosis). Upon treatment, cells were washed twice 
with PBS then fixed with 500µl Cytofix/cytoperm for 30 minutes at room temperature. 
Thereafter the cells were spun down and cytofix/cytoperm aspirated and the pellet was 
further resuspended in 250µl of cytofix/cytoperm (Gobeil et al 2001). The cells were then 
stained with 2µl PARP-FITC for 1 hr in the dark at room temperature. At the end of 
incubation, the cells were washed twice with Perm/Wash buffer, resuspended in 400µl 
Perm/Wash and analyzed by Flow Cytometry by setting the Forward (FSC) and Side 
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Scatter (SSC) on a dot plot to discriminate cell populations and cell debris. On a log 
histogram dot plot, FL3 channel was measured against relative cell numbers. Negative 
control cells were used to set the cells in the negative quadrant before all samples were 
acquired. Aminimum of 10,000 cells per sample was acquired and analyzed using 
CELLQUEST PRO Software (BD Biosciences). 
CHAPTER THREE: SCREENING OF EXTRACTS FROM THE LEAVES OF 
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 3.1 Screening of various plant aqueous extracts for their pro-apoptotic and 
 anti-proliferative activities.   
 
 For screening purposes CHO cells were used as model. Aqueous extracts of various 
plants with various concentrations were used to induce apoptosis in CHO cells. 
APOPercentage'apoptosis assay was therefore employed to measure dye uptake by the 
cells after treating them for 24 hrs. This was done in order to identify the extracts that 
contained pro-apoptotic and or anti-proliferative compounds so that they could further be 
evaluated and discard those which did not induce apoptosis.  
 
 
In this assay, APOPercentage' apoptosis assay was used to stain the cells that were 
undergoing apoptosis. The assay’s mechanism of action is that it uses a dye which enters 
the cells following phosphatidylserine transmembrane movement ('flip-flop' mechanism). 
Following this event, the dye uptake continues until blebbing of the apoptotic committed 
cells occur. No further dye can then enter the dead cells and the dye that has accumulated 
within the cells is not released. The trapped dye can however, be eluted and quantified 
spectrophotometrically. The amount of dye quantified is proportional to the number of 
cells with trapped dye i.e. the higher the absorbance readings of the eluted dye, the greater 
the number of cells which had the trapped dye. Flow cytometer can also be used to 
measure the cells with trapped dye.  
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Following treatment of the cells with the aqueous extracts (figure 3.1) the results showed 
that the crude aqueous extracts from Rhus laevigata induced apoptosis more efficiently 
than the other plant aqueous extracts. The other crude aqueous extracts induced apoptosis 
at high concentrations i.e. from 2.5mg/ml to 20mg/ml. Aqueous extracts from C. 
monilifera did not induce apoptosis in CHO cells even at the highest concentration of 20 
mg/ml. Aqueous extracts from Rhus laevigata however, showed that even at lower 
concentration (0.65mg/ml), the cells became apoptotic. As the interest was to find 
compound(s), which can induce cells to undergo apoptosis at low concentration therefore 
the extracts from Rhus laevigata were chosen for further evaluation. 
 
 
Figure 3.1: Screening of crude aqueous extracts for apoptotic compounds from the leaves of various plants 
measured by APOPercentage' dye apoptosis assay. 
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Aqueous extracts were prepared as indicated in section 2.3.1 and also sub section 2.3.1.1 from the leaves of 
the following plants: Chrysanthemoides monilifera, Rhus laevigata, Acacia karroo, Euclea racemosa, 
Leonatis leonurus, Senecio littoreus and Imperata cylindrica. From the stock of each plant aqueous extract, 
concentrations were prepared ranging from 20mg/ml to 0.625 mg/ml as shown and cells were treated for 24 
hrs incubated at 37oC in humidified CO2 incubator. The rest of the procedure was as described in section 
2.5.3. 
 
 3.1.1 Induction of apoptosis in CHO cells using organic and aqueous extracts 
 of Rhus laevigata measured by APOPercentage'  apoptosis assay.  
 
Following screening of the various plants for apoptosis induction, leaves of Rhus 
laevigata were further extracted with organic solvents of increasing polarities as 
described in section 2.3.1.2. The extracts from the organic and aqueous solvents were 
tested against CHO cells in order to determine the solvent extract that contained the active 
compound.  
 
 
The results (figure 3.2) indicate that most of the apoptosis inducing compound(s) were 
concentrated in the methanol extract followed by the water extract. The other organic 
extracts had almost no effect on the cells indicating that the apoptosis inducing 
compound(s) were not contained in them. In order to confirm that the extracts were 
inducing apoptosis other than necrosis, Annexin V assay was used to discriminate 
apoptotic cells from necrotic cells.  
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Figure 3.2: Screening of aqueous and organic extracts from the leaves of Rhus laevigata tested against 
CHO cells.  CHO cells were induced for 24 hrs with various organic and aqueous extracts from Rhus 
laevigata.  
 
 3.2 Morphological evaluation of apoptosis in CHO cells induced with methan
 ol and crude plant methanol extract assessed by APOPercentage
™
 apoptosis   
 assay (methanol control experiment). 
 
Screening for apoptosis induction was carried out using CHO cells as model cells 
for subsequent experiments. CHO cells were cultured in 6 well culture plates at 
2.5 x 105 cells per ml and were allowed to grow to 90% confluency. Two wells were 
induced with 1% methanol in culture media (20%l methanol in 2mls culture media). 
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Two other wells were induced with the crude plant methanol extract at a 
concentration of 0.5mg/ml in which the methanol concentration was less than 1%. 
The remaining two other wells were left untreated. The cells were then incubated for 
24 hrs at 37oC in a humidified CO2 incubator. Following incubation, cell 
morphology was evaluated using an inverted Nikon light microscope and pictures 
were taken using a Leica EC3 digital color camera. Then media from one of each of 
the wells containing un induced cells, induced cells with methanol and cells induced 
with crude plant methanol extract was removed and replaced with media containing 
1:20 APOPercentage™ apoptosis dye in culture media and the plate was incubated 
for 1 hr at 37oC in a humidified CO2 incubator. Following incubation, the cells were 
washed twice with PBS and immediately examined under inverted Nikon 
microscope and pictures were again taken using a Leica EC3 digital camera. From 
the other remaining wells, floating (apoptotic) cells were transferred to 15ml 
centrifuge tube and the adherent cells were trypsinized and mixed with the tube 
containing the floating cells. The cells were then washed twice with PBS, spun 
down and resuspended in the residual PBS. APOPercentage' dye in complete 
culture media diluted 1:160 was prepared. Thereafter, 250µl of the dye was added to 
the tube and the cells were incubated for 30 minutes at 37oC in a humidified CO2 
incubator. After the incubation period, the cells were spun down and supernatant 
discarded. The pellet was washed 1x with PBS after which the pellet was 
resuspended in 400µl of PBS and the cells were acquired and analyzed on a flow 
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cytometer (Becton Dickson) instrument equipped with a 488 nm Argon Laser as a 
light source within one hour.  Acquisition was done by setting forward scatter (FSC) 
and side scatter (SSC) on a log scale Dot Plot to differentiate population of cells and 
cellular debris. On a linear histogram dot plot, APOPercentage' (FL-3 channel) 
was measured against relative cell numbers. Negative control cells were used to set 
the cells in the negative quadrant before all samples were acquired.  A minimum of 
10,000 cells per sample was acquired and analyzed using CELLQUEST Pro 
software. 
 
This assay was done as a quality control to assess whether apoptosis induction by the 
crude plant methanol extract was due to potent compound(s) contained in the crude plant 
extract and not due to the methanol which was used for extraction. The results (figure3.2) 
showed that methanol at 1% or less did not by itself induce apoptosis. The results showed 
that less than 10% of the untreated CHO cells and methanol treated CHO cells took up 
APOPercentage™ apoptosis dye while 68% of CHO cells induced with the crude plant 
methanol extract took up the APOPercentage™ apoptosis dye indicating that the 
methanol extract induced apoptosis in CHO cells. The morphology of CHO cells treated 
with 1% methanol was unchanged after 24 hrs of induction while the morphology of 
CHO cells induced with crude plant methanol extract was completely changed following 
24 hrs of induction. The cells had rounded off and had lost contact with each another.  It 
was therefore obvious that the apoptotic morphology observed in cells induced with the 
 
 
 
 
  102 
crude plant methanol extract was as a result of the potent compound(s) contained in the 
plant extract, and not due to methanol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Methanol control experiment. The procedure described in section 2.5.1, was followed. Panel 1 
(A) shows the morphology of un induced CHO cells not stained with APOPercentage™ apoptosis dye. 
Panel 1 (B) shows un induced CHO cells but stained with APOPercentage™ apoptosis dye while panel 1 
(C) shows the same un induced CHO cells stained with APOPercentage™ apoptosis dye analysed by Flow 
cytometer. Panel 2 (A) shows the morphology of CHO cells induced with 1% methanol and not stained with 
APOPercentage™ apoptosis dye. Panel 2 (B) shows CHO cells induced with 1% methanol and stained with 
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APOPercentage™ apoptosis dye. Panel 2 (C) shows CHO cells induced with 1% methanol stained with 
APOPercentage™ apoptosis dye analysed by Flow cytometer. Panel 3 (A) shows the morphology of CHO 
cells induced with crude plant methanol extract and not stained with APOPercentage™ apoptosis dye while 
panel 3 (B) shows CHO cells induced with crude plant methanol extract stained with APOPercentage™ 
apoptosis dye and panel 3 (C) shows CHO cells induced with crude methanol plant extract stained with 
APOPercentage™ apoptosis dye and analysed by Flow cytometer.  
 
 3.3. Induction of apoptosis in CHO cells using the crude plant methanol 
 extract measured by Annexin V PE binding assay. 
 
The crude plant methanol extract was further tested against CHO and measured with 
Annexin V assay to confirm whether the positive results obtained by the 
APOPercentageTM apoptosis assays were as a result of apoptotic cell death and not 
necrotic cell death. Annexin V assay was used as a confirmatory assay to the 
APOPercentageTM apoptosis assays because Annexin V is a Ca2+ dependent 
phospholipid-binding protein with high affinity for PS and can be used to distinguish 
apoptotic cells from necrotic cells when used in combination with 7-amino-actinomycin 
D (7-AAD) or propidium iodide.  Translocation of PS to the external cell surface is 
unique to apoptosis however, it also occurs during cell necrosis hence the need to 
discriminate the two. The difference between these two forms of cell death is that during 
the initial stages of apoptosis the cell membrane remains intact, while at the very stage 
that necrosis occurs the cell membrane looses its integrity and becomes leaky. Therefore 
the measurement of Annexin V binding to the cell surface was performed in conjunction 
with an exclusion dye to establish integrity of the cell membrane (Wising et al., 2005). 
Apoptosis and necrosis were therefore estimated after double-staining the cells with 
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phycoerythrin (PE)-labelled annexin V (BD Biosciences, San Diego, CA, USA) and 7-
AAD and analysed using flow cytometry. Live cells with intact membranes were 
distinguished by their ability to exclude           7-AAD which readily penetrates dead or 
damaged cells. Dual analysis was introduced using a quadrant dot plot, in which ‘necrotic 
cells’ were identified as 7-AAD-positive while ‘early apoptotic cells’ were annexin V-
PE-positive only, and ‘late apoptotic cells’ were recognized as double-positive for 
annexin V-PE and 7-AAD. Cells that stained negative for both annexin V-PE and 7-AAD 
were classified as live cells. (Wising et al., 2005). 
 
In this assay CHO cells were treated with the methanol extract with concentrations 
ranging from 0.5mg/ml to 0.063mg/ml.  The procedure was as described in chapter two 
(section 2.5.4). 
 
The results (figure 3.5) showed that the  untreated control cells were primarily negative 
for both Annexin V PE and 7-AAD while the staurosporine treated cells (positive control) 
were 17% positive for 7-AAD indicating that 17 % of the cells were in their late stages of 
apoptosis and 15 % were positive for Annexin V. (In total 32 % of the cells were 
apoptotic).  The methanol extract treated cells showed that the extract induced apoptosis 
in the CHO cells in a dose dependent manner. At 0.063mg/ml, 6% of the cells were in 
their early stages of apoptosis (Annexin V PE Positive and 7-AAD negative), while 13% 
were in their late stages of apoptosis. It can be said that 19% of the cells were positive for 
both Annexin V PE and 7-AAD (apoptotic).   
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There was no dramatic increase in apoptotic cells induced with an increase in 
concentration of the plant extract from 0.063mg/ml to 0.125mg/ml.  There was however, 
a big increase in the proportion of apoptotic cells when the concentration was increased 
from 0.125mg/ml to 0.5mg/ml. At 0.125mg/ml 5% of the cells were positive for Annexin 
V and 15% were positive for 7-AAD (20% of the cells were apoptotic). At 0.5mg/ml the 
cells were 20% positive for Annexin V while 22% were positive for 7-AAD (42% of the 
cells were apoptotic). The picture however, could be different in other cell lines since 
other cell lines may respond differently. These results indicate that the extracts from Rhus 
laevigata contain pro-apoptotic compound(s), which require further investigations. These 
results also confirmed that the APOPercentageTM results were positive, as Annexin V is a 
sensitive assay and can also be used to discriminate apoptotic and necrotic cells. 
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Figure 3.4 An illustration of the principle behind Flow cytometry and how it is used in cell necrobiology 
and shows flow cytometrically the analysis of Annexin V.  (A) FSC normal cells, (B) FSC apoptotic cells, 
(C) Dot plot Annexin V PE stained cells showing normal, early and late apoptotic cells and (D) Histogram 
dot plot showing normal and apoptotic cells. When a cell passes through a laser beam in a flow cytometer, 
it generates light scatter. Forward Side Scatter (FSC) provides information about cell size, while Side 
scatter (SSC) provides information about the cell’s morphological complexity. When a cell dies, its 
morphology changes, and changes in light scatter may reflect these phenomena.  
Necrosis: As shown in figure 3.4, when a cell dies by necrosis, both FSC and SSC tend to increase, likely as 
a consequence of cell swelling. However, as a consequence of plasma membrane damage and leakage of cell 
constituents, both FSC and SSC rapidly decrease. (Lower FSC and SSC values), while normal cells have 
higher FSC and SSC values. 
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 Apoptosis: when a cell dies by apoptosis, its major morphological changes take place in the nucleus. Only in 
the late apoptotic stages the cytoplasm and the plasma membrane are seriously damaged.  
 
 
                                                                     Annexin V  
 
Figure 3.5: CHO cells treated with the methanol extract were tested for Annexin V and were 
acquired and analysed by flow cytometer. 
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  3.4 Induction of apoptosis on different cell lines using the plant methanol 
 extract.  
The crude plant methanol extract was further tested on human cancer cell lines. As 
different cell lines may respond differently to apoptosis induction the plant methanol 
extract at 0.5mg/ml was used to induce MCF, HeLa and Caski human cancer cell lines for 
24 hrs. The procedure described in section 2.5.3 was followed. APOPercentage' assay 
was used as a screening assay to assess apoptosis and measurement was done by Flow 
cytometer.  
 
 
 
 
Figure 3.6: Different cells lines treated with methanol extract stained with APOPercentageTM and analysed 
by flow cytometer. (A) MCF-7 induced cells (B) HeLa induced cells (C) Caski induced cells. 
C 
 
A 
B 
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Following induction of apoptosis with the plant methanol extract for 24 hrs, the 
results (figure 3.6) showed that MCF-7 cells (figure 3.6 A) were 20% positive for 
APOPercentageTM whereas HeLa cells (figure 3.6B) were 40% positive for 
APOPercentageTM and Caski (C) were resistant exhibiting only 10% positive for 
APOPercentageTM. The results showed that the pro-apoptotic compounds contained in the 
plant extract were able to induce apoptosis even in some human cancer cell lines. 
 
 3.5 Caspase-3 activation assay 
 
CHO cells were further tested for the activation of caspase-3, which is a key protease, 
implicated during the early stages of apoptosis as reviewed by (Kaufmann et al., 1999; 
Riedl and Shi, 2004). Its commencement triggers the degradation phase and is the 
hallmark of irreversible cell death of apoptosis. The cells were treated with 0.5mg/ml of 
the methanol extract and rest of the procedure described in section 2.5.6 was followed. 
 
 The results (figure 3.7) showed that the untreated cells were primarily negative for 
caspase-3 whereas those induced with staurosporine were 30% positive for caspase-3 and 
those cells induced with the plant methanol extract were 25% positive for caspase-3. The 
results showed that CHO cells induced with the plant methanol extract contained 
compounds which activated caspase-3 activity which is implicated in the early stages of 
apoptosis and which also proteolytically cleaves and activates other caspases as well as 
appropriate targets in the cytoplasm e.g., guanine nucleotide dissociation inhibitors (D4-
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GD1) and Bcl-2, and in the nucleus, e.g., PARP.  It is therefore a good indicator/marker 
of cells undergoing apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Detection of anti-active caspase-3 antibodies following treatment of CHO cells with the crude 
methanol extract and staurosporine. 
 
 3.6 PARP-1 Cleavage 
 
As reviewed in section 1.5.3 PARP-1 plays a critical role in the base excision repair 
(BER). PARP-1 being a nuclear enzyme is rapidly activated following DNA strand 
breaks, which finally leads to the modulation of various protein activities in DNA 
replication, DNA repair and checkpoint control (Beneke et al., 2000; Süsse et al., 2004; 
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Plummer, 2006). It was therefore necessary to test whether caspase-3 actually activated 
PARP-1. In this assay, CHO cells were also used as a model for testing PARP activation 
upon inducing the cells with the plant methanol extract. HeLa cells were used to see if the 
same phenomenon which can be observed in CHO cells could also be observed in a 
human cancer cell line such as HeLa when induced with the plant methanol extract. In 
this assay CHO and HeLa cells were induced with 0.5mg/ml of the plant methanol extract 
for 24 hrs while positive control  HeLa and CHO cells were induced with 1 %M 
staurosporine for 4 hrs (Zhang et al., 2004; Sordet et al., 2004). The cells were then fixed 
and permeabilized for 30 minutes at room temperature and the rest of the procedure was 
as described in section 2.5.11. 
 
The results (figure 3.8) showed that the untreated HeLa cells were 1% positive for active-
PARP-FITC whereas staurosporine treated HeLa cells were 7% positive for active PARP-
FITC and HeLa cells treated with 0.25mg/ml methanol extract were 25 % positive for 
active PARP-FITC and those which were treated with 0.5mg/ml were 60% positive for 
active PARP-FITC. On the other hand, untreated CHO cells were 2% positive for active 
PARP-FITC while staurosporine treated CHO cells were 40% positive for active PARP-
FITC and CHO cells treated with 0.25mg/ml of the methanol extract were 55% positive 
for active-PARP-FITC and those treated with 0.5mg/ml were 95% positive for active-
PARP-FITC. 
The results further indicated that the plant methanol extract caused DNA strand breaks in 
both HeLa and CHO cells thereby activating PARP.  The activation of PARP was due in 
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part to repair the broken DNA strands. The results were therefore a good indicator that the 
plant methanol extract contains compound(s) that induce apoptosis.  
 
        
 
        
 
        
 
          
 
                                                              PARP-FITC 
Figure 3. 8: PARP cleavage in HeLa and CHO cells induced with the crude plant methanol extract. HeLa 
cells and CHO cells were either left untreated or treated with 1µM staurosporine for 4 hours or treated with 
0.5mg/ml of the methanol extract. 
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 3.7 Mitochondrial depolarization 
 
One of the hallmarks of the apoptosis process is the loss of the mitochondrial membrane 
potential ("#m) (Green and Reed, 2000; Iijima, 2006) and as reviewed in chapter one 
section 1.4.6.2. The crude plant methanol extract was used to induce CHO cells to 
undergo apoptosis. Since mitochondrial membrane potential ("#m) is an early event, the 
cells were tested for mitochondrial membrane depolarization after short time exposures to 
the inducer. 
 
CHO cells were either left untreated or treated with methanol extract at a concentration of 
0.5mg/ml for various times of 30 minutes, 1 hr, 2 hrs and 3 hrs. Positive control cells 
were induced with 1µM staurosporine for 30 minutes. The procedure described in section 
2.5.5 was followed. 
 
The results (figure 3.9) showed that 6% of the untreated CHO cells (A) were depolarized 
while the staurosporine induced cells (B) were 38 % depolarized after 30 minutes of 
inducement. CHO cells induced with the crude plant methanol extract were 47% 
depolarized after 30 minutes of exposure to the inducer (C), however as time progressed, 
at 1 hr 63 % of the cells were depolarized (D) at 2 hrs 82% were depolarized (E) and at 3 
hrs 91% (F) of the cells were depolarized. It means that mitochondria depolarization was 
due to compound(s) contained in the plant methanol extract. It can also be seen that 
mitochondrial depolarization occurred in a time dependent manner. The results also 
showed that mitochondrial membrane potential ("#m) started collapsing at an early stage 
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in the apoptotic pathway as shown by the results obtained following 30 minutes of 
inducement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                           
 
                                                           
 
 
 
 
 
                                                           TMRE 
 
Figure 3.9:  CHO cells tested for mitochondrial membrane depolarization.  CHO cells were either left 
untreated (A) or induced with 1%M staurosporine for 30 minutes (B) or were induced with 0.5mg/ml of the 
plant methanol extract for various times of 30 minutes, 1 hr, 2hrs and 3hrs. (C), (D), (E) and (F) 
respectively.  
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 3.8.  DNA Fragmentation by APO-DIRECT™. 
 
Darzynkiewicz et al., (1997), said that the best methodology to use in cell necrobiology is 
flow cytometry. This is so because one is able to quantify apoptotic cells (apoptotic 
index) as compared to alternative methods (analysis of cell morphology, DNA gel 
electrophoresis). Darzynkiewicz et al., (1997), further said that flow cytometry is rapid, 
objective and very sensitive. However, since identification of apoptotic cells by flow 
cytometry is generally based on a single feature which may not necessarily be the marker 
of apoptosis in every situation, the mode of cell death should normally be confirmed by 
light or electron microscopy. The crude plant methanol extract was therefore further 
tested for its effect on DNA fragmentation on CHO cells using the APO-DIRECT™ Flow 
cytometric method.  DNA fragmentation is one of the steps, which occurs at later stages 
in the apoptosis pathway. It is as a result of activation of endonucleases during the 
apoptotic program. Degradation of nuclear DNA into nucleosomal units is one of the 
hallmarks of apoptotic cell death. The nucleases degrade the chromatin higher order 
structure into fragments of  ~300 kb and into smaller DNA pieces of about 50 kb in length 
and subsequently into 200 bp ladders (Nagata, 2000).  APO-DIRECT™ is a method 
which is used to detect ends of fragmented (broken) DNA. The principle behind the assay 
(figure 3.10) is that the enzyme terminal deoxynucleotidyl transferase (Tdt) specifically 
binds and adds dUTPs to 3' –OH ends of fragmented DNA. Fluorochrome labelled 
antibodies can be conjugated to dUTPs and can be used to detect the broken ends 
(Gavrieli et al., 1992).  In this assay fluorochrome FITC was conjugated (labelled) to 
deoxyuridine triphosphate nucleotides (dUTPs) which labeled the 3'-hydroxyl ends of 
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double- and single -stranded DNA. The reaction was catalysed by the enzyme terminal 
deoxynucleotidyl-transferase (Tdt). Identification of DNA break sites was done by 
staining of DNA strand breaks with FITC-labelled dUTP’s analysed by flow cytometer.  
 
CHO cells were either left untreated or treated with 1.µM staurosporine for 6 hrs or 
treated with 0.5mg/ml methanol extract for 36 hrs and the procedure described in section 
2.5.7 was followed. 
 
The results (figure 3.11) showed that the untreated CHO cells were primarily FITC-dUTP 
negative while CHO induced with staurosporine were 10% FITC-dUTP positive and the 
methanol extract treated CHO were 20% positive FITC-dUTP.  These results also 
confirm that the methanol extract contains potent compound(s), which induced apoptosis 
in and eventual DNA fragmentation. 
 
Figure 3.10: An illustration of TUNEL and In situ end-labelling (ISEL) techniques (Huerta et al., 2007). 
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Figure 3.11: DNA Fragmentation of CHO cells. CHO cells were left untreated (A) or treated with 1.µM 
Staurosporine for 6 hrs (B) or treated with 0.5mg/ml methanol extract for 36 hrs. 
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 3.9 Cellular viability 
 
 
The Neutral red uptake (NRU) cytotoxicity assay is a cell survival/viability assay which is 
based on the incorporation of neutral red (NR) to bind to viable cells. NR is a weak cationic 
supravital dye that readily penetrates cell membrane by non-ionic diffusion and it 
predominately accumulates intracellularly in lysosomes.  If the cell surface or the sensitive 
lysosomal membrane is altered the lysosomes become fragile and other changes gradually 
become irreversible. Cytotoxic substances can produce such changes and cause decreased 
uptake and binding of the neutral red, making it possible to distinguish between viable, 
damaged, or dead cells via spectrophotometric measurements because viable cells will take 
up the dye while the damaged or dead cells will not. Cytotoxicity is expressed as a 
concentration dependent reduction of the uptake of NR following the chemical exposure, 
thereby providing a sensitive, integrated signal of both cell integrity and growth inhibition 
(Babich and Borenfreund, 1991; Rixe et al., 1996; Fotakis and Timbrell, 2005).  
 
Each cell line was induced to undergo apoptosis with various concentrations of the crude 
plant methanol extract, which ranged from 2mg/ml to 0.063mg/ml. Cytotoxicity of the 
crude plant methanol extract was quantitatively measured using the Neutral red uptake 
assay (NRU). 
 
The numbers (table 3.1) represent the mean NRU50 of three replicate experiments and 
standard error of the mean (SEM).  
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The results obtained (table 3.1) showed that Jurkat cells were most sensitive with a 
NRU50 of 0.5mg/ml followed by CHO and 293T cells. Caski were most resistant with a 
NRU50 of 1.5mg/ml followed by MCF7 and H157 cells. The results also demonstrated 
that while the extract was cytotoxic to non-human cell lines such as CHO and 3T3, the 
extract was also cytotoxic to the human cancer cell lines tested.  
 
Table 3.1: NRU50 of different cell lines tested with the plant methanol extract 
 
CELL LINE 
 
NRU50 mg/ml 
(Means + SEM) 
Caski 1.5 ± 0.7 
CHO 0.6 ± 0.1 
HeLa 0.8 ± 0.23 
H157 1.0 ± 0.23 
Jurkat 0.5 ± 0.12 
MCF7 1.0 ± 0.64 
MG-63 0.85 ± 0.12 
3T3 0.95 ± 0.07 
293T 0.65 ± 0.12 
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  3.10 Morphological evaluation of different cell lines induced with the plant 
 methanol extract. 
 
As reviewed in chapter one (sections 1.4.3 and 1.4.4) the study of apoptosis was first 
based on cell morphology (Kerr et al., 1972; Otsuki et al., 2003). Various types of cell 
death have since been defined according to their morphological features without a clear 
reference to specific biochemical mechanisms (Kroemer et al., 2005; Roos and Kaina, 
2006). The word 'apoptosis' is simply a morphological description. Häcker, (2000), said 
that properly defined features of apoptosis provide a reliable basis for the detection of 
apoptosis, which can be used in combination with other apoptosis assays to properly 
evaluate the whole mechanisms underlying apoptosis. 
 
Different cell lines were induced to undergo apoptosis as described in section 2. 5.1 and 
their cell morphology were evaluated microscopically. The cells were induced with 
0.5mg/ml of the plant methanol extract, however, most of the cells looked swollen 
although the nucleus appeared condensed as compared to un induced cells. Classifying 
this observation as apoptosis was difficult therefore the concentration of the extract was 
reduced to 0.25mg/ml so that at lower concentration the extract could induce the cells to 
under go apoptosis and their cell morphology properly described.  
When the cells were induced with 0.25mg/ml  (table 2.2b), some of the cells (Caski, H157 
and MCF7) however, did not show morphological changes in comparison with un induced 
cells. These cells appeared primarily resistant at this concentration because further 
incubation (36 hrs) resulted in progressive proliferation of the cells. Morphologically, the 
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rest of the other cells (CHO, HeLa, Jurkat, MG-63, 293T and 3T3) at 0.25mg/ml, showed 
characteristic features seen in an apoptotic cell and did not proliferate when they were 
further incubated for an additional 12 hrs. These morphological observations were 
important because they helped to determine which cell lines were sensitive or resistant and 
also to determine the probable concentration required to induce apoptosis in a particular 
cell line.  
 
Table 2.2 (a): Morphological description of different cell lines upon induction with 0.5mg/ml of methanol 
extract for 24 hrs.  
 
Cell type Morphological Evaluation (0.5mg/ml) Mode of cell death 
CHO Cells were slightly condensed, and not detached  Apoptosis 
Caski Cells were swollen with vacuolated cytoplasm. ? Apoptosis 
? Oncosis 
HeLa Cells were swollen and not detached from plate  ? Oncosis 
H157 Cells were swollen and some had vacuoles. ? Apoptosis 
? Oncosis 
Jurkat  Cells were swollen, and detachment from each other 
(cells were not growing in clusters)  
? Apoptosis 
? Oncosis 
MCF7 Cells were slightly condensed and were not detached 
from plate 
Apoptosis 
MG63 Condensed nucleus, not detached from plate surface, 
and not swollen. 
Apoptosis 
293T Cells swollen?  Most cells were detached from plate ? Apoptosis 
? Oncosis 
3T3 Cells swollen? Cells were not detached from plate ? Apoptosis 
? Oncosis 
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Table 2.2 (b): Morphological description of different cell lines upon induction with 0.25mg/ml of methanol 
extract for 24 hrs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell type Morphological Evaluation (0.25mg/ml) Mode of cell death 
Caski No discernible morphological changes seen. ? Resistant 
CHO-22 Most cells were condensed and vacuolated.   Apoptosis 
 
HeLa Few cells were condensed and were not detached 
from plate surface. 
Apoptosis 
H157 No discernible morphological changes seen. ? Resistant  
 
Jurkat Cells were condensed and were detached from each 
other.  
 Apoptosis 
  
MCF7 No discernible morphological changes seen.  Apoptosis 
MG63 Slight condensed cytoplasm, not lifted from plate 
surface, not swollen. 
Apoptosis 
293T Few cells were detached from plate surface, were not 
swollen and were not condensed.  
? Apoptosis 
 
3T3 Cells were slightly condensed and remained adherent 
to plate surface (not detached). 
Apoptosis 
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 3.11 Summary 
 
Aqueous extracts from the leaves of Chrysanthemoides monilifera, Rhus laevigata, 
Acacia karroo, Euclea racemosa, Leonatis leonurus, Senecio littoreus and Imperata 
cylindrica were prepared and screened for their anti-proliferative and pro apoptotic 
activities on CHO cells tested by APOPercentage' apoptosis assay. The results showed 
that the aqueous extracts from Rhus laevigata were the most active in inducing apoptosis 
in the CHO cells compared to the other plant extracts.  The leaves of Rhus laevigata were 
further extracted with organic solvents with increasing polarity (chloroform, 
dichloromethane (DCM), ethyl acetate, ethanol, and methanol). The organic extracts were 
again tested on CHO cells to determine the extract which contained the most active 
compound(s).  The results showed that the crude methanol extract was the most active in 
inducing apoptosis in CHO cells as compared to the other organic and the aqueous 
extracts.  
 
A quality control assay on the induction of apoptosis by methanol on CHO was carried 
out to determine if methanol was the cause of apoptosis induction in the methanol extract. 
The results showed that methanol at 1% concentration did not induce apoptosis in CHO 
cells.  The concentration of methanol in the plant extract was less than 1% when the plant 
methanol extract was used to induce apoptosis in the CHO cells.  Induction of apoptosis 
was not therefore due to methanol but was due to compound(s) contained in the leaves of 
the extracted plant. 
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Annexin V binding assay was used to assess mode of cell death because Annexin V when 
used in combination with 7-AAD or propidium iodide can distinguish apoptotic from 
necrotic cells (late apoptosis). The results showed that increasing the concentration of the 
plant methanol extract from 0.125mg/ml to 0.5mg/ml also resulted in the proportional 
increase in both apoptotic (early apoptotic) and necrotic (late apoptotic) cells.  
 
A panel of nine cell lines (Caski, CHO, HeLa, H157, Jurkat, MCF7, MG-63, 293T and 
3T3) were induced with the plant methanol extract and their morphology was evaluated. 
The morphology of the cells was difficult to evaluate when the cells were induced with 
0.5mg/ml of the plant methanol extract. When the concentration was reduced to 
0.25mg/ml it was possible to describe the morphology of Jurkat, MG-63, 293T, CHO, 
HeLa, H157, Jurkat and 3T3 cells, however, Caski, MCF7 and H157 did not show any 
morphological changes at this concentration. 
 
CHO cells induced with the plant methanol extract were tested for the presence of 
specific active caspase-3 antibodies. The results showed 30% presence of specific active 
caspase-3 antibodies in the CHO cells following induction with the plant methanol 
extract.  
 
CHO cells were again induced with the plant methanol extract and tested for collapse of 
mitochondrial potential. The results showed that mitochondrial depolarization occurred in 
a time dependent manner following treatment of the CHO cells with the plant methanol 
extract. 
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HeLa and CHO cells were tested for PARP cleavage upon induction of the cells with the 
plant methanol extract. The results showed that CHO cells were 95% positive for PARP 
while HeLa cells were 20% positive for PARP.  
 
IC50 values of the nine cell lines were determined using NRU assay following induction 
of the cells with the plant methanol extract. The results showed that Caski were the most 
resistant because they had high NRU values followed by H157 and MCF7. Jurkat cells 
were the most sensitive because they had the least NRU values followed by CHO cells, 
indicating that Jurkat cells were the most sensitive to the plant methanol extract. 
 
Finally CHO cells were further tested for DNA fragmentation the final execution of 
apoptosis following apoptosis induction. APO-DIRECT™, a very sensitive single-step 
assay for detecting DNA strand breaks was used. The principle behind the assay is 
described in section 3.8. The results showed that 20% of the cells were positive for FITC-
dUTP. 
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 4.1.  SCREENING ALKYLATING AGENTS FOR ANTICANCER 
 ACTIVITY 
 
 
As reviewed in chapter one (section 1.7), alkylating agents stop cell growth by binding to 
nuclear DNA thereby forming cisplatin-DNA adducts.  The formation of cisplatin-DNA 
adducts prevents the DNA double helix strands from separating and since this is required 
in DNA replication, the cells fail to replicate causing tumour damage as well as normal 
cell damage through the activation of apoptosis (Boulikas and Vougiouka, 2003; Sato et 
al., 2005). For this reason, DNA alkylating agents are a major component of the 
anticancer drug discovery. Brabec and Kasparkova, (2005), Ciesielska et al., (2006) have 
said that although alkylating agents have been shown to be effective against most solid 
tumours, their side effects have been a major concern.  That is why for more than twenty-
five years a lot of work has involved the modification of the structure of cisplatin in an 
effort to improve its effectiveness and hundreds of platinum drugs have so far been tested. 
Ciesielska et al., (2006), further said that although some of the recently designed drugs 
containing platinum have promising biological properties, there is still a need to develop 
cisplatin related compounds with novel ligands and test their antitumor action and 
probably identify compounds, which can overcome the problems faced with cisplatin 
treatment. For this reason, platinum and palladium complexes with novel ligands 
presented in section 2.4 were synthesized and in order to establish whether these 
complexes could induce apoptotic cell death, a number of screening tests were performed 
in CHO cells and selected cancer cell lines. These screening tests included: (a) 
morphological evaluation using light microscopy (b) The APOPercentageTM apoptosis 
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assay (c) The Annexin V binding assay (d) DNA fragmentation (e) cellular viability assay 
(f) analysis of cell cycle perturbations. (g) Mitochondrial depolarization. 
 
 4.2 Induction of apoptosis in various cell lines induced with complexes 15, 57, 
 58 and cisplatin. 
 
The principal mechanism through which the APOPercentage' assay works has been 
reviewed in chapter one (section 1.4.2). In order to screen for apoptosis induction, various 
cell lines were treated with 0.5 mM of complexes 15, 57, 58 and cisplatin for 24 hours. 
The cells were acquired using the FACS procedure described in chapter two (2.5.3). 
Analysis was also done by FACS by setting the non stained (untreated) cell population in 
the first quadrant (101) of the forward side scatter histogram dot plot and cells which 
appeared in the second (102) or third quadrant were regarded APOPercentage TM 
positive (apoptotic/necrotic). Apoptotic/necrotic cells were reported as percentage of cells 
positive for APOPercentage TM over total cells acquired (10,000) multiplied by 100. Two 
independent experiments were done on each of the cell line.  
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Table 4.1: A panel of cells lines were treated with cisplatin, complexes 15, 57 and 58 and screened for 
apoptosis induction. 
CELL LINE INDUCER % of cells positive for  APOPercentage
TM 
      (Mean + SEM) 
MG-63 Untreated    3 ± 0.82 
 Cisplatin  97 ± 0.41 
 Complex 15 99 ± 0.00 
 Complex 57 96 ± 0.82 
 Complex 58  89 ± 0.41 
MCF7 Untreated   8 ± 0.41 
 Cisplatin  95 ± 0.41 
 Complex 15 99 ± 0.00 
 Complex 57 49 ± 2.45 
 Complex 58 45 ± 1.22 
HeLa Untreated 8 ± 1.60 
 Cisplatin 75 ± 2.45 
 Complex 15 96 ± 0.41 
 Complex 57 92 ± 1.63 
 Complex 58 66 ± 0.82 
H157 Untreated  9 ± 0.41 
 Cisplatin 80 ± 0.82 
 Complex 15 96 ± 0.41 
 Complex 57 96 ± 1.22 
 Complex 58 60 ± 1.63 
3T3 Untreated   8 ± 0.81 
 Cisplatin 84 ± 1.63 
 Complex 15 94 ± 0.82 
 Complex 57 91 ± 1.63 
 Complex 58 97 ± 0.41 
CHO-22 Untreated   8 ± 2.45 
 Cisplatin 74 ± 0.41 
 Complex 15 98 ± 0.41 
 Complex 57 99 ± 0.00 
 Complex 58 62 ± 4.08 
293T Untreated 15 ± 2.45  
 Cisplatin 89 ± 3.27 
 Complex 15 95 ± 0.82 
 Complex 57 99 ± 0.00 
 Complex 58 81 ± 2.45 
Caski Untreated 6 ± 0.81 
 Cisplatin 73 ± 1.60 
 Complex 15 97 ± 0.00 
 Complex 57 97 ± 0.00 
 Complex 58 88 ± 0.82 
Jurkat Untreated   8 ± 2.45 
 Cisplatin 95 ± 0.41 
 Complex 15  97 ± 0.00 
 Complex 57 99 ± 0.00 
 Complex 58 95 ± 0.41 
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The table 4.1 shows the results of APOPercentage' apoptosis assay following treatment 
of the cells with various complexes. The results showed that the untreated 293T cells 
were 15% positive for APOPercentage TM apoptosis assay while the other un treated cell 
lines (H157, 3T3, CHO-22, Caski, Jurkat, MCF7, MG-63 and HeLa) were less than 10% 
positive for APOPercentage TM apoptosis assay. The results of the treated cells showed 
that APOPercentage TM apoptosis assay for cells treated with cisplatin and the newly 
synthesized platinum and palladium complexes were more than 50% positive tested 
against the panel of cell lines however, complexes 57 (a palladium based complex) and 
58 (a platinum based complex) were not very active against MCF7 cells (49% and 45% 
positive for APOPercentageTM apoptosis assay respectively). Complex 15 (a palladium 
based complex) was highly active against all the cell lines tested.  
 
 4.3 Morphological evaluation of cells exposed to complexes 15, 57, 58 and 
 cisplatin. 
 
Different cells lines respond differently to apoptosis inducing stimuli because their 
molecular pathways which lead to cell death may also act differently and therefore may 
also cause different morphological appearances. As previously indicated in chapter 3 
(section 3.10) it is necessary to evaluate the morphological features of a dying cell, as this 
helps in planning for future experiments.  
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In this assay, various cell lines were exposed to 0.5 mM of the complexes 15, 57, 58 and 
Cisplatin for 24 hrs and their morphology was evaluated by an inverted light microscopy 
as described in section 2.5.1.   
 
Table 4.2: Morphological evaluations of cell lines induced with complexes 15, 57, 58 and cisplatin to 
undergo apoptosis. 
Cell type Inducer Morphological Evaluations Mode of cell death 
Cisplatin Cells shrunk and were not detached Apoptosis 
Complex 15 Nucleus shrunk, cytoplasm swollen, not detached Apoptosis 
Complex 57 Cells shrunk and were not detached Apoptosis 
 
 
Caski 
Complex 58 Cells shrunk and were not detached Apoptosis 
Cisplatin Cells moderately shrunk, few detached Apoptosis 
Complex 15 Nucleus shrunk, cytoplasm swollen, few detached Apoptosis 
Complex 57 Nucleus shrunk, cytoplasm swollen few detached Apoptosis 
 
 
CHO-22 
Complex 58 Cells moderately shrunk, few were detached Apoptosis 
Cisplatin Cells shrunk and were not detached Apoptosis 
Complex 15 Cells shrunk and were not detached Apoptosis 
Complex 57 Cells shrunk and were not detached Apoptosis 
 
 
HeLa 
Complex 58 Cells shrunk and were not detached Apoptosis 
Cisplatin Cells shrunk and most were detached Apoptosis 
Complex 15 Cells shrunk and were not detached Apoptosis 
Complex 57 Cells shrunk and were not detached Apoptosis 
 
 
H157 
Complex 58 Cells shrunk and were not detached Apoptosis 
Cisplatin Cells shrunk Apoptosis 
Complex 15 Cells shrunk Apoptosis 
Complex 57 Cells shrunk Apoptosis 
 
 
Jurkat 
Complex 58 Cells shrunk Apoptosis 
Cisplatin Cells shrunk and were not detached Apoptosis 
Complex 15 Cells shrunk and were not detached Apoptosis 
Complex 57 Cells shrunk and were not detached Apoptosis 
 
 
MCF7 
Complex 58 Cells shrunk and were not detached Apoptosis 
Cisplatin Cells shrunk and were not detached Apoptosis 
Complex 15 Cells shrunk and were not detached Apoptosis 
Complex 57 Cells shrunk and were not detached Apoptosis 
 
 
MG-63 
Complex 58 Cells shrunk and were not detached Apoptosis 
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Cisplatin All cells shrunk and were completely detached  Apoptosis 
Complex 15 All cells shrunk and were completely detached  Apoptosis 
Complex 57 All cells shrunk and were completely detached  Apoptosis 
 
 
293T  
Complex 58 All cells shrunk and were completely detached  Apoptosis 
Cisplatin Cells were condensed and were not detached Apoptosis 
Complex 15 Cells were condensed and were not detached Apoptosis 
Complex 57 Cells were condensed and were not detached Apoptosis 
 
 
3T3 
Complex 58 Cells were condensed and were not detached Apoptosis 
 
 
To show the general picture of  cells induced with the complexes, CHO cells were 
cultured in six well culture plates at 2.5 x 10 4 and were allowed to grow to form a 
monolayer. The cells were then induced with 0.5 mM of complexes 15, 57, 58 and 
cisplatin for 24 hrs. Following induction, the cells were inspected using an inverted Nikon 
light microscope and pictures were taken using a Leica EC3 digital color camera. 
 
 
The pictures in figure 4.1 depict the general morphological observations also seen in the 
other cell lines induced with the complexes. 
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Figure 4.1: Morphology of CHO cells following 24 hrs of exposure to complexes 15, 57, 58 and cisplatin.  
Picture 1 shows untreated CHO cells.  Picture 2 shows CHO cells induced with cisplatin 
and the arrow 2a shows a cell with vacuoles.  Picture 3 shows CHO cells induced with 
complex 15 and arrow 3a shows a cell with a swollen cytoplasm (ballooned shape) while 
its nucleus is shrunk/condensed shown in 3b. Picture 4 shows CHO cell induced with 
complex 57. Arrow 4a points to a cell with a swollen cytoplasm while its nucleus 
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shrunk/condensed 4b. Picture 5 shows CHO cells induced with complex 58 and arrow 5a 
shows a condensed cell. 
 
 4.4. Evaluation for dose dependence 
 
 
Following the morphological evaluation shown in table 4.2, the dose response of 293T 
cells was assessed against complex 15 (a palladium based complex) and complex 58 (a 
platinum based complex). The concentrations of the complexes ranged from 0.5 mM to 
0.031mM and the cells were induced for 24 hrs. There after the APOPercentage' 
apoptosis assay described chapter (two section 2.5.3) was followed. The cells were 
acquired and analyzed by FACS as described in chapter two (section 2.5.3). The results of 
the average of three independent experiments were obtained and then percentage of 
apoptotic cells (APOPercentage' positive cells) was plotted on the Y axis against 
complex concentration on the X axis on bar graph. 
 
The results shown in figure 4.2 showed that in both experiments apoptotic cells were less 
than 11% positive The unexposed cells were used to define the basal level of 
apoptosis/necrosis in these cells as there is always a variation in the basal level of 
apoptosis/necrosis in any given cell population and this also varies from one cell line to 
another. Even untreated cell population contain a minor percentage of cells that are 
positive for apoptosis. Therefore there was a need to include a negative control to avoid 
false positives.  As can be seen both complexes i.e. complex 15 (graph A) and complex 
58  (graph B) induced apoptosis in 293T cells in a dose dependent manner. 
 
 
 
 
 
  135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 4.2: (a) and (b) 293T cells tested against various concentrations of complexes 15 and 58 measured 
by APOPercentageTM apoptosis assay and analyzed by flow cytometer. 
 
 4.5 Annexin V binding assay. 
Changes in the plasma membrane are one of the earliest features of apoptosis. The 
Annexin V binding assay was used to confirm the data obtained by APOPercentageTM 
apoptosis assay and ascertain whether the mode of cell death was due to apoptosis 
induction. When the cells were treated with the complexes they showed typical 
morphology of cells undergoing apoptosis and the results of APOPercentageTM apoptosis 
assay confirmed this observation. A human cancer cell line 293T was used as a model cell 
line to also confirm the APOPercentageTM apoptosis assay results. In this assay kit, 
Annexin V conjugated to phycoerythrine (PE) was used to identify cells in their early 
phase of apoptosis (Annexin V positive, 7-AAD negative) while the vital dye 7-amino-
actinomycin D (7-AAD) was used to identify cells that were in their late stages of 
apoptosis or were already dead/necrotic (Annexin V positive and 7-AAD positive).  
 
293T cells were exposed to 0.5mM of cisplatin, complexes 15, 57, and 58 for 24 hrs and 
the procedure described in chapter one (section 2.5.4) was followed. 
  
A 
B 
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                             Panel A                                          Panel B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            Annexin V PE                                     Annexin V PE 
Figure 4.3: Annexin V binding assay of 293T cells tested against complexes 15, 57, 58 and 
cisplatin. 
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The results (figure 4.3) showed that the untreated cells were about 13 percent Annexin V 
positive (panel B 1) and out of the positive cell population about 11% of the cells were in 
their late stage of apoptosis while 2% were in their early stage of apoptosis as shown in 
Panel A 1. Cisplatin induced 98% of the cells to apoptosis (panel B 2), and 50% of the 
induced cells were in their late stage of apoptosis (panel A 2). Complex 15 induced 97% 
of the cells to apoptosis (panel B 3), and 42% of the induced cells were in their late stage 
of apoptosis (panel A 3). Complex 57 induced 97% of the cells to apoptosis (panel B 4), 
and 80% of the induced cells were in their late stage of apoptosis (panel A 4) while 
Complex 58 induced 96% of the cells to apoptosis (panel B 5), and 46% of the induced 
cells were in their late stage of apoptosis (panel A 4). The exposed cells showed that that 
they were very sensitive to all the complexes. All the four complexes induced more than 
95% of the cells to apoptosis. These results showed that the screening for apoptosis done 
by the APOPercentageTM apoptosis assay was compatible with the Annexin V assay.  
 
 4.6 Mitochondrial depolarization. 
 
One of the early features in the apoptotic pathway is mitochondrial depolarization as 
reviewed in chapter one (section 1.4.6.2). Disturbances in the mitochondria may lead to 
the opening of the mitochondrial permeability transition pore complex, which lead to 
organelle swelling, and rupture of the outer membrane, which result in the release of 
cytochrome c. Once cytochrome c is released from the mitochondria, it combines with 
Apaf-1, and procaspase-9 to form the apoptosome. Caspase-9 processes and activates 
other caspases, which organize the orderly biochemical execution of the cells. It should 
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be noted however, that cytochrome c release might depend on the cell type. In some cells 
cytochrome c is available in excess, and caspases can be activated. However, as pointed 
out by Green and Reed, (1998), some cells contain large caspase inhibitors, which inhibit 
the release of cytochrome c, as a result caspase-dependent apoptosis is not induced 
instead the eventual loss of electron chain may drive the cell towards a necrotic cell death. 
Since one of the hallmarks of apoptosis is the loss of mitochondria membrane potential 
("#), its measurement is therefore important, because it provides an early indication of 
apoptosis in the apoptotic pathway. 
 
293T cells were exposed to 0.5 mM of complexes 15, 57, 58 and cisplatin for 1 hr and 
5 hrs and tested for mitochondrial membrane depolarization with TMRE probe. A more 
detailed procedure is described in chapter 2 (section 2.5.5). TMRE is a highly fluorescent 
cationic lipophilic dye and is also mitochondria-specific. The dye is rapidly taken up and 
retained by live cells and for this reason it is used to determine "!m in intact cells. Its 
retention is dependent on mitochondrial transmembrane potential (Krohn et al., 1999). 
 
The results (figure 4.4) showed that 5% of the untreated cells were positive for TMRE, an 
indicative of mitochondrial depolarization. Following 1 hr of exposure to cisplatin about 
16% of the cells were positive for TMRE, also an indicative of mitochondrial 
depolarization and at 5 hrs the cells showed 87% mitochondrial depolarization. When the 
cells were exposed to complex 15, about 28% of the cells showed mitochondrial 
depolarization and at 5 hrs about 40% of the cells showed mitochondrial depolarisation. 
Cells that were exposed to complex 57 showed 58 % mitochondrial depolarization after 1 
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hr of complex treatment and 90% mitochondrial depolarization at 5 hrs. Cells treated with 
complex 58 showed 7% mitochondrial depolarization after1 hr of treatment and 25% 
mitochondrial depolarization following 5 hrs of treatment. 
 
The results further showed that mitochondria in the untreated cells were intact as 
exhibited by the retention of TMRE fluorescence by the cells, as TMRE is mitochondria 
specific. The treated cells however, showed that the cells lost TMRE fluorescence in a 
time dependent manner indicating that mitochondria depolarization was as a result of 
complex treatment.  
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                                                               TMRE 
Figure 4.4: Mitochondrial depolarization of 293T cells tested with complexes 15, 57, 58 and 
Cisplatin measured by tetramethylrhodamineethylester (TMRE). 
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 4.7 Detection of active caspase-3 
 
 Complexes 15, 57 and 58 were further screened to determine if their mechanism of 
action resulted in caspase-3 activation since the caspases play an essential role in the 
execution phase of apoptosis as reviewed in chapter one (sections 1.4.6.1, 1.4.6.2, 1.4.7 
1.4.7.1 and 1.4.7.2). Caspases are the main effectors of apoptosis or programmed cell 
death (PCD). They are a family of cysteine proteases that cleave proteins after aspartic 
acid residues and they irreversibly commit cells to die (Riedl and Shi, 2004). When 
caspases are activated they cause characteristic morphological changes seen in a cell that 
is undergoing apoptosis such as shrinkage, chromatin condensation, DNA fragmentation 
and plasma membrane blebbing. As reviewed in chapter one section (1.4.6.1), induction 
of apoptosis via death receptors results in the activation of an initiator caspase such as 
caspase 8 or caspase 10. These caspases can then activate other caspases in a cascade. 
This cascade eventually leads to the activation of the effector caspases, such as caspase 3 
caspase-6 or -7. These caspases are responsible for the cleavage of key cellular proteins 
that leads to the typical morphological changes that are observed in cells undergoing 
apoptosis. Caspase-3 is a key protease that is activated during the early stages of 
apoptosis. It is synthesized as an inactive proenzyme that is processed in cells that are 
undergoing apoptosis by self-proteolysis and/ or cleavage by another protease.  Active 
caspase-3 is therefore used as a marker for cells that are undergoing apoptosis. In this 
assay the antibodies specific for active caspase-3 were used to recognise cleaved caspase-
3 in 293T cells exposed to cisplatin, complexes 15, 57 and 58. Since caspase independent 
apoptosis has been reported (Shih et al., 2003), it was necessary to test whether these 
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complexes induced apoptosis via caspase activation in these cells or not. Cells were 
exposed to 0.5mM of complexes 15, 57, 58 and cisplatin for 24 hrs to induce apoptosis. 
Thereafter the cells were permeabilized, fixed and stained for active caspase-3 as 
described in chapter two (section 2.5.6). 
 
Following treatment of the cells with the complexes, the results (figure 4.5) showed that 
the untreated cells were 7% positive for specific active caspase-3 antibodies, whereas 
cells treated with cisplatin, complexes 15, 57, and 58 were respectively 43%, 36%, 29% 
and 13% positive for specific active caspase-3 antibodies. The results showed that the 
complexes induced apoptosis through the activation of caspase-3 in 293T cells.  
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                                                Active caspase-3 FITC 
 
Figure 4.5: Detection of active caspase-3 in 293T cells induced with complexes 15, 57, 58 and cisplatin.  
 
 4.8 Detection of chromosomal DNA fragmentation 
 
One of the hallmarks of apoptosis cell death is the digestion of genomic DNA by an 
endonuclease, which generates a ladder of small fragments of double-stranded DNA. The 
amount of DNA fragmentation is assumed to be proportional to the cell death and DNA 
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fragmentation occurs at later stages of the apoptosis pathway. In some cell systems 
however, Hirata et al., (1998), reported that DNA fragmentation is not detected regardless 
of clear demonstration of characteristic cytoplasmic changes of apoptosis. In this study, 
all the cell lines tested with the complexes clearly demonstrated typical cytoplasmic 
changes seen in apoptotic cells (table 4.2). Two cell lines, 293T and Jurkat were treated 
with 0.5mM of cisplatin, complexes 15, 57 and 58 for 36 hrs because DNA fragmentation 
usually occurs late in the apoptosis pathway. In order to determine whether these cell 
lines had their DNA degraded upon exposure to the complexes, the terminal 
deoxynucleotidyl transferase dUTP nick end-labelling (TUNEL) assay (Vermes et al., 
1995) was performed as indicated in chapter two (section 2.5.7). The principle of the 
assay is described in chapter 3 (section 3.8). The assay is suitable for both quantitative 
and qualitative analysis. In this assay cells were quantitatively acquired and analyzed by 
flow cytometry.  
 
The results (figure 4.6) showed that the untreated 293T cells were typically negative for 
FITC-dUTP while cisplatin, complexes 15, 57 and 58 were 11%, 64%, 55% and 61% 
respectively positive for FITC-dUTP. The insert shows FITC-dUTP against counts. 
 
The results (figure 4.7) showed that the untreated Jurkat cells were 1% positive for FITC-
dUTP while cisplatin, complexes 15, 57 and 58 were 48%, 56%, 53% and 61% 
respectively positive for FITC-dUTP. The inserts show FITC-dUTP against counts. These 
results clearly showed that the complexes caused DNA fragmentation in the Jurkat cells. 
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Figure 4.6: DNA fragmentation of 293T cells induced with cisplatin, complexes 15, 57 and 58. 
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Figure 4.7: DNA fragmentation of Jurkat cells induced with cisplatin, complexes 15, 57 and 58. 
 
 
 4.9 Analysis of cell Cycle 
 
 
In chapter one (section 1.5) a review of the cell cycle and some of the genes implicated in 
the cell cycle regulation have been presented. Apoptosis can occur at any stage of the cell 
cycle because the mechanisms of chemical interactions necessary for apoptosis are 
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present throughout the cell cycle. Alenzi, (2004), indicated that there is a link between 
apoptosis and cell proliferation as suggested by some studies that have demonstrated the 
presence of large numbers of dying cells in proliferating cell populations in vivo.  
 
During apoptosis, calcium and magnesium-dependent nucleases are activated resulting in 
the degradation of DNA  (Wyllie et al., 1984). Nicks and fragments within DNA can be 
caused by exposure of cells to harmful environmental agents such as mutagenic chemicals 
or radiation (Papamichos-Chronakis et al ., 2006) and these can be detected by electron 
microscopy (EM) (Huerta et al., 2007), DNA analysis to look at a Sub-G1 peak as 
reviewed in chapter one (section 1.5), using strand break labelling (TUNEL) to detect 
broken DNA (chapter 3 section 3.8), (Huerta et al., 2007), using Hoechst binding to 
detect DNA conformational changes ( Ioannou and Chen, 1996), DNA laddering and  In 
Situ end labelling and ELISA. (Huerta et al., 2007), 
 
The Sub-G1 method relies on the fact that subsequent to DNA fragmentation and 
following permeabilization, the low molecular weight  (LMW) DNA inside the cytoplasm 
of the apoptotic cells leaks out during the subsequent rinse and staining procedure. The 
lower DNA content of these cells means they contain less DNA. Following staining with 
DNA-binding dye, cells that have lost DNA will take up less stain and will appear to the 
left of the G1 peak (the so- called “sub-G1 peaks, “A0” cells i.e. cells with lower 
fluorescence level than G0+G1 cells) and are thus considered apoptotic. The major 
disadvantage of this method is that apoptotic G2-Phase cells that exhibit a reduced DNA 
content, could represent the DNA content of a G1- cell. Therefore it may not be detected 
as apoptotic. This would result in underestimation of the apoptotic population. 
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In this assay, propidium iodide (PI) was used to stain DNA. Propidium iodide (PI) 
intercalates in the DNA helix and fluoresces red. It has the advantage that it is excited by 
488nm light and can be used on most common flow cytometers. However, it requires 
cells to be fixed or permeabilized and is therefore not a rapid assay. PI also stains double-
stranded RNA and this should first be removed with ribonuclease. The intensity of the PI 
signal is directly proportional to DNA content. 
Cell cycle is one of the methods used to detect DNA fragmentation. Analysis of the cell 
cycle also helps to know the stage at which a prospective drug candidate halts the cells 
from progressing  to the next phase of the cell cycle so that drugs can be designed to 
target  that stage as reviewed in chapter one (section 1.5.5). In section 4.7 of this chapter, 
293T and Jurkat cells were treated with complexes 15, 57, 58 and cisplatin and DNA 
fragmentation was done using the APO-DIRECT™ assay. In the cell cycle analysis assay, 
HeLa cells were used to analyze DNA fragmentation and to assess the stage at which cell 
progression was halted. HeLa cells were treated with 0.5mM of complexes 15 and 58 and 
the procedure described in chapter two (section 2.5.10) was followed.  
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                                  Sub G1/ (“A0” apoptotic cells) 
 
Figure 4.8: Cell cycle analysis of HeLa cells tested against complex 15. 
 
 
 
 
 
 
HeLa un treated 
Complex 15_12 hrs 
Complex 15_24 hrs 
Complex 15_ 36 hrs 
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The table 4.3: Cell cycle analysis of HeLa cells treated with complex 15. With reference to figure 4.8, 
Marker M1 represented A0 (apoptotic cells, sub G1) (Marker M2 represented G1 of the cell cycle while 
Marker M3 represented S phase of the cell cycle and Marker M4 represented G2/M phase of the cell cycle. 
HeLa cells were induced to undergo apoptosis with 0.5mM of complexes 58 for 12, 24 and 36 hours. The 
reduction in staining/DNA content of these cells was measured by flow cytometry. 
 
Time Sub-G1 G1-Phase S-Phase G2-Phase 
0 2 % 74 % 8 % 15 % 
12 hrs 6 % 70 % 8 % 16 % 
24 hrs 15 % 60 % 10 % 15 % 
36 hrs 23 % 51 % 11 % 15 % 
 
 
 
The results (figure 4.8) showed that the majority of the cells were typically in the G0/G1 
phase of the cell cycle.  The results further showed that there was a reduction in the 
number of cells in G1 as time progressed and subsequent increases in the number of cells 
in sub-G1 (apoptotic cells).  It can also be seen that most of the cells were halted at G0/G1 
and became apoptotic while a few cells progressed through to S and G2/M phases.   
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                                     Sub G1 (“A0” apoptotic cells) 
 
             Figure 4.9: Cell cycle analysis of HeLa cells tested against complex 58. 
 
 
 
 
 
 
 
HeLa untreated 
Complex 58-12 hrs 
hrs 
Complex 58-24 hrs 
Complex 58_36 hrs 
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The table 4.4: Cell cycle analysis of HeLa cells treated with complex 58. With reference to figure 4.9, 
Marker M1 represented A0 (apoptotic cells, sub G1). Marker M2 represented G1 of the cell cycle while 
Marker M3 represented S phase of the cell cycle and Marker M4 represented G2/M phase of the cell cycle.  
 
Time Sub-G1 G1-Phase S-Phase G2-Phase 
0 1 % 73 % 9% 15 % 
12 hrs 3 % 70 % 6 % 21 % 
24 hrs 11 % 58 % 8 % 23 % 
36 hrs 42% 37 % 10 % 11 % 
 
 
The results (figure 4.9) showed that the majority of the cells were typically in the G0/G1 
phase of the cell cycle.  The induced cells showed that there was a reduction in number of 
cells in G1 as time progressed and subsequent increases in the number of cells in sub G1 
(apoptotic cells).  The results further show that as time progressed most of the cells were 
halted at G0/G1 and became apoptotic while a few cells progressed through to S and 
G2/M phases.  
 
In both cell cycle experiments cells induced with complex 15 and 58 showed that there 
was not much difference in the number of apoptotic cells between 0 and 12 hrs, however, 
the number of cells in the sub-G1 population started increasing at 24 hrs time point and a 
marked increase in apoptotic cells was observed at 36 hrs time point.  
As reviewed in chapter one (section 1.5) there are many factors that can cause cells to be 
halted in a given phase of the cell cycle. It is possible that the complexes formed complex 
DNA adducts (section 1.7.2) which halted the cell cycle progression thereby activating 
several genes, which are involved in cell signalling pathway such as p53, pRb, CDKs and 
others. The activation of genes, which are involved in the apoptosis pathway can cause 
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cell cycle arrest at any phase of the cell cycle and also activate genes that are involved in 
DNA fragmentation. The actual mechanism(s) through which the complexes halted the 
cell cycle progression and the subsequent DNA fragmentation was not investigated.  
 
  4.10 Cellular Viability 
 
Neutral Red Uptake (NRU) cytotoxicity test described in chapter 2 (section 2.5.8 and 
2.5.9) was used to evaluate the cytotoxicity of the complexes. 
The NRU50 results (table 4.5) showed that most cytotoxicity was observed in 293T cells 
tested against all the complexes under investigation followed by Jurkat as shown by their 
reduced retention in the uptake of the NR dye (numbers highlighted in red).  Less 
cytotoxicity was observed in H157 exposed to cisplatin and to complex 58, as shown by 
their increased retention of the NR dye. Complex 58 also showed less cytotoxicity to 
Caski as also shown by their increased retention of the NR dye (numbers highlighted in 
blue).  
The causes of cisplatin resistance are still not yet clear. (Damia and D`Incalci, 1988; 
Elwell et al., 2006). However, Damia and D`Incalci,  (1988), suggested that the 
mechanisms underlying cisplatin resistance could include the reduction of cisplatin 
accumulation inside cancer cells, the ability of the cells to detoxify cisplatin, the ability of 
the cells to repair the cisplatin-DNA adducts faster, modulation of apoptotic pathways, 
up-regulation in transcription factors, and a higher concentration   of glutathione and 
metallothioneins (MTs). Cisplatin also fails to selectively kill cancerous cells over normal 
cells (Sakinah et al., 2007). Further investigation of the palladium complexes needs to be 
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done since they are potential anticancer agents.  The cells could be treated with the 
complexes over a period of time and see if they could eventually become resistant. There 
is need to investigate whether the complexes could selectively kill cancerous cells over 
normal cells because this study did not carry out this investigation. 
 
Table 4.5: NRU50±SEM (mM) of various cell lines tested with various complexes.  
CELL LINE NRU50 
(Cisplatin) 
Mean + SEM 
NRU50 
(Complex 15) 
Mean + SEM 
NRU50 
(Complex 57) 
Mean + SEM 
NRU50 
(Complex 58) 
Mean + SEM 
Caski 1.10 ± 0.09 0.04 ± 0.02 0.05 ± 0.01 0.05 ± 0.01 
CHO-22 0.09 ± 0.02 0.05 ± 0.01 0.06 ± 0.01 0.06 ± 0.02 
HeLa 0.04 ± 0.03 0.05 ± 0.04 0.04 ± 0.02 0.03 ± 0.01 
H157 2.00 ± 0.40 0.08 ± 0.01 0.08 ± 0.01 1.10 ± 0.10 
Jurkat 0.01 ± 0.01 0.01 ± 0.02 0.04 ± 0.01 0.04 ± 0.01 
MCF7 0.70 ± 0.40 0.06 ± 0.01 0.06 ± 0.02 0.07 ± 0.03 
MG 63 0.06 ± 0.02 0.09 ± 0.01 0.06 ± 0.01 0.09 ± 0.01 
293T 0.01 ± 0.01 0.01 ± 0.01 0.03 ± 0.01 0.01 ± 0.02 
3T3 0.05 ± 0.01 0.04 ± 0.01 0.05 ± 0.01 0.05 ± 0.01 
 
 
 4.11 Summary 
 
Two palladium based complexes assigned numbers 15 and 57 and one platinum based 
complex assigned number 58 have been tested for apoptosis induction in human, mouse 
and CHO cell lines. Selected assays used in the study of apoptosis have been used in this 
study. One of the earliest features of apoptosis is the translocation of the membrane 
phospholipid phosphatidylserine (PS) from the inner to the outer surface of the plasma 
membrane.  To test this feature, the APOPercentage! apoptosis assay was used. The 
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principle behind this assay is described in chapter 3 (section 3.1) and the results showed 
that both the palladium and the platinum complexes induced apoptosis in MG-63, MCF7, 
HeLa, H157, 3T3, CHO, 293T Caski and Jurkat cells as shown by the positive results of 
APOPercentage! apoptosis assay.  
 
When the cell membrane phospholipid phosphatidylserine (PS) is undergoing 
translocation from the inner to the outer surface of the plasma membrane during apoptosis 
(flip-flop mechanism), it exposes binding sites for Annexin V,  a 35-36 kDa which is 
Ca
2+
- dependent, phospholipid binding protein with a high affinity for PS. However, 
translocation of PS also occurs during necrosis. Annexin V binding when used in 
conjunction with vital dyes such as 7-Amino-actinomycin (7-ADD) or propidium iodide 
(PI) can be used to test early apoptotic cells and late apoptotic cells. One of the cell lines 
293T lost attachment upon treatment with the complexes and Annexin V binding assay 
was used to test on 293T cells induced with complexes 15, 57, 58 and cisplatin as a 
positive control. The results for the Annexin V binding assay showed that the cells treated 
with complexes 15, 57 58 and cisplatin were 97%, 97%, 96% and 98% positive for 
Annexin V respectively and of these 42%, 80%, 46% and 50% were positive for both 
Annexin V and 7-AAD (late apoptotic) respectively. The two assays (APOPercentage! 
and Annexin V) showed that the complexes induced apoptosis in the cells. 
 
One other feature that is involved in early apoptosis is the activation of aspartate-specific 
cysteinyl proteases (caspases). Caspases are enzymes that play a critical role in apoptosis 
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when activated and failure of apoptosis is one of the major contributing factors to tumour 
growth and autoimmune diseases. Three caspases-3, -6 and -7 are involved in the 
execution phase of apoptosis. 293T cells were treated with complexes 15, 57, 58 and 
positive control cisplatin and were evaluated for activation of active caspase-3,  which is 
involved in the early stages of apoptosis. The results showed that the treated cells were 
positive for active caspase-3 detected using specific antibodies. 
 
 Mitochondria play a fundamental role in the regulation of programmed cell death 
(apoptosis). They contain pro-apoptotic proteins such as apoptosis inducing factor (AIP) 
and cytochrome C embedded in the mitochondrial membrane. These factors can however 
be released following pole formation in the mitochondrial membrane called the 
permeability transition pole (PT). Cytochrome C when released from the mitochondria 
into the cytosol, is able to interact with Apaf-1 and leads to the recruitment of pro-
caspase-9 to form the apoptosome as reviewed in chapter one (section 1.4.6.2). The 
formation of the apoptosome leads to the activation of caspase 9 and the induction of 
apoptosis.  293T cells were further tested for collapse of the mitochondria transmembrane 
potential upon exposure to the complexes 15, 57, 58 and cisplatin. The results showed 
that the mitochondria depolarization (collapse) increased with time. 
 
The NRU50 of the complexes 15, 57, 58 on different cell lines were determined in 
comparison to the positive control cisplatin. The Neutral red uptake cytotoxicity assay is a 
cell survival/viability assay based on the ability of viable cells to incorporate and bind 
neutral red (NR) a weak cationic supravital dye that readily penetrates cell membranes by 
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non-ionic diffusion and predominantly accumulates intracellularly in lysosomes as 
reviewed in chapter three (section 3.9). It was shown that cisplatin had less cytotoxicity in 
Caski, H157 and MCF7 cells. Complex 58 a platinum-based complex, also showed less 
toxicity against H157 as shown by the increased retention of the dye by the cells. NRU50 
of complexes 15 and 57 (palladium based complexes) showed increased cytotoxicity 
against the entire panel of cell lines tested as shown by the reduction in the retention of 
NR dye by the cells. 
 
Inconsistencies of non-linear dose and response relationships usually cause problems in 
judging the validity of a drug.  293T cells were treated with different doses of complexes 
15 (a palladium based complex) and complex 58 (a platinum based complex) and changes 
in apoptosis response was evaluated. The results showed that both complex 15 and 58 
induced apoptosis in 293T cells in a dose dependent manner. 
 
Apoptotic cells show characteristic features such as shrinkage, loss of contact between 
neighbouring cells, chromatin condensation and detachment from the growth surface. 
Saraste, (2002), indicated that these morphological changes occur due to molecular and 
biochemical events such as activation of caspases which cleave DNA into 
oligonucleosomal fragments and also cleavage of specific protein substrates which 
determine the integrity and shape of the organelles or cytoplasm. A panel of cell lines 
which comprised CHO, Caski, HeLa, H157, Jurkat, MCF7, MG-63 293T and 3T3 cells 
were respectively treated with complexes 15, 57 58 and cisplatin and their cell 
morphological was evaluated using light microscopy. The results showed that when 
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complexes 15 and 57 were exposed to CHO cells and Caski, the nucleus of the cells 
condensed and surprisingly, the cytoplasm of the cells swelled as shown in figure 4.1. 
When 293T cells were exposed to complexes 15, 57, 58 and cisplatin, they condensed and 
completely detached within 24 hrs. In general, the apoptotic morphology observed in all 
the cells upon exposure to the complexes were characteristic of features of cells 
undergoing apoptosis. The results of bioassays that were so far performed were in 
conformity with the observed morphological features. 
 
One of the hallmarks of apoptosis is the degradation of DNA by endogenous DNases, 
which cleave internucleosomal regions of the DNA into fragments of 180-200 base pair 
(bp). 293T and Jurkat cells were treated with complexes 15, 57, 58 and cisplatin and were 
evaluated for DNA fragmentation. The results showed that the complexes 15, 57, 58 and 
cisplatin caused DNA fragmentation in these cells.  
DNA fragmentation can also be evaluated by analysis of the cell cycle whereby cells 
appearing at the SubG0/G1 peak of the cell cycle are considered apoptotic. This maybe 
because the cell was halted in a particular phase of the cell cycle and became apoptotic. 
Following permeabilization fragmented 180-200 base pairs leak out of the cells and this 
results in a population of cells with reduced DNA content. Staining of such cells with 
DNA intercalating dye for example propidium iodide produces a DNA profile 
representing cells in phase G0/G1, S-phase and G-2M phase. Apoptotic cells however, 
appear as SubG0/G1 population to the left of the G0/G1 peak. In order for the peak to 
appear in the SubG1 area, cells must loose enough DNA. The disadvantage of the method 
however is that when cells enter apoptosis from the S phase or G2/M phase of the cell 
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cycle, or if there is an aneuploid population undergoing apoptosis, they may not appear in 
the SubG1 peak. Also cells that have lost DNA for any reason, other than apoptosis, will 
also appear in the SubG1 region. To test for DNA fragmentation cell cycle analysis 
method was done on HeLa cells. The HeLa cells were treated with complexes 15 and 58 
and cell cycle analysis showed that the complexes 15 and 58 caused cell cycle arrest at 
the G0/G1 phase and subsequent DNA fragmentation.  
 
To put everything together, both the palladium based complexes 15 and 57 and the 
platinum based complex 58 induced apoptosis in 293T cells in a similar fashion.  
Morphological observations and NRU50 revealed that the complexes also induced 
apoptosis in Caski, CHO, MG-63, H157, 3T3, MCF7, Jurkat and HeLa cells. 
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  CHAPTER FIVE: GENERAL DISCUSSION 
 
            Herbal Medicine 
 
            Screening of methanol extracts from the leaves of Rhus laevigata 
            Conclusion         
            Future work  
 
            Alkylating agents as anticancer agents  
 
            Screening of platinum and palladium-based complexes for antineoplastic activitie 
            Conclusion 
            Future work 
 
 
 5.1 Herbal Medicine 
 
Plants have been used as medicines for centuries and they have been considered to be 
potential sources for the screening and isolation of many drugs including anticancer 
agents. In the traditional system, medicines prepared from plants initially took the form of 
crude drugs such as tinctures, teas, poultices, powders, and other herbal formulations. It 
has been suggested by Gurib-Fakim, (2006), that the knowledge of herbal medicines for 
curing of specific diseases developed through trial and error over many centuries and that 
the specific plants to be used and the methods of application for particular ailments were 
passed down through oral history from generation to generation and eventually the 
information regarding medicinal plants was recorded in the herbals. In more recent 
history, the use of plants as medicines has involved the isolation of active compounds, 
5.1 
5.2 
5.3 
5.4 
5.5 
5.6 
5.7 
5.8 
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which began with the isolation of morphine from opium in the early 19th century. This 
discovery prompted more research into medicinal plant drug discovery and led to the 
isolation of early drugs such as cocaine, codeine, digitoxin, and quinine, in addition to 
morphine. Balunas and Kinghorn, (2005), said that the search for pharmacologically 
active compounds from medicinal plants still continues today. Taraphdar et al., (2001), 
Balunas and Kinghorn, (2005), reported that drugs isolated from medicinal plants are 
more favoured than synthetic drugs because they are isolated from living systems and 
therefore are biologically friendly than the totally “synthetic drugs,” making them good 
candidates for drug development. The isolation and characterization of active compounds 
from medicinal plants have provided important anticancer agents that have been used as 
lead compounds in anticancer drug discovery. Screening of medicinal plants for 
anticancer compounds is important as it can lead to the isolation of novel lead compounds 
that can be used in anticancer drug discovery. 
 
 5.2 Screening of methanol extracts from the leaves of Rhus laevigata 
 
In order to search for new antitumor compounds, methanol extracts from the leaves of 
Rhus laevigata were screened and tested for the presence of pro-apoptotic and anti-
proliferative compound(s). The mechanisms underlying inhibition of cell growth and 
stimulation of apoptosis were evaluated.  
 
The leaves of Rhus laevigata were extracted with organic solvents of increasing polarity 
and the extracts were tested for pro-apoptotic and anti-proliferative activities on CHO 
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cells. The results showed that the methanol extract induced apoptosis in CHO cells more 
than the other extracts indicating that the methanol extract contained the active 
compound(s) which were responsible for apoptosis induction. As a control, CHO cells 
were treated with 1% methanol only and compared with the plant methanol extract which 
contained less than 1% methanol. The results showed that cells treated with 1% methanol 
were not induced to apoptosis while those treated with the plant methanol extract were 
induced to apoptosis. These results indicated that apoptosis induction was due to 
compound(s) contained in the plant methanol extract and not due to methanol. 
 
The plant methanol extract was also used to induce apoptosis in different human cell 
lines,  Caski, HeLa, H157, Jurkat, MCF7, MG-63, 3T3 and 293T and mouse cell line 
3T3. Morphology of the cells was evaluated following treatment of the cells with the 
extract in comparison with untreated controls. Morphological evaluation was based on the 
recommendations by Kroemer et al., (2005). The results showed that Caski and H157 did 
not show discernible apoptotic morphological changes when induced with 0.25mg/ml of 
the plant methanol extract while the other cell lines showed distinct apoptotic 
morphological features. It therefore meant that Caski and H157cells were more resistant 
to apoptosis induction when treated with the plant methanol extract than the other cell 
lines.  This was also demonstrated by the NRU cellular viability/cytotoxicity assay, which 
also showed that an increase in the concentration of the extract was required in order to 
achieve 50% killing. To investigate the mechanisms underlying the dynamic 
morphological changes several tests were done.  
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MCF7, Caski, HeLa and CHO cells were tested for translocation of phosphatidylserine 
(PS) from inner to the outer layer of the plasma membrane following treatment of the 
cells with the plant methanol extract. Apoptosis was measured using the 
APOPercentage! apoptosis assay.  The results showed that Caski were more resistance 
to apoptosis induction as compared to the other cell lines.  
 
CHO cells were further tested for translocation of phosphatidylserine (PS) from inner to 
the outer layer of the plasma membrane following treatment of the cells with different 
concentrations of the plant methanol extract. Apoptosis was measured using the Annexin 
V binding assay. The results showed that the extracts induced apoptosis in the CHO cells 
in a dose dependent manner.  
 
 Mitochondrial depolarization, which is one of the early events that occur during 
apoptosis was investigated in CHO cells following treatment of the cells with the plant 
methanol extract. The results clearly showed that mitochondrial depolarization started 
within 30 minutes following exposure of the plant methanol extract to the cells and within 
three hours there was almost complete mitochondrial depolarization.  
 
Caspase-3 cleavage was also analysed in CHO cells using anti-active caspase-3 
antibodies following treatment of the cells with the plant methanol extract. The results 
showed that the extracts activated caspase-3. The positive results for caspase-3 were a 
good marker for cells undergoing apoptosis.  
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Further investigation of Poly (ADP-ribose) Polymerase-1 (PARP-1) was done on CHO 
cells and HeLa cells following treatment of the cells with the plant methanol extract. The 
results showed that specific active PARP proteins were more prominent in CHO cells 
than in HeLa cells, which meant caspase-3 activated PARP-1 to a greater extent in CHO 
cells than in HeLa cells. It also meant that CHO cells were more susceptible to apoptosis 
induction with the extract than the HeLa cells.  The PARP results also show that 
treatment of the cells with the plant methanol extract induced DNA fragmentation as 
PARP is a DNA strand break sensing molecule. 
 
Different cell lines CHO, Caski, HeLa, H157, Jurkat, MCF7, MG-63, 3T3, 293T and 
mouse cell line 3T3 were induced with the plant methanol extract to undergo apoptosis 
and their IC50 was determined using the NRU50 assay. The NRU50 assay showed that 
Caski were most resistant followed by H157 and MCF7. NRU50 assay also showed that 
Jurkat cells were the most sensitive followed by CHO, 293T and HeLa as shown in table 
3.1.  
 
Finally TUNEL staining of CHO apoptotic cells, indicative of DNA strand breaks which 
is one of the hallmarks of apoptosis was observed when the cells were induced with the 
plant methanol extract for 36 hours.  
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 5.3 Conclusion 
 
 
Traditionally the leaves of Rhus laevigata are used therapeutically as anti-inflammatory. 
The results provide strong evidence that the plant contains pro-apoptotic and anti-
proliferative compound(s), and the results support the traditional use of the plant as anti-
inflammatory. The results also mean that the plant contains compound(s) which may be 
used as lead compound(s) in anticancer drug discovery and therefore needs to be further 
evaluated.  
 
 5.4 Future work 
 
This study has shown that the crude extracts from Rhus laevigata contain pro-apoptotic 
and anti-proliferative compounds. The methanol extracts induced apoptosis in CHO cells 
as well as in human cancer cell lines MCF7 and HeLa cells.  The extracts however, failed 
to induce apoptosis in Caski cells.  This screening work has therefore provided the basis 
from which more work needs to be done.  Future work will therefore involve: 
1. Characterization and elucidation of the structure(s) of the compound(s) contained 
in the crude methanol extract through bioassay guided fractionation.  
2. Determination of the pathway through which the compound(s) induce apoptosis. 
 
 5.5 Alkylating agents as anticancer agents 
 
The role of anticancer drugs is mainly to slow down and most likely halt the growth and 
spread of a cancer. Many anticancer drugs target DNA and these anticancer agents are 
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said to work by damaging the DNA of the affected cancer cells, by inhibiting the 
synthesis of new DNA strands so as to stop the cell from replicating as the replication of 
the cell allows the tumour to grow, and by stopping mitosis or stopping the actual 
cytokinesis (Hurley, 2002). Stopping mitosis stops cell division (replication) and may 
eventually halt the progression of the cancer. As reviewed in chapter one (section 1.7), 
alkylating drugs act by covalently modifying bases in DNA, often also resulting in DNA 
cross-links (Borst and Rottenberg, 2004; Drabløs et al., 2004).  This causes mispairing of 
the nucleotides as a result, leading to mutations (Hurley, 2002). This alteration results in 
the DNA being fragmented by repair enzymes in their attempt to replace the alkylated 
bases (Drabløs et al., 2004).   
 
Cisplatin is one of the alkylating agents, which has been used for many years as an 
antineoplastic agent. It induces its cytotoxic properties through binding to nuclear DNA 
(cisplatin–DNA adducts) that activate multiple signalling pathways. These pathways 
include those involving p53, Bcl-2 family, caspases, cyclins, CDKs, pRb, Protein Kinase 
C (PKC), Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinostol 3-kinase 
(PI3K)/Akt) and subsequently interfering with normal transcription, and/or DNA 
replication mechanisms (Gonzalez et al., 2001; Pasetto et al., 2006). 
 
Minor variations in the structure of cisplatin have been found to have great effect on the 
anti-tumour activity. However, almost all trans-compounds tested have so far been found 
to be ineffective against tumours, while the cis-counterparts have been found to be active 
(Farrell, 1989). 
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 5.6 Screening of cisplatin and palladium-based complexes for antineoplastic 
 activities 
 
In this study two palladium-based complexes, which were assigned numbers 15 and 57 
and one platinum-based complex assigned number 58 were screened for their 
antineoplastic activity in comparison to cisplatin.  
 
The complexes were tested on nine cell lines namely CHO, Caski, HeLa, H157, MCF7,     
MG-63, 293T, 3T3 and Jurkat cells for induction of apoptosis. Morphological evaluation 
using light microscopy showed that all the complexes induced apoptosis in the nine cell 
lines tested. 293T cells completely detached when they were exposed to complexes 15, 
57, 58 and cisplatin. 
 
One of the early events which occur during apoptosis is the translocation of 
phosphatidylserine (PS) from inner layer to the outer layer of the plasma membrane. 
APOPercentage! apoptosis assay is an assay which measures cells that are undergoing 
apoptosis or are already apoptotic. Each of the nine cell lines was treated with each of the 
complexes 15, 57, 58 and cisplatin and were evaluated for apoptosis induction using the 
APOPercentage! apoptosis assay. The results showed each of the complexes induced 
more than 60% apoptosis in each of all the nine cell lines.  
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The translocation of phosphatidylserine (PS) from inner layer to the outer layer of the 
plasma membrane can also be measured using the Annexin V binding assay which when 
used in conjunction with vital dyes such as 7-AAD can be used to discriminate early and 
late apoptotic cells. 293T cells were treated with complexes 15, 57, 58 and cisplatin and 
analyzed with Annexin V binding assay.  The results showed that the cells were positive 
for Annexin V and it was possible to distinguish early and late apoptotic cells(necrotic 
cells). The results indicated that the complexes were inducers of apoptosis.  
 
Mitochondrial collapse occurs early in apoptosis and is followed by decreased 
mitochondrial membrane potential. Changes in mitochondrial membrane potential were 
examined following treatment of 293T cells with complexes 15, 57, 58 and cisplatin for 1 
hr and 5 hrs. The results showed that there was increased mitochondrial depolarization in 
cells treated with complex 57 and cisplatin at 5 hrs as compared to cells treated with 
complex 15 and 58 for the same time period.  
 
293T cells were further treated with complexes 15, 57, 58 and cisplatin and examined for 
activation of caspase-3 which is involved in the execution of cell death. The results 
showed that all the complexes activated caspase-3 in 293T cells although complex 58 
treated cells had reduced caspase-3 activity in comparison with the other complexes. 
 
The NR assay was done following the procedure by Babich and Borenfreund, (1991); 
Rixe et al., (1996); Fotakis and Timbrell, (2005) to determine the NRU50 (IC50). Each of 
the nine cell lines was treated with each of the complexes and examined using the NRU 
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assay. The NRU50 showed that cisplatin had less cytotoxicity to H157 and Caski cells 
while complex 58 showed less cytotoxicity to Caski cells. This was shown by the high 
retention of the dye by these cells. The NRU50 assay further showed that complexes 15 
and 57 both palladium based complexes, were cytotoxic to all the cell lines as shown by 
the reduction of the cells in the retaining of the NR dye following exposure to the 
complexes. Jurkat and 293T cells were very susceptible to both the palladium and 
platinum based complexes. 
 
Jurkat and 293T cells were further treated with complexes 15, 57, 58 and cisplatin in 
order to determine if the complexes induced DNA degradation in these c ells. DNA 
fragmentation was assessed by use of the TUNEL assay. The results showed that all the 
complexes induced DNA fragmentation in these cells.  
 
Complex 15 (palladium-based) and complex 58 (platinum-based) were used to induce 
HeLa cells to undergo apoptosis and cell cycle analysis followed. Apart from showing 
DNA fragmentation cell cycle analysis can also be used to show the stage at which a 
compound can halt the cells from moving to the next phase of the cell cycle.  Prospective 
drug candidates can then be design to target that particular stage. The results for the cell 
cycle analysis showed that both complexes caused cycle arrest at G0/G1-phase of the cell 
cycle, and that both induced DNA fragmentation. 
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 5.7 Conclusion 
 
The platinum and palladium-based complexes have been tested for induction of apoptosis 
in different cell lines derived from hamster, mouse and human. Both the palladium and 
platinum based complexes induced apoptosis in the panel of cell lines tested in a similar 
fashion particularly in 293T cells which were properly investigated. Although both the 
platinum and palladium complexes induced apoptosis in the panel of cell lines in a similar 
manner, the palladium-based complexes induced apoptosis more than the platinum 
complexes. Complex 58 however was also more cytotoxic than the parent compound 
cisplatin. 
 
 5.8 Future work 
 
Despite the antineoplastic activity of these complexes, there was still the problem of 
solubility as the complexes were soluble with the aid of DMSO. Problems such as the 
ability of cells to detoxify cisplatin, failure of cisplatin to selectively kill cancer cells, 
solubility of cisplatin in body fluids and faster repair of cisplatin-DNA adducts among 
others pose a big challenge. That is why there is need to study other anticancer agents 
such as palladium complexes and see if they can overcome the problems associated with 
cisplatin as an anticancer agent. The palladium complexes therefore be further evaluated. 
To this end, future work will involve: 
1. Synthesis of more palladium complexes that are soluble in water.  
 
 
 
 
  174 
2. Testing of the complexes on normal cells and cancer cells and see if they can 
selectively kill only the cancerous cells. 
3. Determination of the pathways through which the complexes induce apoptosis in 
different cell lines.  
4. Investigation of the mechanisms through which the complexes halted cell cycle 
progression, which resulted in DNA fragmentation. 
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